Transcript
Page 1: STPN_2014_(Atypical Antipsychotics. Part 1 + 2)_Extended

����������

��

�� ��������� ����������� ������ ������

�������� !�����"�#$��%�&!'$()* !"#$+"�,�(�!-�.(���/0!� $- ��� "%� !�- +�$"�(%�!1��"�)!23

45657689:8;<=>?@74ABC7DE8F:?G8HIGJK7G8LMGJK7F=G>N7G8NO?H?9::P

QRSTUVWXUYUZ[\]VW[XUYU]_XU_aVaVbURSV[WUcd_efgSSVRWYR_XRW[S[USVY_ehZUeUVijVkVYR_X_XUcYUZS UlVWXUYUVe_mWYU[nVWRUYUYRWm_enVWbUhefcYRUTnVWmS[WYU[nVmUYRWUT_[nVUe_YSRUT_[nVaSXUWYU[nVehRWUT_[nV_eW[mWYU[nVYWeUYSRUT_[nVRUYSRUT_[VUVSRXU[T_eoVpeU[UZS USVU eST_aW[UqV[WV_aRSbS[c[_bVrXWYSV[SVY_ma_eqsXVa\qaUXfV_XeUZUXSef[\SV__dS[[_XUVYSXRWVYU]_XR_Y[_lVWXUa[_XUVWtT_u_V_[RSX[_u_VW[XUYU]_XUWoVvSbV[SVbS[SSVaVeU[USVb\VZWX_Vb_tSbV[WdesTWXfVU[cTUaUThWef[hsVYRSTY_ZXUXSef[hsVrwwSXUa[_XfV_YRSTSeS[[_u_VYRSYWRWXWVhV_[RSX[_u_VYWxUS[XWoVyVTW[[_bVXS_RSXUZS _bVU eST_aW[UUVYRSTYRU[qXWVY_Y\X WVhXW[_aUXfVa_mb_t[_SVm[WZS[USVwWRbW_ce_uUZS U]VbUgS[SlVWXUYUZ[\]VW[XUYU]_XU_aVaVaSXSVUbSszU]qVTW[[\]V_VYWX_uS[SmSVgUm_wRS[UUoV

{|}~������|���������������������������������������������������

��������������� ¡

����� ¡

¢���� ¡

£��

¤��¥������¥���¥�¦��§��¦¦����������©�¥������ª¦¦��������§��¦©��������§���������������§��«¬­®��°��±«¡¬����²��¥¥�������³®µ

¶��������¥���������¥�·������¥��¹�º�¦¥���������������»����º����¼��������©��§�����¥�¼��·��������¥��µ�½�»�������º���»����º�¾������º�»�������������·�����������¾������¾��»�¦����������¾��������·���·���������������������·���·�����������������������������������¥�¾���¥�µ�¿�������À�º������������§�¥�·�������¥�»���Á���¥��¥À������§���¥��������¼�������Á������������������»�¥·�»�����·�����������¥�������¾���������·���·��������������§���¥�����¾¥�������������µÂ��·��¥�����������������¥�·����·�ª�����¥�º�����������¦�¥·�����¾�������������Ã��·��¾�����¥���������·�����·�����º·����¥����������¾��»�����������������������������������¥���¥�����ÄÅÅÆÇ�����������»��������� ����¥�����������������º���ÁÃ���¥�»����À��§����������§����º·�À����º��·���º�µÈ�¥�·��������������������¾���º��¹�º�¦¥��

�����¥�»����¾�����������º��·�»����������¥�����¥�·�»����¥���������·�É�»�¦�·��������¥�����������¾�©��·�������ÊÅË¿µ�¶�·���¥©ÁÃ���������Ã���¥�·����������¾�©��·���������¥��������¾���º��¹�º�¦¥����µ�½�º����������¾�©��·��������¥�����º�������¥�·������·��������º����¾���

¦�������»����É�������©¥�����¾������¾�������¾�©��·�����������¥������¥�µ�Ì����º�·��������������������»���º�¦�������»����¾����¥��º��©�������¥��������������º»�¥���������º��������¥��¥�¾�¥�������¹�º�¦¥�����»�¼�������������������¥����¥�����������������·����������·������¹�º�¦¥���������������º����°����Í���°�±µ�Î���À���������»¥©¾���������©¥�����������¾������������¥������¥���¦�������»����¥����¥©����¥���©���©�¼��§����¹�º�¦¥����µ�Ë�»����»¥©¾��������������������������º��Ä������·¦���·���Ç�»�������������§������������§�����������������¥�����¹��º�¦¥�������������¥��º�»����¼��§¹���������¼�Á»��·�����¥©¹��������¥�·�¥������¦������¾����¾������¾��»�¦�����µ�½������������»¥©¾����������·�·��������¥���

��¥©ÁÃ�����¥����¥����Ï����»�¥����Ð���·���·�������·���Ä������©¥����� ����������¾�����Ç��¼�����»������»��»©��§�� ������¦�������ª¦�¦���µ�Æ�������·©����¥���·¦���·����¾��¥�»�����·�����º·©����¾��»���������Á�������¥�·�·���¾������·��»�¦�·���������·©��¥©Á���¾��������������������¼�À»����������·¦���·������·�»��§���¥�À������¹§�������¥����¥�»©������������������������·���·�����¾»���������������¾��������¥�»�����Á��©»���©Á�·�»��§���¾�������¥����¥©�¹�������¼�Á»��·����¥��¹�º�¦¥����µÑ»��·��º�·�����º·��¥�º�������¾��������

��¥©¹��� ����¼�Á»��·����¥��¹�º�¦¥������������������¥©¹�����Òc_xUeeqxUU���¥�·�»������¥������¥��¾�����¾��·�º¾�����»���������À�����������������¥�»������¾����»�������¥������§����ÊÅË¿��¥¾����������¥�������������������������������������É�������º���·���YWRaWefdhbU[VY_e_tUXSef[\]�ĬÓÔÇ���������������ÁÃ���º������¥���º���Á�¥��·������©���������¥�·�»������¥���µ�Å������ª����������������¥�¥©Á����¥���·�������©Á�º��©���¥�·�»������¥���µ�È���¥���º�������¥����§�������������������������·�»����º����Ä°�ÕÍ��Ê�Ç��·�����¥����������º��������»�����¥·��§��¾���¼·������¦�¥·�����·�À»©�¥�º�����·����»���·����¥����¦©�������¥������¥�¼������·���µ�Ê���¦©������ÊÅË¿���¥�����¥��¹�º�¦¥����������»�·�·©����º��������¥©¹����·�ª¦¦������������¥�����§�������������¥�»��������¥��¥���·����������£�����������±µ¬Ó���������¾¥�Á������¥��§�©Á�¥��§��¾���¥��

��������������� ��¼��§¹��������»������¥��

Page 2: STPN_2014_(Atypical Antipsychotics. Part 1 + 2)_Extended

��

����������

��� ������ ���������������� ���������

������������ �!�"��#$�%�&! !��'�()���*+,��-+,,�./0,!1! ��!���12342��)!�5��6�&�23��� �,&!7)�12,�!&),�!+,,�2!8�(36�1!�-),�"9'�:;'��<�'��<�#'�12,(3��!�1�,)=0!�&��38!�,6��� 2!*)!3)�12�1�2+,��!�5���*�=�3�,(3�,3��,�4�2�!+,����6��!�2= &,�";>#$�?36*)�,)3�5��'�1!+,3�)@�*�A, �423�,36��8�!2=/B,�!�7)�*�,B3��=7�./!&),���*)5���8�@C�0��36�12,��@1���3�,,�&���,),��@C�)3*)��@C� !0!�,6�"<�#$�D�!���,(�@���82! ���=�)!&,C�1!+,3�)���)!&B3��8�!2=B,�!7)*-��!2=A3�,-�./�*+,��-+,6���12�3&+,,� !)@��(�@C�,��,*�(�@C�0��36�12,�,*/*�30��!�,,�12�+3**,��!��, =!�5��6�,�!=0,!�5��6�,�4�2�!+,,�"��9'���9#$�E3&�)�2@3�,**�30��!�,-�12301��!�!7)�*�- 5��!2=A3�,6�./�*+,��-+,,�12,�A, �423�,,��3�)��5&��*�&���,),��@�,��!2=A3/�,-�,'����,�*��3&�)�2@�,�12�0=&),��@�,�1*,C�/),(3*&,�,�*,�1)��!�,'��!12,�32�FGHIJHK�HL�MN$�"��;#��@-�,�,�1���B,)3�5�=7�&�223�-+,7��3B0=��@2!B3���*)57��!��7+,�!)�2�@C�1323B,�!�,6�,��!2=A3�,3��./!&),���*),���*�=C���6�&�23$O),�=�-+,-�PQRS/23+31)�2�����&�23�12,��0,)�

&�!&),�!+,,�TU/&�3)�&�,�2,)�,(3*&��=�V<�W9��X+Y��@*��8�B03�,7�XDZ['��@ @�!7\3�=��� �,&���3/�,3�1�*)*,�!1),(3*&,C�,��,8,)�2�@C�V)�2�� �@CY�1�)3�+,!�����!�1��32C��*),���=)!�!)32�,(3*&,C�1,2!�,0�@C��362�����&�2@$�]! ,(3*&�3�*,�!1/),(3*&�3�,��,8,2��!�,3'��*=\3*)��-3��3�XDZ[/�362��!�,'�-��-3)*-�&�7(3�@����12�+3**3��3�32!/+,,�*,�C2��, ,2��!��@C�*3)3�@C��*+,��-+,6�":�'�:�#$���&!0!�PQRS/23+31)�2��� !)�2�!B,�!3)�,��!2=A!3)�*,�C2���@6�1!))32��!&),���*),�)�2�� /�@C��362�����,'�&!&�*�30*)�,3'�2!*)�2�!B,�!3)�,�03*,�C2��, ,2=3)�2!8�)=�1,2!�,0�@C��362�����"9�'�;<'���:'��>>#$�_�2�� �@3�XDZ[32�,(3*&,3�TU ��362��@'�2!*1���B3��@3���&�23�,��,11�&!�/13'����!,8��5A36�*)313�,�1�0�32B3�@���,-�,7�PQRS/!�)!���,*)���":a'�;;#$�b*�,�*3�36*)���R�/1�0�8�@C�0�4!�,���@C�23+31)�2���VR

�'�R

<'�,�

R�Y�*�- @�!7)�*�2! �,),3���*)2�6�12�0=&),���6�

1*,C�),(3*&�6�*,�1)��!),&,'�)���3�!),��@3�,�&���,),��@3�2!**)2�6*)�!��� �,&!7)��*�30*)�,3�*�,B3�,-�R

���1�*230��!���6��362�)2!�*�,**,,�

��12342��)!�5��6�&�23'��03�R�/23+31)�2@�2!*1�/

�!�!7)*-���!��@���82! ����!�1��32C��*),�TU ��362�����"<'�>�'�>9'��9�#$�R

�/1�0�8�@3�23+31)�2@'�

���)�,(,3��)�R�/1�0�8�@C�23+31)�2��'��@ @�!7)�

031��-2, !+,7�V!&),�!+,7Y�c&*123**,2=7\,C�,C��362�����"��#$�O),�=�,2=-�R

�/23+31)�2@'�0�4!�,��

!&),�,2=3)�XDZ[32�,(3*&,3��362��@'�1��@A!-�,C�*1�*�8��*)5��3�32,2��!)5�,��,8,)�2�@3�V�,1321�/�-2, =7\,3Y�1�*)*,�!1),(3*&,3�1�)3�+,!�@��!�1��32C��*),�1,2!�,0�@C��362�����,�����3&!)5��*3�8��5A33�,C�&��,(3*)�����*,�C2���=7�,�1=�5*!+,7���./0,!1! ��3�V2,*$��Y$�_!&!-�*,�C2���!-�,�1=�5/*!+,-��2=11@�1,2!�,0�@C��362�����*� 0!3)��!�1��32C��*),�&�2@�defgdhijklmedknjklmeokipqgdj'��! @�!3�@3�.respqddtpqtuq�"���#$PQRS/�1�*230=3�!-��362�)2!�*�,**,-���123/

42��)!�5��6�&�23�&��)2��,2=3)*-�,�R�/23+31/

)�2!�,'�)!&B3�2!*1���B3��@�,��!�TU/&�3)&!C$�%�*&��5&=�*),�=�-+,-�R

�/23+31)�2���)�2�� ,)�

c&*123**,2=7\,3�,C�&�3)&,'�R�/!�)!���,*)@�(!/

*),(�����**)!�!��,�!7)�!&),���*)5�TU/&�3)�&�":�#$�%�&! !��'�()��1�0�036*)�,3��PQRS/!�)!���,*)���=�3�,(,�!3)*-�(!*)�)!�2! 2-0���1,2!�,0�@C��36/2�����12342��)!�5��6�&�2@'�(!*)5�, �&�)�2@C�*�30=3)���vewsgdhiekltvwelxng�VRyKzMN�{MG|H�P}JNH}z~�R{PY'�&�)3�!��*32�)��,�32�,(3*&,C��362����'�,�37\,C�2!*12�*)2!�3��@3�&�2&��@3�12�3&+,,$�D&),�!+,-�c),C��362�����12,��0,)�&�1��@A3�,7�&�2),&!�5�����=2���-�*32�)��,�!�"���'��<�#$��,A5�a���1,2!�,0�@C��362�����U�*��-��30,!�5��6�123/42��)!�5��6�&�2@�,�33)�12�3&+,,���R{P�">�#'����,�3����,C�!&),���*)5��3�*�,B!3)*-�1�0�036*)�,3��!�)!���,*)���R

�/23+31)�2��'�1�*&��5&=�*=81�1=�-/

+,-�TU/&�3)�&'�&��)2��,2=7\,C�,C�!&),���*)5'��3�c&*123**,2=3)�R

�/23+31)�2@$�D&),���*)5�c),C�TU/

&�3)�&�1��@A!3)*-�,*&�7(,)3�5���1�0�036*)�,3��0�4!�,�!��!�R

�/23+31)�2@�">;'�:�'���;#$�%230�!/

2,)3�5��3���303�,3�&�� !1,�!�,���!� !1,�!'�����3��!��132,0��!�1�0!��-3)�1��@A3���3��@*��8�B03/�,3�a/E_���12342��)!�5�=7�&�2='��@ �!���3��O��,�&3)!�,����"a#$

��������Z3C!�, ��*,�C2��, !+,,��362��!�5��6�!&),���*),���&�2&��@C�*3)-C'��*=\3*)��-3��6�

XDZ[��362��!�,�":�#

Page 3: STPN_2014_(Atypical Antipsychotics. Part 1 + 2)_Extended

����������

��

�� ��������� ����������� ������ ������

��������� !"#��$�%����&'()�*'��+�� ��,��!-'

��"�.��,��!� �/�.���0�!102�,/�%"� %!/3�4 ��0�5�'!2������+�� ��,3�6%"74!8�0� ����$���,3�%� �'�,������+0�97 -8�6�:;<=�>���% ,�6�?2�$- 608�5

�'

!2����@"�%! ���6�-/�.0�-�A���% !10�6�?2�$- 608�!� !B��0- �6�&'()

�*'��+�� ���63���-%�"#%9��@!�

��+�� ��!�?!�9-%!7 ��@C0��6�9 �0%"� �4�,��1�' !@�"04�-%0���9 0�����2!40�-0B�!"!�D��-��"0�!?9�EF�0����-��297 �!% 060�97C���2�$- 60�����!2��'�!"0�!�0�-��� ��0�!��!��0�!102�,��%"� %0�G��HI=�J��%"0�04�-%0��2!��,��B�6��8 ��� �13�4 ��@"�%!2!�5�'!2������+�� ���6��� ��+0�9� �!� 0�-0/� 04�'-%���2�$- 60��:

�'!� !B��0- �6�G�&KI=�

L�0 04�-%���?�!4��0��19"# 0��+�� ����- 0��!�1!%�"�B04�-%�B������0"8���6,/�!� 0�-0/�' 04�-%0/�����!�! �6�%�-6�������2 6��.2!� -8�0� �1��!% �13�4 ��6�0--"�2�6!�00��!�?2���6,/�2�@��6�"#+!/���%!?!��3�4 ��B!"����02�"����@"�'%0�9� ��-0/� �101� 04�-%�B��2�$- 608�%� !10�!�G���I3� �B2!�%!%�%"�?!�0��@"�%0�9� ��B��2!.����0�66�2��00�%� !10�!�@�"#�,1�M0?�����0�$�G�K�I=��6�2��0��%� !10�!���"�4��,1��!+0�� !13�- �!2!'7C01�M0?�����0�$3�2���"�0 �"#���9/92M!� �9��0/�%�B�0 06�,���9�%+00�0��!18 #�G�K&I=��6�2��0��%�' !10�!� !%.��6,?,6!� �-��+0�04�-%0���!�9M��08��!18 0�9�?2���6,/�2�@��6�"#+�6�G�N�I=O�"#M���?�!4��0��6�%�1���-!+00�6-�B��-��% �!�

�-0/04�-%0/��!�9M��0$���0�M0?�����00�-�$4!-���02!� -8��!?"04�,1���2 0�!1�-��� ��0��6,/�0�!2�����B04�-%0/���+�� ���6�GKN3�&�3��PHI=�J�'101��1��B�40-"���,/�2!��,/3�����-��2- 6�����2�1��- �0�97C0/���$���!"#�,��1�/!�0?1,�0�%"0�04�-%���?�!4��0��%��%�� �,/���+�� ���63�-�%"0�04�-%�$� �4%0�?���08���"�?����@�! 0 #�6�0'1!�0���!� !%�$�����2%0$���@�4�,$�A���% �EQRSE3���0-!��,$�6��-��6��1�6�?!�9@�.��$�"0 ��! 9��3�%!%�TUVWTXYZ[\]Y_aZZ_bXcbdadeYfYb�Dgg;h'ijklmnk�ijkioonpnjmnF�G���I�0"0�TUVWTXYZ[\]Y_aZZqrXsYZt_uXavawYY�Dgg;h'ijklmnk�xyxz{|�}|jkp~�nF�GH3����I=�;nij��xzz�0�;ikk�n�G�HPI�����2�"87 �!�! 07�%!%�-�0.���97�1� 06!+073�%� ��!8����6,?6!�!�-�0.��0�1�9��6�8�-�?�!�083�1�20%!1�� �?��$�-�2!+0�$�0"0�2����--0�$=�R���2�"88�%"0�04�-%0�����86"��08�A1�+0��!"#��$�0�20������ ��- 03�6,?6!���$���01����0�1�EQRSE3��y�p~n��G�P&I���0-,6!� �-�0.��0��A1�+0��!"#��$�� ?,6406�'- 03��pimn�G�H�3��HNI���A1�+0��!"#����� 9���0�3�-�0.��0��A1�+0��!"#��$�496- 60 �"#��- 0�0��C9C��0��A1�+0��!"#��$�!��- �?00=�)!%.��!6 ��,���0-,6!7 ��@C97���29%+07�0� ��-06��- 0�6-�/�A1�+0��!"#�,/�����.06!�0$���%!%���B! 06�,/3� !%�0���?0 06�,/���496- 6��A1�+0��!"#��$�� '- �!�����- 03�-�0.��0��496- 60 �"#��- 0�6�1�.'"04��- �,/�%�� !% !/�0�!���% 06����9�"�C��0�=�Q- 0��!8��!-���- �!�����- #�2!���B������1��!���0?6�- �!3� !%�%!%�2��-0/�����������6�20"�-#�-��#�?�,/�A�02�10�"�B04�-%0/�0--"�2�6!�0$=�E�B"!-���0--"�2�6!�07��~��ij��0��~{�nj�np��G�&I3���-68C����19���.�"! �"#�,1���@�4�,1���!%+081�-��- ����,��-0/0%0���0���01����00�EQRSE3�0?������!+0�� !3���"94!6M�B��EQRSE3���0@"0?0 �"#'

��������-��@C!"0����!?606M�$-8��!��������0�1!�����!�! !�!�! 003����������-�0.��00�%��! 06��'- 0�D 6��4�-%0/�-��-�@��- �$F3������������-��-�@'��- 0��"!%! #3��N�������-�0.��00�%��+�� �!+00�6�01!�083������������ ����+�"�9- ��1"����- 03����������2��0+0 ��A1�! 003��K��������!�9M��08/��!18 0�0�N���������-��-�@��- 0�0-�, ,6! #�B��6�6�-0 9!+08/3�%�B2!�A ��@,"�����@/�201,1=�������'%��- ��1�0--"�2�6!�00��x�x�nz�x�=�0?���N��!+0��' �63��!/�206M0/-8�6� �4��0��K�1�-8+�6��!� ��!�00�!� 02����--!� !10������6�29�2����--003�9�K�3&����!@"72!"!-#�!�! 083�0?��0/�9�N3N�����91������$�0� 8.�"�$�- ����03�0��%�"�������-��@C!"0�����' ����1� 06!+003�0?��0/������91������$�0� 8.�"�$�- ����0=���0--"�2�6!�00�;nij��xzz�0�;ikk�n�G�HPI�0?��K���20! �04�-%0/��!+0�� �63�- �!2!7C0/� ��6�.'�,10��!-- ��$- 6!103���"94!6M0/��"96�%-!10�3�9�&����!?60"!-#�!�! 08=J��86"��08���B! 06��$�A1�+0��!"#��- 0�

6-"�2- 60����0�1!�EQRSE�-68?,6!7 �-�9B�� ��0'�1�-��� ��0��1�- 6�"�6,/�2��!10���B04�-%0/�0����!2�����B04�-%0/�- �9% 9�3�����+0�97C0/-8�6�������� !"#�97�%��93�0�6�?�0%��6��0�1�0?@, %!�%�� 0%!"#��B��-��� ��0�!�GH3��N3�H�3���&I=��������������������������������������� �¡

���¢£���¤����¥��¦�§��§�����¤��©��©��G���Iª����6�2��4�-%0$�!-��% ���-�0.��0��1� 06!+00«��A1�+0��!"#�,$�!-��% �����0 9�"��0��A1�+0$«��4!- ��� -��4�������!4!"�«��-�96�"04��0�1�2�?,�EQRSE�6���8 ��- #�6�?�0%��6��08�0�6,�!.����- #�-0�2��1!�6�?�!- !7 «

��-01� �1,���"��- #7��!?��M!7 -8���-"��-�0.��08�2�?,�0"0�� 1��,�EQRSE=

J��86"��08�2!���B��-0�2��1!��@,4�����2��+�'�06!7 -83��-�@�����9�2� �$�0���2��- %�6=�Q1�� -8���81!8�?!60-01�- #�6,�!.����- 0�-01� �1! 0%0�� �2�?,�!� 02����--!� !3����-01� �1,����6-�B2!���86"87 -8�����-��2- 6�������-"���!4!"!���0�1!�EQRSE=�E�- �8�0����"��- #7��!?��M!� -8���-"��� 1��,�����!�! !�G��&3��P�3���&I=)�"!�2��!10���B04�-%0/���$����6�6�B�"�6��1�

1�?B����"94!7 ��@0"#�97�-��� �0���B04�-%97�0����6!+07���$���!10�82���M6!�- 6�"!�1�?B!=���?2�$- 60��-��� ��0�!��!�%"� %0�10M��0�����'2�"8� -8���2 0��1�A%-���--0�9�1,/���+�� ���63����6�?2�$- 60���!�2��!10���B04�-%0����$���,�6��-��6��1�0�B0@0 �����=�> ���-�@�����6,�!.����6�bZw ae¬Z_rX_ceaswYXv_­q®­Y�Dnjzpx��°n��njzx��±pnx«�°±F3�B2���-��6����6"08�0��-��� ��0�!����-��29� -8�"�%!"#�,10�²*³L'A�B04�-%010�0�' ����$���!10�0�����%+0810�B"9 !1! ��B04�-%0/���$����6�������� !"#��$�%��,�G�KI=�E�"�% 06������6��.2��0��-��� ��0��6,/���$����6�&3N'20B0'2��%-0 �0� !10��1���6,M!� �4!- � 9�-��� !��,/��!?�82�6���$����6�°±��!�K���3�4 ��-602� �"#- 69� �������6�1�0�B0@0 ����1�6"08�00���$����6�:;<��!�2��!10��6,����$���,�°±�GNNI=EQRSE�A���% 06�,���0�2����--003���-%�"#%9�

��0���6,M!7 �9��6��#�-��� ��0���B04�-%�$���$�� �!�-10--00=�)�1����1�����66029� �B�3�4 ��

Page 4: STPN_2014_(Atypical Antipsychotics. Part 1 + 2)_Extended

��

����������

��� ������ ���������������� ���������

������� �� !�"�����#$�% & �#�! '��(�!��"��"!�)� ��"�*�%"+ �"�,�� ���+��-./�0�1234�5� #�� ��������� ���! '��(�6���6����"��+ �� �7� ,�)* ��(��� 8�� 9�"(� ,���� �*�%"+ ���! '��( :���6����,�+�&�(��� ("#$��6� �+�&�# +; '��(�6�� ���+<�=��(�#$(5�>�"�� ���+"� !�"���,"8�59���#$�,�%��+ ��,"� �5*�,�#$��, ?4�+�� ,"@ � �7�);58*�� 64��� 8�� �����"(� ,���� �+�8��� +��$�����A�� ��(��#5'"?+���*���"��'��6�>%%�(� ,���� �BCDEB�5���(����F:�7"@ ����,<�G"("?� �*5@ ��),"��"?�:��� '��( +�,,�*�� �+�BCDEB��57���� ?�"(� ,���� �*�%"+ ��,F:���6����,�123���#";#?)���?�,,�*�� �+�"��"!�� ��"�H)IG

�B)��@�7����,�JK�

����L�<�M,�*�� ��BCDEB�7�,FA"���5��,��$�,��)(#���'��!��������� �"4�'���7� ,�* ��(�"(� ,"@ ���� @"��#$��6��;�"���6��,?& �0���+"��*��*� ��F:�H)IG

�N)"5����@�7����,4��"�7�#�8���F:��"���#":�

������� ��,F:���6����,�-./4� ��� 8"��� :�"()� ,����$<�N(� ,"@ ?�H)IG

�N)��@�7����,�7�*",#?���

"(� ,����$����"*�����! '��( :���6����,�OPQRSPOPTUVWXY�Z[\]_�\abca_d�[e4��"�7�#�8����!���"�*���f1�8�#5*�'("�,�7��*�#!�,"��+�+�&!�4���5g���,#?9)g :�,��:�*?g59����"*�����! '��(59� ����,"@ 9�(��F�!�#�,��!��+�&!"<�B��,��+���+�Z7� ;# & ��#$������*��6e���+"��*��*� ��F��H)IG

�N)"5����@�7���F�

-./4�,���# ' �����H)IG�NhB)��@�7����,�123� �[4�

7�*,��!"9��?�*����� � &"@ �Z���?9��'5,��, ��#$)����$e4� �"(� ,����$�������� ��,F:���6����,�,��)��"�",# ,"���?4����"(� ,����$���6����,�[� �123����"���?��� 8����6��"�7���?8�� �,��!��7�� �*"�,,�*�� ?�BCDEB�i�jk<�=��(�#$(5�,���# ' �����H)IG

�N)

��@�7����,�H)IG�3h)��@�7���F��("&F,"9��,�&;58*")

9g���*�6��, ���"�>(�7���� �59g �� :�(#��( 4��� ��"�7�#�8��F�7�� +5g���,������"�lNmn>�! '��( :����+�&�F:� ������6���":4�(����F���7����*59��*�6��, ��������� �"�,�123� �[�i�j4��ok<�I�6��; �#�! '��( �� ��#�*�,"� ?� ���&*"� ��

��,F:�7� :����7�F:�#�("���,���F:����*��,���)��p�+#�+���,?&"�����7� +���� �+�8 ,���F:�+�)*�#�6�7� : '��( :��"�����6��,<�D*��6� &��" ;�#���,"# *�F:� ��;g�7� &�"��F:���6��; �#�! '��( :�+�*�#�6�A &�%��� �?,#?���?�+�*�#$���,,�*�� �+�7� :���+ +�� '��( :����*��,4�+�:"� &+�*�6��, ?�(����F:��,?&"������#�(� ,�F+���(��(5�����F+�"��"!�� &+�+�,�����A�� �!#5�"+"��F:�/q-3)��@�7����,<�n�>� +��"(��"&F,"�+F+�A &�+ +�)� ("+������?��?�%��@ (# * ��Zrre4�(��"+ �4�* &�@ #7 ��Zqs)L��e� �*�<�t%%�(�F4��("&F,"�+F�� + ��"�#�(�+�����59�"(� ,����$� ��"�7�&�","� ����,F:��;p�(��,�5�!�F&5��,4�0��" ;�#���7�75#?�)�F��+�*�# �7� :�� '��( :�� +7��+�,� �(�!� � ,)�F:��"�5A�� 6�7� �A &�%��� �����,����,����<�B��* �,��:�7� :���+ +�� (�,�"��"!�� ��F�/q-3�,F&F,"9���" ;�#���A ��( 6��7�(�������,����,59)g :�7� : '��( :��"�5A�� 64�,(#9'"?��"�5A�� ?� �7�#� ��#$�( :�%5�(@ 64�,� +"� ?4��(����� �7��@��� �!"� �%��+"@ 4��";�'�6�7"+?� � ���)@ "#$�F:�,&" +�*�6��, 6�i��j4��jok<�uvUwxQPyzP{P|vV4� �*5@ �5�+"?�"��"!�� ��"+ �/q-3�5�8 ,���F:4��' �"���?�>%%�(� ,��6�+�*�#$9�7�)& � ,�F:�� +7��+�,�A &�%��� 4�,����,��+?�("(�

*�% @ ���";�'�6� �*�#!�,��+����6�7"+?� 4��"�)����6��,"�,� +"� ?� ���@ "#$�F:�%5�(@ 6�7��#�������!�� # �:��� '��(�!��,,�*�� ?�>� :����*��,�7��*��",#?9��,F��(���7��&���"� ,�59�+�*�#$�(�!� � ,�F:��"�5A�� 6�7� �A &�%��� �i�4��o4�o�4��H�4��o�4����4���j4����4��jok<�B�#�(� ,�F��"�)�"!�� ��F�-

�)��@�7����,4��"7� +���!"#�7�� *�#4�

�" ;�#���>%%�(� ,���7�*",#?9��! 7��#�(�+�@ 94�,F&,"��59�7� :��� +5#?���"+ �Z�"7� +��4�"+%�)�"+ ��+e4�������/q-3)"��"!�� ��"+ 4�(����F��,F&F,"9��! 7��#�(�+�@ 9�5�8 ,���F:�*"8��7��#�� ���g�� ?�&"7"��,�("��:�#"+ ��,�i�}4���j"k<�G�4�'���5��,��$�+�&�# +; '��(�!��*�%"+ �"���� +������A"9g�!��&�"'�� ?�,��"&, � �7� :�� '��(�6�� +7��+"� ( 4�7�*�,��8*"���?��"(8����+�%"(��+4�'���5� '��8�� ��7�75#?@ �*�%"+ ���! '��( :���6����,�75��+�#�("#$��!��,,�*�� ?���6����(� )�"�j)! *��(� *�%"+ �"���#";#?��4�������7��*��),�"g"���! 7��#�(�+�@ 94�,F&,"��59�~B~�i���k<��w�WTxY�UP�XY�YXvVTXP�����;p�(��,�5�8 ,���F:�Z/\�ac����a]��.a]\�����\�d�/�.e��' �"���?�,�&+�8)�F+�"�"#�!�+�*�(#"�"� ,��6�7"+?� �5�#9*�6�i}}4��j�4��j}4��jok<���(#"�"� ,�"?�7"+?�$�0��* �� &�(�!� � ,�F:�*�+���,4�'"g��,��!���"�5A���F:�5�7"@ ����,4����"*"9g :�A &�%��� �6�i��jk4�0����;�����'5,��, ��#$�"�(�7��(�!� � ,��+5�,�&*�6)��, 9�NN=�i�Hok<�=�("&"��4�'���"� 7 '�F�4�������� 7 '�F��"�� 7� :�� ( �(�+7��� �59��*�% @ ��/�.�,F&,"��F6�/q-3)"��"!�� ��"+ �io�4�L�4�L}4����4��o�4���jk<

��������������������������������������������� �������� �����¡�

¢£�¤¥¦§ ©ª¥«¬­�®­­°±¥®¬

-�)7�*� 7�*�%"+ ��,F:���@�7����,�?,#?���?�

7��,"# �59g +�,�Uxw²xPXWYQ³XPTzPxw�Zrbaµb\��¶c�]\b�a·d�r e<�n"(�58��;F#���("&"��4�-

�)��@�7���F�

!�"9��(#9'�,59���#$�,�7��@���":�(�!� � ,��)!��%5�(@ �� ��,"� ?�i�H4�jok<�D;�"�58���4�'����� 8�� ��>(�7���� �-

�)��@�7����,�,�r 4��")

;#9*"�+���5���#�'��F:�7"@ ����,4����"*"9g :�A &�%��� �64�(����# �5������?8���$9�(�!� � ,)�F:��"�����6��,� �,F�"8������$9���!"� ,��6�� +7��+"� ( �i��j4��L�k<�n��+����!�4�7�("&"��4�'���7����@ �59g���,# ?� ��(#�&"7 �"��"�/q-3��7����*5�+59���6����"��+ �� 9�,�+�* "#$��6�r ��7����*5���?�-

�)��@�7���"+ �i��4��L�k4�"�

�5;:��� '��(���,,�*�� ��rr�,F&F,"����� 8�� ��7#������ �-

�)��@�7����,�,�r �i}�k<�

B� +5#?@ ?�-�)��@�7����,�r �5� # ,"���7���)

� �"7� '��(59�/q-3)7��,�* +���$� �"(� ,"@ 9�7 �"+ *�F:���6����,�1��#�?�(��F�!�#�,��!��+�&!"<�D*�"(��&", � +���$�¹*�&")��,��º����?,#?���?�# )��6��6� ���� ��:"�"(����7���,���5��6�»)�;�"&��6�(� ,�6<�G"( +��;�"&�+4��# A(�+�,F��( 6�5��,��$�-�)"(� ,"@ 4��",���("(� ��# A(�+�� &( 64��"�5)

A"���/q-3)�7����*5�+59�"(� ,"@ 9�7 �"+ *�F:���6����,�ijok<�G"(4�&�"' ��#$�F���"�5A�� ?��");�'�6�7"+?� �5�7�8 #F:��;�&$?��5#5'A"9��?�7�*�

Page 5: STPN_2014_(Atypical Antipsychotics. Part 1 + 2)_Extended

����������

��

�� ��������� ����������� ������ ������

������� �!�"�#!�$!%�������&�$ !�#�'��(�)*'�#!� *�

+,-.��/01� �'�*�$*$��2��$!�����2�3 �'������!)#�#!4�5%5�6*7 �!�8�&#! �&9�$!��:5#$;!!�<��=>�?�#��*�#!%�!��&����*#!4%�@ABACADCE�FG�AH>�<��/=1��8I���&44�!# �#�!�#�� 9�(

�)�!�(

�)�8��I��5�"���

#��I� I*#�"!��!!���8I�:I�# *&9#���$�I��5����I�)�2%���JI���&9;���"� ���"�8��! I�##�)3"!��!�#)#��� �"�'I*:!!�KLMNO1�8�$*�*&!1�P ��$�'#! !�#*4�3::�$ !�#�� 9�8I!��28�&#�#!!�?!�$�#�!#�$�'�� �� *���I !I��$!�$*I �P�$� *$Q��!"�� �%*I*$ �I�!#��I !I��*##���R)�JI*�#���$I!����!��*�!�! �� ���� 58#�� !�(

�)I�;�8 �I��>�SI�"�� �'�1�#���#�)

$I* #��8�$*�*#�1�P ����&�$ !�#2��(�)*# *'�#!� 2�

�2�2�*7 �$�'#! !�#2����:!;! �5����I��2%�Q!)�� #2%�!�8I�84 � �57 �I*��! !7�8I�$�'#! !�#�'������ �!4�TTL���Q!�� #2%�"���&4%�$�'#! !�#2%�#*)I56�#!��8I!�6!��:I�#!!>�M !��*##2��8����&47 �8I��8�&�Q! 91�P ��*'�#!� 2�(

�)I�;�8 �I���"�'5 �

!"� 9�8� �#;!*&9#57�$&!#!P��$57�;�##�� 9���$�")8�#�*;!!�#�$� �I2%��!����$�'#! !�#�'����:!;! *�8I!�6!��:I�#!!�</�=>�

UVWXYXZ[ZX\]VWV_VYXW]aI��!�8I�P!%���I� �#!#��2��I�;�8 �I21�8�)

Q*&5�1���#*!J�&96���� �8�#!��8I���&47 �b* !)8!P#�� 9c�TTL>�T !8!P#2��*# !8�!%� !$!�!"�7 ��#*P! �&9#��J�&96����I��� ���$� �"�!&!�!#2"�8��) !8*"�I�;�8 �I�����I� �#!#*1�P�"�$�(

�)I�;�8 �I*">�

d#�!�!�5*&9#�� 9�"5&9 !I�;�8 �I#�'��8I�:!&4�$*Q��'��*# !8�!%� !$*1��8I���&47e*4��'��$&!)#!P��$57�5#!$*&9#�� 91�5Q��#��8����&4� ��I*�#!)�* 9�:*I"*$�&�'!P��$57�*$ !�#�� 9�8I�8*I* ��1��8!I*4�9�&!69�#*���!#�8*I*"� I�f�*::!##�� 9�$�(�)I�;�8 �I*"1�#*�8I*$ !$��!�"�I4�"57���ghijgk

lijmnopqrsningtujvgp>�a�I� �#!#��2��I�;�8 �I2�8I��� *�&47 ���!#�!��#*!J�&���:!&�'�#� !P�)�$!��I��#!%�!�I*�#��JI*�#2%��!����I�;�8 �I��>�w*���'��#46#!����#9��J#*I5Q�#��0� !8���x)y@)I�;�8 �I��1���� �4e!%�!�����8�� !8��>�w�$� �I2��8�� !821�4�&44�9�8I��"� �"�3$� �#�!�#���8�� ) I*#�&4;!�##���"��!:!$*;!!�"zwS�f�8I��5$ *� I*#�$I!8;!!���!#�'��'�#*1{�8��I*���&47 �4�#*�!��:�I"2�<�|1��0=>�

}~�����VWXYXZ[ZX\]VWV_VYXW]

w*!J�&96*4�8&� #�� 9�3$�8I���!!�x)y@��)

I�;�8 �I����J#*I5Q�#*���8I�:I�# *&9#���$�I�1�'����#!����&�P�#2���8I�;���2�"��5&4;!!�8*"4 !�!��#!"*#!4>�w��I�#2�8I�:I�# *&9#���$�I2�8I�)�;!I57 �4����"#�'!��8��$�I$��2��4�I*1��$&7P*4�"�#�*"!#�I'!P��$!�1�!���5e�� �&47 �#!�%��4e!��$�# I�&9�!%�*$ !�#�� !�KI!�>��O>�?*Q#���*"� ! 91�P ��8!I*"!�#2��#��I�#21�8I��;!I57e!��4����@�1�$�# I�&!I57 �*$ !�#�� 9�"���$�I !$*&9#2%���:*)"!#��2%�#��I�#��1�#��#��"���&!"J!P��$!%>�N*$!"��JI*��"1�*$ !�*;!4�x)y@

��)I�;�8 �I�����8I�:I�#)

*&9#���$�I������ �$��!� *&9#���*$ !�*;!!�"���)$�I !$*&9#�'��85 !�!�5��&!P�#!7��2���J�Q��#!4���:*"!#*����-�>�S*$�!����&5P*����(

�)I�;�8 �I*"!1�

�����*�!�!"*4�"��5&4;!4�*$ !�#�� !�8!I*"!�)#2%�#��I�#�����&�$ !�#2"!�*'�#!� *"!�x)y@

��)

I�;�8 �I���#��! �!#��I !I��*##2��R)�JI*�#2��%*I*$ �I�<�|=>�T$ !�*;!4�x)y@

��)I�;�8 �I����2�2)

�*� �'!8�I8�&4I!�*;!7�"�"JI*#2�3$�8I���!I57)e!%�!%�$&� �$>��$�&��.����8!I*"!�#2%�#��I�#��1�3$�8I���!I57e!%�x)y@

��)I�;�8 �I21� *$Q��3$�)

8I���!I5� �x)y@��)I�;�8 �I21�P �1�8�)�!�!"�"51�

� I*Q*� �:5#$;!�#*&9#2��*# *'�#!�"�x)y@��)�!�

�[�����w��I�#*&9#2��$�# 5I2�"�#�*"!#�I'!P��$���I�'5&4;!!�$�'#! !�#2%�:5#$;!��<8���01�x|1�|�1�|�1����1���!�">=

shagiakhmetov
Размещенное изображение
Page 6: STPN_2014_(Atypical Antipsychotics. Part 1 + 2)_Extended

��

����������

��� ������ ���������������� ���������

�������� ! "#$�$%�%�&$� �'$($%)$'$�*$+',�-�./0�

1,&2*�$3�,+$*4�%�56)&!2$),(7)$*�"(,) �,'$)2+*�%�$#)$8 )22���91

�:�� ! "#$�$%�%;+;%, #�# �< �

=55 &#;4�>#$�2�,)#,'$)2+*�%�$#)$8 )22���91�:�

� ! "#$�$%�-���4���?/0�@2) �'2+*���91�:�,'$)2+*,�

2���91�:�,)#,'$)2+*,�%�$#)$8 )22�'2" �"$(A�

�2+,!22�* *3�,);�"2�,*2B);C�) D�$)$%�&$�;�2�'2""$&,*",4�"$�%2B2*$*64�"$%;8, #�# �," %�#2> E&6F�=55 &#2%)$E#7�::G�"�2�82+$5� )22�-���/0�@63C�$)2> E&$ �%% B )2 �H@H4�"$�) &$#$�;*�B,));*4�"$%;8, #���91

�:�E%A+;%,FI6F�E"$E$3�

)$E#7�%�+$) �* B2,(7)$D�2�B$�E$(,# �,(7)$D�JKL�2�6* )78, #�"($#)$E#7�M

��� ! "#$�$%�3 +�&,&2C�(23$�

2+* ) )2D�%�=&E"� EE22���91�:��2�M

��� ! "#$�$%0�

N#2�B,)); �'$%$�A#�$�#$*4�>#$�E63C�$)2> E&$ �%% B )2 �H@H4�%�"�$#2%$"$($<)$E#7�$E#�$*6�OE*0�)2< P4�*$< #�),�68,#7�%;E%$3$<B )2 �E �$#$)2�),4�>#$�"�2%$B2#�&�&$*" )E,#$�)$*6�"$%;8 )2F�=&E"� EE22�"$E#E2),"#2> E&2C���91

�:�� ! "#$�$%�

2�$3QAE)A #�"�$&$')2#2%)6F�2�,)#2"E2C$#2> E&6F�=55 &#2%)$E#7���91

�:�,'$)2E#$%�%�<2%$#);C�*$�

B (AC�-R�/0�9 &$#$�; �::G4�),"�2* ��,+ ),"2)4�,�2"2"�,+$(4�&($+,"2)4�&% #2,"2)4�+2"�,E2B$)�2�(6�,E2B$)4�A%(AF#EA�=55 &#2%);*2�>,E#2>);*2�,'$)2E#,*2���91

�:�� ! "#$�$%0�S�#,3(2! �"�2% B �

);�",�,* #�;�TUVWXYUUYZ[\]W TU_W �OE*0�)2< P�) &$#$�;C�::G�%�$#)$8 )22���91

�:�� ! "#$�$%0�

S�<2%$#);C�*$B (AC�,)#,'$)2E#;��������� ! "#$�$%�

E)2<,F#�E"$E$3)$E#7�,#2"2>);C�,)#2"E2C$#2&$%�"$%;8,#7�&$�#2&,(7);D�6�$% )7�&,# C$(,*2)$%�2�&$*" )E2�$%,#7�B 52!2#�abc�2�'2" �($&$*$!2F4�%;+%,))6F�,)#,'$)2E#,*2�adM��-.4�?e4�??/0G$E* �#); �2EE( B$%,)2A�%;A%2(2�"$%;8 )2 �

"($#)$E#2��������� ! "#$�$%�%�($3)$D�2�%2E$>)$D�

&$� �6�",!2 )#$%4�E#�,B,FI2C�82+$5� )2 D4�>#$4�$> %2B)$4�A%(A #EA�&$*" )E,#$�);*�* C,)2+*$*�%�$#% #�),�E)2< )2 �&$�#2&,(7)$'$�6�$%)A�E �$#$)2),�-�e4��?4�.e4�e�4����4���f/0�g,)); 4�"$(6> )); �E�"$*$�I7F�GN14�#,&< �"$B#% �<B,F#�"$%;8 )2 �"($#)$E#2�����

���� ! "#$�$%�%�&$� �"�2�82+$5� )22�-���4����/0

9 �%;+;%, #�E$*) )2A4�>#$�6E2( )2 �&$�#2�&,(7)$D�����

���$"$E� B6 *$D�) D�$#�,)E*2EE22�

*$< #�2* #7�3$(78$ �+),> )2 �%�&$*" )E,!22�&$')2#2%);C�),�68 )2D�"�2�82+$5� )220�1,&4�>,�E#2>); �,'$)2E#;�����

���� ! "#$�$%�#,)B$E"2�$)�

2�36E"2�$)�6(6>8,F#�) &$#$�; �&$')2#2%); �B$�* );�6�",!2 )#$%4�E#�,B,FI2C�82+$5� )2 D�-ff4����4����/0�S,<)$�+,* #2#74�>#$�=55 &#�36E"2�$),�* ) �%;�,< )4�> *�=55 &#�#,)B$E"2�$),0�H,+)2!,�* <B6�)2*2�E$E#$2#�%�h%;�,< ))$E#2�,'$)2+*,i�j�E# " )2�%)6#� )) D�,&#2%)$E#2�2(2�=55 &#2%)$E#2�Oklmnklo�lpqrnst�uvvnwlwxP4�y

klm4�2+* �A *$D�%�"�$�

! )#,C�"$�$#)$8 )2F�&�,),($'2>)$*6�",�,* #�6�=)B$' ))$'$�(2',)B,�j�E �$#$)2),4�>7A�%)6#� ))AA�,&#2%)$E#7�6E($%)$�"�2)2*, #EA�+,�����z0�1,)B$�E"2�$)�j�"$>#2�"$();D�,'$)2E#�Oy

klm�{�ef�zP�-�.�4�

�RR/��������� ! "#$�$%�2�+),>2# (7)$�"� %$EC$B2#�

%�=#$*�"(,) �36E"2�$)�Oyklm�{��f4��zP�-�.�/0

:'$)2E#;���91�:�� ! "#$�$%�#,&< �6* )78,F#�

NG@�6�",!2 )#$%4�"$(6>,FI2C�# �,"2F�#2"2>);*2�) D�$( "#2&,*2�-ff/0�|�$* �#$'$4�"$&,+,)$4�>#$�

,'$)2+*�%�$#)$8 )22���91�:�� ! "#$�$%�E)2<, #�

"$#� 3( )2 �"2I24�6�$% )7�'(F&$+;�%�&�$%2�-�e/4�6(6>8, #�E &E6,(7); �56)&!22�-e�/4�E)2<, #�,'� EE2F�2�2*"6(7E2%)$E#7�-��4��f�/�2�"$%;8, #�&$**6)2&,3 (7)$E#7�-���/0�q}np~w�n�ut�duot�u}�-?�/�%�&,> E#% �)$%$'$�

"$BC$B,�&�# �,"22�&$')2#2%);C�),�68 )2D�"�2�82+$5� )22�"� B(,',F#�B$3,%(A#7�&�,#2"2>)$*6�,)#2"E2C$#2&6�#,)B$E"2�$)�2(2�B�6'$D�=55 &#2%�);D�,'$)2E#�����

���� ! "#$�$%0�

��������������������������������������������

��������  ¡�������¢�����£�¤¥¦§����������

 ¡¡ ©�������������������ª�«

¬­J�-�Rf/ .?�

�c­�-�Rf/ fe�

® °�-�.f/ f��

L±b�-�.f/ �R�

±c�-���/ RR�

b±��-�.f/ ���

c­²�-�.f/ ?�

£�¤¥³�����������������������

S;E$&$"$# )#); �E ( &#2%); �$3�,#); �,'$)2�E#;�����

��L�� ! "#$�$%�"2*,%,)E �2)4�d���?�.4�

²�fR�?µ�2�B�6'2 �=55 &#2%)$�"$B,%(AF#�%;+%,)�)6F�H@H�'2" �($&$*$!2F�-�f�/0�1$>)$�#,&�< �3;($�"$&,+,)$4�>#$�,#2"2>); �,)#2"E2C$#2&2�2�$3�,#); �,'$)2E#;���91

�:�� ! "#$�$%�"$B,%(AF#�

'2" �($&$*$!2F4�%;+%,))6F�%% B )2 *�¶|�e���2�& #,*2),�-���4����/0�1,&< �3;($�"$&,+,)$4�>#$�$E#�$ �%% B )2 �¶|�e���"$%;8, #�6�$% )7�E �$�#$)2),�%�'2""$&,*" 4�E#�2,#6* 4�5�$)#,(7)$D�2�"2�25$�*)$D�&$� �-�R�4���?/0�1,&2*�$3�,+$*4�E"$E$3)$E#7�adM��,)#,'$)2E#$%�%;+;%,#7�'2" ��($&$*$!2F�%�+),>2# (7)$D�E# " )2�$"$E� B6 #EA�����

���� ! "#$�,*2�-��R4���.4��f�/0�1,&< �3;($�

"$&,+,)$4�>#$�¶���?�.�+),>2# (7)$�=55 &#2%) �"$B,%(A #�'2" �($&$*$!2F4�%;+%,))6F�¶|�e��4�> *�,*5 #,*2)$*�-��4�f�4���R/0�·F3$";#)$4�>#$�E"$E$3)$E#7�$3�,#)$'$�,'$)2E#,�����

���� ! "#$�$%�

¶���?�.�"$B,%(A#7�'2" �($&$*$!2F4�2)B6!2�$�%,))6F�adM��,)#,'$)2E#,*24�"� B$#%�,I, #EA�"� B%,�2# (7);*�2E#$I )2 *�+,",E$%�E �$#$)2),�%% B )2 *�) $3�,#2*$'$�2)'232#$�,�WX W_¹º\U»¼X_] ½\¾¿�j�&(F> %$'$�5 �* )#,�E2)# +,�E �$#$)2),�j�X�C($�5 )2(,(,)2),0�g,))$ �),3(F�B )2 �B *$)E#�2�6 #�"�2)!2"2,(7)$ �+),> )2 �,&�#2%,!22���91

�:�� ! "#$�$%�2�E$C�,))$E#2�5$)$%$'$�

6�$%)A�E �$#$)2) �'2> E&$D�,&#2%)$E#2�%�"�$! EE �"$B,%( )2A�,)#,'$)2E#,*2���91

�:�� ! "#$�$%�'2�

" �($&$*$!224�%;+%,))$D�¶|�e���-��R/0��91

�@�,)#,'$)2+*�#,&< 4�$> %2B)$4�2* #�# �,�

" %#2> E&2D�"$# )!2,(�%�$#)$8 )22�$"� B ( ));C�),�68 )2D�",*A#20�À;($�"$&,+,)$4�>#$�) D#�,(7�);D�,)#,'$)2E#���91

�@�� ! "#$�$%�²µ��R��R�&$*�

" )E2�6 #�B 52!2#�" � B (&2�),%;&$%4�%;+%,));D�C�$)2> E&2*�%% B )2 *�H@H�-���/0�g�6'$D�E ( &#2%�);D�) D#�,(7);D�,)#,'$)2E#���91�

S@�� ! "#$�$%�

²µ���f�f�&$*" )E2�6 #�),�68 )2A�",*A#24�%;�

Page 7: STPN_2014_(Atypical Antipsychotics. Part 1 + 2)_Extended

����������

��

�� ��������� ����������� ������ ������

��������� !"�#����$��%�#�&'()���*�+,-.�/���0�1�%�2%#���� �"%��3��4"�!�����5��% !��+(67

�8(

"�9�2!�"���3���#���!�"�2%%�4�:%���;<<�=!%�������� !����:��%%�>?@�2� :�� A4B"��%C� =�5�����$�(�%D�EFE�="� �#G�$�#�� !"%"ADG�C!��4:�=�$���$�%B�!�:H=��+(67

�8("�9�2!�"�����$� !�!�C���$:D�!�5�G�

C!�4��A !"��%!H�=�5�%!%�������"AI��%DG�������(���� A4B"��%C� =%#�2"%#����%�#�EFEG����!:%C%���!�%B�;<<�=!%��� !%���2�$��:��%%�:�=�#�!�"��J��=!%��� !%�2"%�� !"�#����$��%%�EFE.�8��:�5%C����2"�$�#�� !"%"������%����!��I��%%�=�#4%��9%%�2%#���� �"%��� �5�:�2�"%$�:�#G� �%$�!�:H !�ADG�C!�� �C�!����J�4:�=�$��+(67

�8(�%�K

�("�9�2!�"���

!�=L����$� !�!�C��.�M�:���!�5�G�C"��#�"��D�4:�=�$��K�("�9�2!�"��� �%L��!�;<<�=!%��� !H��!%2%C��B�

��!%2 %B�!%=��.�7�=G�5�:�2�"%$�:���$�����G��#5N=5G�2"%#��D�#�J�2�"�$����$��%�#�"% 2�"%$���G�4:�=%"���:� 2� �4�� !H�2� :�$��5��=�#2�� %"���!H�$�<%9%!�>?@G���������J� A4B"��%C� =%#����$�(�%�#�EFE.�O!%�$������ �%$�!�:H !�AP!���!�#G�C!����!�"�2��!%C� =%B�$���B�88Q����������P!�C"��#�"��J�K�(4:�=�$�G�%���!�#G�C!��%B�;<<�=!%��� !H��2"�$�:D(�! D�2"�%#AR� !������ �"�!��%��"5C� =%#%�#�B�(�%�#�#%�*��S-.�8��:�5%C��#��4"���#�5�:�2�"%$�:�2"�$�!�"�R��!�;<<�=!%��� !H�:A"� %$����*��+-.�Q"%��$������$������ �%$�!�:H !�AP!���!�#G�C!��2"��� B�$ !�����!�5��%�#��88Q����!��I��%%�+(TU

�V(

"�9�2!�"�����$���!�5��%�#�#����!��I��%%�K��%#��!�

4�:HI������C��%�G�����5����$� !�!�C���$:D�=�#2��( �9%%�"� !"�J !��>?@G���������B� A4B"��%C� =%#����$��%�#�EFE�*�+�-.�W��$��#�% :�$����%%�4�:��2�=�����G�C!��#%"!���2%��A:ACI��!�=�5�%!%�����<A�=9%%�A�2�9%��!��G� !"�$�PR%B�$�2"� %�JG�2"%(C�#� !�2��H�A:ACI��%D����=�""�:%"A�!� �$%��#%=�J�$�2"� %���J� %#2!�#�!%=%.+(TU

�X(2�$!%2�"�9�2!�"���;= 2"� %"A�! D�% (

=:PC%!�:H�����9��!"�:H��J���"���J� % !�#��%�D�:D�! D�2"�$#�!�#�2� !!"�� ="%29%����J�#�($%<%=�9%%�#E6'G�C!���2"�$�:D�!� AR� !�����%������5��%��<�"#�*��+-.�Y :%�5���"%!H��!$�:H�����+(67

�F("�9�2!�"�BG� !�%!��R��"��� =���!H��4�%B�

"�:%����!�:H=����"�5A:D9%%�2%R���5��2���$��%DG����%��� !"���%D��� �D�%� �!�#G�C!��4:�=�$��+(67

�F(

"�9�2!�"���#�L�!�2���I�!HG���%B� !%#A:D9%D�2�($��:D!H��� ��4�L$��%��$�<�#%���%���"�$"���:%�����=�"��%�$�<�#%����� !"%�!A#��3���2"%:�L�R�#�D$"��Z>[\][_�V\\[ ab_c�>V\d�*+S-./���0�1�%�e�S,�0f��=���:% H�4�:���;<<�=!%�(

�����:�C��%%�� !"�J�I%��<"��%%G�C�#�2:�9�4�G����#�����;<<�=!%���G�C�#�5�:�2�"%$�:�*�+�G��+)-.�Q%#���� �"%������ !�DR����"�#D�2"�B�$%!�=:%(�%C� =%��% :�$����%D���=�C� !�����!%2% %B�!%=��$:D�:�C��%D�2 %B�!%C� =%B� � !�D�%J�A�2�9%��!��G� !"�$�PR%B�4�:���HP�Q�"=%� ���.

ghijklmnopqprsrptunlonvnwqpou

M�:HI������C��%����"�5A:D9%%�=�5�%!%���B�<A�=9%J��!��$%! D�+(67

S("�9�2!�"�#.�O!%�"�9�2!�(

"��:�=�:%�������2"�%#AR� !��������5%22�=�#2��%�=�"��5�:����5��#��5�G���%�!�=L�����:�C������2"�9� ��"�5A:D9%%��� !"���%D�*,0G���1-.�8=!A(

�:%��9%D�%�!�"� ��=�;!�#A�2�$!%2A�"�9�2!�"�����=��!�= !��<�"#�=�$%��#%=%���!%2 %B�!%=��� �D����� �!�#G�C!��"D$�88Q�Z�����2%�G�=:���2%�G�%:�2�"%$��G��:����2%��%� �"!%�$�:d�D�:DP! D�#�R��#%���!�5��% !�#%�+(67

S("�9�2!�"��.�Q�#%(

#��=�!�B�:�#%���G���!�5��% !��+(67S("�9�2!�"���

2���I�P!�!�=L��A"����H��9�!%:B�:%���%�5:A!�#�!����xyX�%�5%22�=�#2�G�C!���� ��P��C�"�$H�A:ACI��!�2�#D!H�%�=�5�%!%�����<A�=9%%�*+SG���)G��S)-.�F!%#A:D9%D�+(67

S("�9�2!�"��G���2"�!%�G� �%L�(

�!�A"����H�=�!�B�:�#%������:�4��J�=�"��*��1-.�F�:�=!%�����+(67

S(��!�5��% !��@z���(S10��%�{[�

V|+)�+��A#��HI�P!�$�<%9%!�>?@G���������J�� !"�#�%� A4B"��%C� =%#����$��%�#�EFE�%�&'()���*�+�G��0�-.�7�=L��"D$� �:�=!%���B���!�5��% !���+(TU

S("�9�2!�"������� !�DR����"�#D�2"�B�$%!�

=:%�%C� =%��% :�$����%D���=�C� !��� "�$ !��$:D�:�C��%D�4�:���%�8:H95�J#�"��*,S-.M�:HI������C��%��+(67

S("�9�2!�"��%#�P!�%�

��"�5A:D9%%�2%R���5��2���$��%D.�8�!�5��% !��+(67

S("�9�2!�"��� �%L�P!��22�!%!�%��� G��� �D�%�

�C�#�"D$� �:�=!%���B�+(67S(��!�5��% !���% :�(

$A�! D���=�C� !���2�!��9%�:H��B����"�= %5����B� "�$ !��$:D�:�C��%D��L%"��%D�*+)G�)+-.�

ghij}lmnopqprsrptunlonvnwqpou

F"���%!�:H�����$�����%�!�"� �2 %B�<�"#�=�(:�5���2"%�:�=�+(67

1(2�$!%2�"�9�2!�"��.�W�(2�"��BG�

��=�!�"����!%2%C������!%2 %B�!%=%�Z�����2%�G�:A"� %$��G�%:�2�"%$��G��#% A:H2"%$G�=:���2%��%�"% 2�"%$��d�%#�P!��� �=��� "�$ !���=�;!�#A�2�$(!%2A�"�9�2!�"���*�+�-G���(�!�"�BG����!�=�$�����4�(:���4��"AL���G�C!���#% A:H2"%$G�%��� !��J� ���J���!%$�<%9%!�"��J�%���!%$�2"� %���J��=!%���( !HPG�%#��!��� �=��� "�$ !���=�+(67

1("�9�2!�"�#G�

�� �:�=!%���J��5��% !�+(671("�9�2!�"���Ve�0�2"�(

2D! !�A�!�"���%!%P��5��2"�=�5�%!%���5��$�J !�%D�*�-.�W(!"�!H%BG�2�=�����G�C!��+(67

1(��!�5��% !��

�:%DP!����5%22�=�#2�:H��J���J"�5��������:�(5%C��� ��"�#����#���!%$�2"� ��!�#�*���-.�'�!�#A�L����%4�:HI�D�2:�!�� !H�;= 2"� %%�+(67

1(

"�9�2!�"����4��"AL������!�:�#A �G�5%22�=�#2��%�:�4��J�=�"��*)1G���+-.E����� C%!�:� HG�C!���#% A:H2"%$�D�:D�! D� �(

:�=!%���#�K�N,(��!�5��% !�#G�����!%$�2"� %�����

%���!%��5�!%����� ��J !����5���%�=%B�$���A�2�9%(��!��G� !"�$�PR%B�I%��<"��%�JG� �D����:% H� ��5�� 2� �4�� !HP�%�4%"�!�:H���4:�=%"���!H�2"� %(��2!%C� =%��$�<�#%������"�9�2!�"�.�FC%!�:� HG�C!��!�=�J� �:�=!%���J�4:�=�$���2�:���$� !�!�C���$:D����C%!�:H��5��A %:��%D��� ��4�L$��%D�$�(<�#%�����#���=�"!%=�:H��J� % !�#�G�!�=%#��4("���#G��� =�����:� H�%$�D���!�#G�C!���!%2%C�� !H���!%2 %B�!%=��#�L�!�4�!H�%���� �D�����J� ���(!�5��%�#�#�=� �"�!��%����#�"�9�2!�"�#�*�+�-.�W�$�J !�%!�:H�� !%��4��"AL���G�C!���#% A:H2"%$�D�:D�! D�#�R��#�=��=A"��!��#���!�5��% !�#�+(67

1(�%�+(67

�W("�9�2!�"���%�C!��%��#%�#%I�(

�D#%G�="�#��2�"��JG������#�L����4~D �%!H��5����!%$�2"� %����� ��J !�����������*�-.�Q�=�����G�C!���#% A:H2"%$�A:ACI��!�=�5�%!%�����$�#����

Page 8: STPN_2014_(Atypical Antipsychotics. Part 1 + 2)_Extended

��

����������

��� ������ ���������������� ���������

�������� ��!"#$��%&$'!(�)�*+�(,�-���.�/#0&-�"���%� �.���#�(�(�1$#/�$'�2-�(#1��%���2-���34&(!�5��6���4&($�.�%���+7�"���%'�5�8�6�+�/#$'�2)�9�:#*.&��&-;�<��!+$'".�4�#4#/.&��4$��$&0&����4�!%�������=%�$���5�>>6;�?�(@&�/2$#�"#(�:��# �0%#�#����$�&%!��A**&(%���2����%�4&".&!!��%#��5�B>6;�C�($���0&!(�)��!!$&4#�����)�/2$#�".#4&�#�!%.�3.#���# �0%#����!+$'".�4�!%#$'�@&�A**&(%��&� �(�(����".�����+�"�,�&�%#� �!%.�4�7D�)�4�!%���&-���/#$'9#-�4&".&!!�&- �"#�9(�$&�EFGHI�5��J6;K&$&(%���2-���%�1#��!%�L3M?

83.&,&"%#.#��

IN�BOO8��#!$�/$�&%�4&*�,�%�"&.&4&$(�����2(#� ��2:����2-�).#��0&!(�����&4&��&��PKP�5�L�6 ���%�(@&�"#4��$�&%�(&%����3��4+,�.#����+7�1�"&.3$#(#�#,�7�5B�6;�?�(@&�#/��.+@&�# �0%#�IN�BOO8��:��0�%&$'�#�#!$�/$�&%�4&*�,�%�QRH�"#!$&�).#��30&!(#1#���&4&����PKP�5�L�6;�<��!+$'".�4�%�(@&�:��0�%&$'�#�+$+09�&%�"#(�:�%&$��QRH �%#14��(�(�!+$'"�.�4�G

�SJ �#/$�4����&�'9�����%�1#��:�#��

��#%�#9&����L3M?83.&,&"%#.#� �0&�����!+$'".�4 �

+$+09�&%��)�$�9'�0�!%�0�#�5�L�6;�<��!+$'".�4�+$+09�&%�"#(�:�%&$��(#1��%���#-�1�/(#!%��(�(�+�:4#.#�2) �%�(���+�"#4�&.1�+%2)��#:4&-!%��7�!%.&!!��(.2!;�T#(�:��# �0%#���&��#�!�/$#(�4#-�L3M?

83.&,&"%#.#��!��:����&1#�!"#!#/�#!%'�!��@�%'�

�2.�@&��#!%'�A%�)�!%.&!!3��+4,�.#����2)���3.+9&��-�*.#�%�$'�2)�(#.(#�2)�*+�(,�-�5�8O6;�C2.�@&��+7�!"#!#/�#!%'�$+.�!�4#���+!�$���%'�(#.%�(�$'�2-��2/.#!�4#*��������A**&(%���#�(#�3"&�!�.#��%'��**&(%���+7���(#1��%���+7�!��"%#3��%�(+�!��:2��7%�!�!��&.1�:�#��#4�#�.&�&��#1#�L3M?

�<3�1#��:�����L3M?

83��%�1#��:���5O86;

?�(���#/.�:#� �#4�#:��0�#�+!%��#�$&���:�3��%&.&!#����#!%'�L3M?

83.&,&"%#.#��!&.#%#�����

��".#,&!!�)�.&1+$�,�����!%.#&������(#1��%���2)�*+�(,�- ���%�(@&�%# �0%#�L3M?

83��%�1#��!%2�"#�23

9�7%�(#.%�(�$'�2-�+.#�&�'�4#*��������!&.#%#3�����5O86;M&4���#�#4#/.&��2-�UGF��#�2-��+$'%��#4�$'3

�2-���%�4&".&!!��%��#.%�#(!&%���:��0�%&$'�#�+$+09�&%�(#1��%���2&�*+�(,���+�"�,�&�%#��:.&$#31#��#:.�!%� �!%.�4�7D�)�4&".&!!�&- ���!.���&����!�"$�,&/# �".�0&��4���#&�+$+09&��&��&���$�&%!��!$&4!%��&��.&4+(,���4&".&!!���2)�!��"%#�#����!%�%�!%�0&!(��:��0��#�#".&4&$�&%!��+@&�(�(#�,+�"&.�#-��&4&$��%&.�"���V�&D&�4#���!%+"$&������%�4&".&!!���#1#�4&-!%����5���6;�C#.%�#(!&%�� �"#���#���1�/�.#������#/.�%�#1#�:�)��%��!&.#3%#���� �%�(@&���$�&%!��"#$�2���1#��!%#��L3WX

�F �

0�!%�0�2���1#��!%#��L3WX�N�����%�1#��!%#��L3WX

�G �

L3WXJ���L3WX

83.&,&"%#.#��5�>O6;

YZ[\]_]abcdabebfgdahi�(��:�&!%�# �($#:�"���A**&(%���&&�%�"�03

�2)��&-.#$&"%�(#����$&0&����.&:�!%&�%�2)�!$+0�&��9�:#*.&���;�K.&4��<<T�($#:�"���#/3$�4�&%����/#$'9���#%�#!�%&$'�2��!.#4!%�#��(�j�3�4.&�#.&,&"%#.��;�C�%#�@&��.&���($���0&!(�&���".&($���0&!(�&��!!$&4#������"#(�:2��7% �0%#�".�!#&4��&��&���%�1#��!%��j

��4.&�#.&,&"%#.#��

�4�:#(!����(�%&.�"���%�"�0�2�����%�"!�)#%�3

(����5��8 ���>6���#$��:�"��#��5�J>6�"#�29�&%��)�A**&(%���#!%'���#%�#9&����(�(�"#:�%���2) �%�(����&1�%���2)�!��"%#�#��".��$&0&����%&.�3"&�%�0&!(��.&:�!%&�%�#-�9�:#*.&���;�P�!"&.�34#����&&%��&�'9+7�#%�#!�%&$'�+7��**���#!%'�(�j

�3.&,&"%#.�� �0&��($#:�"�� ��#�4#/��$&��&�

�4�:#(!����(�!+/A**&(%���#-�4#:&�.�!"&.�4#���+!�$���&%�&1#���%�"!�)#%�0&!(#&�4&-!%��& ��#��&�&1#�(�%�$&"%#1&��2-�A**&(% �".��A%#����/$74�&%!��"#�29&��&�(#.%�(�$'�#1#��2/.#!��4#*��������+!�$&��&�1$+%���%&.1�0&!(#-��&-.#%.��!��!!��;�k%��4���2&�"#:�#$�7%��&(#%#.2���!!$&4#��%&$���".&4"#$#@�%' �0%#�:��0�%&$'�#&�".&�#!)#4!%�#���%�1#��:���($#:�"����(�j

�3�4.&�#.&,&"%#.�����4�

��%�1#��:�#��(�G�3.&,&"%#.����#@&%�#".&4&$�%'�

&1#�!%#$'��2!#(+7���%�"!�)#%�0&!(+7�A**&(%��3�#!%'���4&$�%'�&1#�l�%�"�0�2�m�!.&4���%�"�0�2)�5���6;�n#$&&�%#1# ���%�4&".&!!��%2�����!&.�������.%�:�"�� �#/$�4�7D�&��2.�@&��2����%�1#3��:�#��(�j

�3�4.&�#.&,&"%#.�� �+!�$���7%�A**&(%�

%�"�0�2)���%�"!�)#%�(#� �#!#/&��#���#%�#9&�����&1�%���2)���(#1��%���2)�!��"%#�#��5�J �8� ���8 ��BJ ��B� ��OJ ��O� ���� ����6 ���+�&�'9�7%�!#"+%!%�+7D�&�4&".&!!���2&�".#��$&����5���6;�k%��($���0&!(�&���/$74&����%�(@&�!#1$�!+7%!��!�4���2���#�%#� �0%#��&�#/$�4�7D�-�!#/!%�&��2����%�"!�)#%�0&!(���4&-!%��&����%�4&".&!!��%�����!&.���+!�$���&%���%�"!�)#%�0&!(#&�4&-!%��&�!+/#"%���$'�2)�4#:�%�"�0�2)��&-.#$&"%�(#��5>O ��L� ��B�6 �.���#�(�(���<<T�$�9&��2)�:��0�3�#1#�!.#4!%���(�j

�3�4.&�#.&,&"%#.���5��> ��J> �

�LL6;�T#(�:��# �0%#�%�(���(#�/���,���".&"�.�3%#��"#�29�&%�+.#�&�'�4#*��������oUp�!)#4�2��!�($#:�"��#��#/.�:#��5B �>O ���L ��J> ��>� ��LL ��B�6;�q#.#9#��:�&!%���.#$'�j

�3�4.&�#.&,&"%#.#��

��.&1+$�,�����!%.#&���;�?�( ���".��&. �!0�%�3&%!� �0%#�A**&(%���.%�:�"��� ���%�4&".&!!��%� �#%�#!�D&1#!��(�($�!!+�QrIIF�sQturvuwxwuyz{�rxv�I|w{z}z{�Iwut~txwuyz{�Fx~zvw|uw��rx~� ���:��0�%&$'�#-�!%&"&���#"#!.&4+&%!��j

�3�4.&�#.&,&"%#.����5��O6;�

i.#�&�%#1# ���4�#-�#��!$&"#��"$�,&/#3(#�%.#$�.+3&�#���!!$&4#������/2$#�"#(�:��# �0%#�4#/��$&��&�!&$&(%���#1#�j

�3��%�1#��!%��-#)��/����(�*$+#(3

!&%��+�:��0�%&$'�#�+!(#.�&%���!%+"$&��&���%�34&".&!!���#1#�A**&(%����+�&$�0���&%�(#$�0&!%�#�.&!"#�4&�%#��5��J6;����%&.&!#����#!%'�j

�3�4.&�#.&,&"%#.#����.&3

1+$�,���+.#����4#*��������oUp�#/��!��&%!��%&� �0%#�(#.%�(�$'�2-�4#*�������&&%�4�#-�#&�".#3�!)#@4&��&;�T#(�:��# �0%#���4#*����&.1�0&!(#-����&.��,���".&*.#�%�$'�#-�(#.2 �"#���#��&:#3(#.%�(�$'�2) �+0�!%�+7%����#.�4.&�&.1�0&!(�&��&-.#�2 �".#&,�.+7D�&!��!74���:��p ���(#%#.2)�4#*�������$�&%!��(#%.��!��%%&.#��5�J ��� ���L6;�k%���*�(%#��%�(@&��#@�#�#/��!��%'��&".#".#.3,�#��$'�#���:(�-�+.#�&�'�A(!".&!!���"&.&�#!0�(��4#*��������oUp���%# �0%#�#/.�%�2-�:�)��%�4#*������:4&!'�".#�!)#4�%�1$���2��#/.�:#��:��!0&%�"&.&�#!30�(���#.�4.&��$��� �(�(#%#.#�+�4#*�������&&%�%�(#&�@&�!.#4!%�# �(�(����#.�4.&��$���5�B� ���> ���O6;�C�!��:��!�A%�� �(#�(+.�.+��:��"&.&�#!0�( �

Page 9: STPN_2014_(Atypical Antipsychotics. Part 1 + 2)_Extended

����������

��

��� � ������ ��������������������� ������

������������� �!"�����#�"$%��&�'��"��(���)�*�+���"�,-.�/012�032��342��4567�8"�������!��� &�"�$9�:�+��&�;���!&�"�"�,-.��� ��(���#�"$%��&�'��"��(���)�*����/<42�4�6����������������2�#���#���;�=�#��!���#&�>�! '?��� ���@�A�?�B&�9���A�#&���"����&��*����=9�����������;�>�! �9���C����"�/�12���67�D�! ��( '�#�"$%����� ��&� ��(��;��'��"�=���)�*����#�&��A��'�&���&�#!�9�&�>�! �����C!&"���&�#�>�$9�E

�+F�� �&���"�/5�62� � ����G�+

����!(2�""�������HIJKL���F� !�&����'!���"������&�#!�9�&�>�! �����C!&"�������@�#�������� ��+#�����/��32��1<67�8������C�!"=@��"�G����&*�&�&(2�>&��*�&�F���&� "�&��#����M���� "�&��#���M�="+�=�&!=�*�N�$*���;�F�&���*��F��&��;��@�9"�&����������������/���67�O�()�

�+��������A�#&��$��*�?&�F��(%���@��>�+

����&� G����"���;'�=A��� ��&� ��(��;��"$!"�F�G+����=�!���&�����2���!#���;�=!(����#��!���#&�>�+! �9�&��*����=9�!���&������;�>�! �9�#��� A�C��@�EPQ�/5367�D� �@���2�>&�� ��&� ��(����""���+����:

�+�;���!&�� ���������@��>�&��(���!��G��&�

�� ��(�$C�'��"��(���)�*���2�����������������!���&������/�12�4�62�#���B&�*�'��"��(�*����*���"��!&��&!=�!��G���$*���G��#�!����&*$" ����A�#&�+��"7�8"�������:

�+��&�;���!&�����@� !���2���"��� � �

��""��������@���#���2�"�!!&���"��"��&� ��&� ��(+�$C�'��"��(� �&�9���*���"�������*$�/�0�67�R��!!�>�! �=���)�*���"�=�&����=�%�@�)�����2�

"�@�� %�=����@����#!�9�)��*� ���;��2�#���#�+��;�����FN���#�"$%�������)�*����;�>�! �C���C+��&���!*�!!���"�;���"��*�*�@;��/��67�8���!&�=N���"��*=�'!&���"����2�>&��;�#����)�*����;�>�! ���!�!&�=����"��&���(�$9�#�� �� �"$9�!&�' &'��9�!"=@����!�"�@�� ��"����*���%(��� �&��$9�#�@�+&�"�$9�#!�9�&�>�! �9�!�*#&�*�"2�&�;��� � ����+F�����!&�C �������"�����@��'?N�����;�&�"�$���� �;��&�"�$����!!&��C!&"��!"=@��$�!�;�#�)'� +A��C���)�*����;�>�! �C���;�'&�*�&��;�>�! �C���C��&���!*�!!���"�,-.7�S� G��'!&���"����2�>&��"�!�*(=9�F��(�$9�%�@�)�����C�#�"$%����>�!&�&��"!&��>��*�!&��"�����"�;�������=� �&�9��+��&�+*�+&��&���!)���@$�T.UVWX�M�;��"��;��)��*��&�2�"�+"��>����;��"� �&�F���@*���)�*����"�,-.�/�42��5<67�Y�����"$!� �=� �&�F���>�! �=�� &�"��!&(�"�����+"�;�������=�.UVW��#�����=�&�F�������@ �C�'��"��(�#��)���&��(��;����)�*������F�����"$��G���$C� �;��&�"�$C���)�A�&�'�&� �9�#�A���&�"�/���67JF���'G���2�>&��#!�9�@�#���F�$��!�!&�=��=�'�

G�"�&�$92�"�@�� �?N���"!���!&"���!��G���=�B !+#��!!���QP

�+!'FZ�����A$�QVE[+��A�#&���2�#��"��+

;�?&!=����' A���#�����C!&"��*���&�#!�9�&�>�! �9�#��#���&�"�/�3067�R����>�! �������$����*��!&��+�'?&�@��>�&��(����!��G�����)�!)�������"���=�QP

�+!'FZ�����A��QVE[+��A�#&����"�#��)���&��(+

��C� ������;�##� �*#��#���%�@�)������/5�67R����>�! ����!!����"���=�#� �@$"�?&2�>&��

��=���� "�&��;����&�#!�9�&�>�! �;���&"�&�2�#���&���#���&�#�>�$*����C����#&� �*�2���#��*���;���#�������*2����F9���*����!&�>(�0��\�F�� �+�$�!&�����$9�E

�+��A�#&���"2�"�&��G��"��*=�B !+

&��#���*���$��!�*#&�*$�T]DHX�"�@�� �?&�'G��

#���!"=@$"�������&�;���!&��!�<��\�E�+��A�#&���"�

/5167�H���';�C�!&����$2���&�#!�9�&�>�! �����C+!&"��� ��@�#������@"�"��&!=�'G�����)����F�� ��$��5�\�!&�����$9�E

�+��A�#&���"�/�142��<12��5�67�

L��)������>���=� ��@�#���*�]DH�)� &�>�! �����"�@�� �?&2�����;��#��)��(�F�@�#�!��!&�2�!"=@��+�$C�!�"$!� �*���! �*��;���'��A�&�@�2�B#�#��#��+ �"2�*�&�F���>�! �9����'%���C2�;�#��!���A��C���9�������&�>�! �*���C!&"��*2�!��(�@����;����>�+"��&��;�� ����>�! ���#��*�������/�1�67N������C��!�F����!&(?�OOD2��&��>�?N�C��9�

�&�&�#�>�$9�E�+F�� �&���"2�="�=�&!=�"��=�������

� &�"��!&(���@��>�$9�#��� A�C���)�*���"�;��*�@���*F�>�! �;��#'&�7�_"��#����@������=�Q[�M�=����/Q[�abc6����F���> ��/Q[�decff6�M�"�"��>��$�"���;'�=A�?�*�&���$9�����*F�>�! �9�)'� A�C�!�+�&"�&!&"�����/��67�OOD�#�"$%�?&�"$!"�F�G��������)�*����#���*'N�!&"�����"��F���> '�Q[2�"�&��"��*=� � �;���#�������#�"$%��&� ��A��&��A�?���)�*����#���*'N�!&"�����"�@����=����Q[7�

ghijklmniopqrosqtmjuvmwrmjrxopmyzz{|}}~����{����v��}�z{�

�����������������������������������������������������������������������������������������������������������������������������

�v��vm�y�����y �z�¡m��¢���~m�z�z�m£�¢��z��¤m¥��z�z�z���m¦�z����~m

�§���z��§m©��z��m�m¦��§�~��¤

[ªa«¬�­ec�®­°±®f�®«­±°d ea­±d2�­ec�²abf³d�ªad­�²±³cf�µdc³����®bc¶�°ba­a­°±®f�®­°±®f�®«­±°d ea­±�fa·®°±«c2�®b±°±°b®·afc2�®ª±dµf°b±³c2�®dc«®°±«c2�·±°b®+d±³a«c2�±fa°cb±³a«c2�µc­±®°±«c2�fµb®d±³a«c2�af®«·®°±«c2�°®f±°cb±³a«c2�b±d°cb±³a«c�®«³�dcb­±«³afc7�.a«­cª°ab®b�f±«±®f�d­µ³±cd�³a�«a­�®ffa²�±³c«­±¹±«¬�®�³±d­±«­±ºc�¹c®­µbc�a¹�°d ea­ba°±�®­±º±­�d°c­bµª�a¹�c®e�d°c±¹±�®«­±°d ea­±7�»a²cºcb2�±«�°b®­±c�²c�®«�a¹­c«�a¼dcbºc�®�°®b­±µf®b�c¹¹±±c« �a¹�®�cb­®±«�®«­±°d ea­±�³bµ¬�¹ab�®�°®b­±µf®b�°®­±c«­7�½«�­e±d�­ecabc­±®f�d­µ³�²c�®­­cª°­�­a�d°c±¹�­ec�°add±¼fc�bafc�a¹�aªªa«�°e®bª®afa¬±®f�­®b¬c­d�a¹�®­°±®f�®«­±°d ea­±d�²±­e�bcd°c­�­a�­ec�®º®±f+®¼fc�³®­®�a«�­ec�°®­ea¬c«cd±d�a¹�de±·a°ebc«±®7��,bcf±«±®f�³®­®�¹baª�®«±ª®f�ªa³cfd�a¹�de±·a°ebc«±®2�³cªa«d­b®­c�­e®­�®«­±°d ea­±�¾®­°±®f±­¿�ª®�«a­�a«f�®­­b±¼µ­c�­a�5+»W

�[�bcc°­ab�®«­®¬a«±dª2�¼µ­�b®­ecb�­a�­ec�®¼±f±­�a¹�

­ecdc�³bµ¬d�­a�®­�®d�®�³±bc­�5+»W�[�bcc°­ab�®¬a«±d­d�®«³�

5+»W�.2�5+»W

32�5+»W

0�®«³�F

��®³bc«cb¬±�bcc°­abd�°a­c«­�

®«­®¬a«±d­dÀ±«ºcbdc�®¬a«±d­d7�Wecdc�bcc°­abd�®bc�±«ºafºc³�±«�bc¬µf®­±a«�a¹�³a°®ª±«c�®«³�«abc°±«c°eb±«c�bcfc®dc�±«�°bc¹ba«­®f�ab­cÁ�®«³�­eµd�°f®d�®�b±­±®f�bafc�±«�a¬«±­±ºc�°cb¹abª®«c2�ªa­±º®­±a«�®«³�ªaa³7�Pcc«­�d­µ³±cd�e®ºc�®fda�bcºc®fc³�­e®­�³±¹¹cbc«cd�±«�°e®bª®afa¬±®f�®­±º±­�ª®�®fda�®­­b±¼µ­c�­a�­ec�³bµ¬d�®¼±f±­�­a�®¹¹c­�­ec�dca«³�ªcddc«¬cb�dd­cª7�Wec�cÁ±d­c«c�a¹�ªµf­±°fc�®­±ºc�a«+¹abª®­±a«d�a¹�®�bcc°­ab2�aµ°fc³�²±­e�­ec�®­±º®­±a«�a¹�³±¹¹cbc«­�Â+°ba­c±«�®«³�"+®bbcd­±«�°ad­µf®­cd�­ec�°add±¼±f±­�a¹�f±¬®«³�­a�±«³c°c«³c«­f�bc¬µf®­c�³±¹¹cbc«­�±«­b®cffµ+f®b�®d®³cd7�Wecdc�f±¬®«³d�®«�®fda�³±¹¹cb�±«�­ec�³c¬bcc�a¹�±«­b±«d±�c¹¹±® �TÃ

ª®ÁX�¹ab�c®e�d°c±¹±�±«­b®cffµf®b�

d±¬«®f±«¬�°®­e²®7

Ä���Å������®­°±®f�®«­±°d ea­±d2�Æ+ad±ff®­±a«2�QVE[2�E

�2�E

�Ç2�E

�È2�5+»W

�2�5+»W

32�5+»W

02�:

�2�bcc°­ab�

®¹¹±«±­�°ba¹±fc2�±«­b±«d±�c¹¹±® 2�¹µ«­±a«®f�dcfc­±º±­2�Â,.P2�/15È6ÂW,ÆÈ2�É+®bbcd­±«2�ÃPÊ7

Page 10: STPN_2014_(Atypical Antipsychotics. Part 1 + 2)_Extended

Page 1/1

shagiakhmetov
Пишущая машинка
shagiakhmetov
Пишущая машинка
Амисульприд
shagiakhmetov
Пишущая машинка
Арипипразол
shagiakhmetov
Пишущая машинка
Азенапин
shagiakhmetov
Пишущая машинка
Клозапин
shagiakhmetov
Пишущая машинка
Илоперидон
shagiakhmetov
Пишущая машинка
Лурасидон
shagiakhmetov
Пишущая машинка
Оланзапин
shagiakhmetov
Пишущая машинка
Палиперидон
shagiakhmetov
Пишущая машинка
Кветиапин
shagiakhmetov
Пишущая машинка
Рисперидон
shagiakhmetov
Пишущая машинка
Сертиндол
shagiakhmetov
Пишущая машинка
Зипрасидон
shagiakhmetov
Пишущая машинка
Профиль рецепторной аффинности ААП (pKi)
shagiakhmetov
Пишущая машинка
Page 11: STPN_2014_(Atypical Antipsychotics. Part 1 + 2)_Extended

����������

��� � ������ ��������������������� ������

��������� �����!�"#��$�% &#'()� !"#*!�+�'� ,�-'���./ ��#,�����!$�� �,�*�#!�'$� 0��!�( 12

3454657897:;<=>?6

3@AB6CD7E9>F7GHFIJ6F7KLFIJ6E<F=M6F7MN>G>899O

PQRSTUVWTXTYZ[\UVZWTX]T\WT_ UUaTQRUZVTbcdefRRUQV]XQ]WQVZRZTRUXdgYTdTUhiUjUXQW WTbXTYR]_TkUVWTXT_U_dlVXTZmUVQTXTXQVldmUVaT]gdebXQTSmUVlRZVXTZmUlTXQV]TSZmUTdXRQTSZmU_RWTVXTZmUdgQV]TSZmUdVZlVXTZmUXVdTXRQTSZmUQT]XRQTSZUTU]RQWTZSdnUodTZTYR]_TRUT]]dRS VZTpUZVU] QRaRZbZaUqWVXRUZRUXl dprWU[pTWeUWdTYTWRdeZ[RU]cRZZ]WTU]XR_WQVUX]T\WQXZkUV_WTZ]WTU_VsStU_Z_QRWZtUVZWTX]T\WT_VnUuRaUZRUaRZRRUU_dTZT_RUa[UYV]W UasRaUZVcdrSVWeUTZbSTTSgVdeZgrUXQRSXYWTWRdeZgrUqvvR_WTZ]WeUXQRSRdRZZtUXQRXVQVWVUgU_Z_QRWZtUXVwTRZWVnUxUSVZZaUWRQRWTYR]_aUT]]dRS VZTTUXQRSXQTZpWVUXX[W_VUg]WVZ TWeUlasZRUlZVYRZTRUvVQaV_bdtTYR]_T\UaTfRZRkUVWTXTYZ[\UVZWTX]T\WT_ UU]RWRUTaRryT\]pUSVZZ[\UUXVW tRZRlRUfTlvQRZTTnUzVZZ[RUS_dTZTYR]_T\UT]]dRS VZTkU]UXQTaRZRZTRaUZVTcdRRUVdTSZ[\UsT WZ[\UaSRdRkUfTlvQRZTTU]TSRWRde]W grWUUW amUYW U{VWTXTYZ]We|U]bQRaRZZ[\UVZWTX]T\WT_ U]plVZVUZRUW de_U]UT\UVZWVtZTlaaUUWZfRZTTU}b~�

i�bQRwRXW Q mUZUTmU

`lasZUSVsRUUcdefRkU]WRXRZTmUXQRSRdpRW]pUT\U]X]cZ]WerU[]WgXVWeUUQdTUXQpa[\UVtZT]W U}b~�

h�bQRwRXW Q UTUayZ[\UVZWVtZT]W �cQVWb

Z[\UVtZT]W U}b~�i�mU}b~�

�mU}b~�

�U]RQW ZTZ [\U

TU�iUVSQRZRQtTYR]_T\UQRwRXW Q nU�_VlVZVUQdeU

SVZZ[\UQRwRXW Q UUQRtgdpwTTUXQRvQZWVdeZtUgQ ZpUSvVaTZVUTUZQVSQRZVdTZVmUYW mUU] rUYRQRSemUTaRRWU_QTWTYR]_RUlZVYRZTRUUQRtgdpwTTU_tZTWTZ[\UvgZ_wTkmUaWTVwTTUTUZV]WQRZTpnU�]]dRS VZTpUX]dRSZT\UdRWUWV_sRUX_VlVdTmUYW UQVldTYTpUUvVQaV_dtTYR]_kUV_WTZ]WTUdR_VQb]W RZZ[\U]QRS]W UatgWUZ]TWeU_gSVUcdRRUtdgcb_TkU\VQV_WRQU]UgYRW aU]cRZZ]WRkU lSRk]W TpUZVUgQ ZRUW QTYZ[\UX]QRSZT_ nUPgyR]W ^VZTRUaZsR]W VUV_WTZ[\U_ZvQaVwTkUQRwRXW QVmU]XQpsRZZ[\U]UV_WTVwTRkUQVldTYZ[\U�bcRd_ UTU�bVQQR]WTZ mUXQRSRdpRWU lasZ]WeUSTvvRbQRZwTQ VZZkUQRtgdpwTTUdTtVZSVaTUZRlVT]Ta[\UZgWQT_dRW YZ[\U_V]_VS nU�QTUqW aUdTtVZS[UWV_sRUatgWUQVldTYVWe]pUXU]WRXRZTUZgWQRZZRkUqvvR_WTZ]WTU��

����UUWZfRZTTU_VsStU_Zb

_QRWZtUXgWTUZgWQT_dRW YZkUXRQRSVYTU]TtZVdVn

������������������� �¡¢£¤��¢�� ¥�¦§���©�ª«§¥¬�­­®¬�®©�°±²©�±

�©�±�³©�±�©�µ«¶·

�©�µ«¶·©�µ«¶·

¹©�

º�«»¤¬¤ �§»©� »§¼�­½��¼¼�¢¢§¥��©�¾¢¿�»¤¢¢®®�À¼¼¤��¾¢§¥�½©�¼¿¢¬�§¢�­½¢�®�¥¤­¤��¾¢§¥�½©�ÁÂÃÄ©�ÅƵ ÇÁ·Âª©�È«�»»¤¥��¢©�ÉÄÊË

ÌÍÌÎÏÐÐÌÍÑÒ�ÓÒÔÕÐÖ×ØÏÙÏÚÑÌØÐÌÔÌ�ÛÜÕÒÝÌÖÏÞÍÑÛÒß

à­�¥¥�¡¤¥�¤� »¤á¥��¾­¤¢�®�§�¼�»â�§­§ã���»¤¬¤ �§»§¾� »¤á¿¥â��»�¾�ä��¾§åâ§æ¢§¥�½�¤á�¢«¥�¾¤¢¢§ã§�»¤å¿­½�����¾å��â§á¤ç¥�¾�®�­�ã�¢á��¥�»¤¬¤ �§»§âË�è§ã­�¥¢§�À��â� »¤á¥��¾­¤¢�®â©� §­«¢£¤��­��¡�¥��¡¢£¤��㧢�¥�£�â§ã¿�����¾�»§¾��½�­�é½�§á�¢� ¿�½�¾¢¿�»�­¤�§¡¢§ç� ¤»¤á�¡��¥�ã¢�­�Ë�觧�¾¤�¥�¾¤¢¢§©��¢��㧢�¥��â§æ¤��­�é½�å�ê­§�«»§¾��½�¾§åá¤ç¥�¾�¤��㧢�¥��Ë�à­ä¡¤¾§¤�⤥�§�åᤥ½�å�¢�â�¤��§¢¬¤ ¬�®�ZgWQRZZRkUV_WTZ]WTUTdTUZgWQRZZRkUqvvR_WTZ]WT©�¥§ã­�¥¢§�§�§»§ç� §­¢£ç��㧢�¥��§ê­�á�¤��â�¥�â�­½¢§ç�¾¢¿�»¤¢«¢¤ç����¾¢§¥�½ä���â�¥�â�­½¢§�¥��â¿­�»¿¤��¾¥¤�§â §¢¤¢�£�­¤�§¡¢§ã§�§�¾¤��� §¥­¤�¥¾®å£¾�¢�®�¥�»¤¬¤ �§»§âË�ë�¥��¡¢£ç��㧢�¥��¾���§â�¥­¿¡�¤��⤤��⤢½é¿ä�¾¢¿�»¤¢¢ää����¾¢§¥�½���¾£«å£¾�¤���¡¤¥�¾¤¢¢§��§��æ¤�§�¾¤�©�¡�§��� §­¢£ç��㧢�¥�©�¢§�¾�⤢½é¤ç�¥�¤ ¤¢�Ë�ì¢��㧢�¥��æ¤�¾���§â�¥­¿¡�¤�®¾­®¤�¥®�¢¤ç�»�­½¢£â�­�ã�¢á§â©�­�«é¤¢¢£â�¾¢¿�»¤¢¢¤ç����¾¢§¥��©�¢§�¥ §¥§ê¢£â�å�«ê­§�»§¾��½�»¤¬¤ �§»©� »¤ ®�¥�¾¿®�¤ã§����¾�¬��� §á�á¤ç¥�¾�¤â��㧢�¥����­��¡�¥��¡¢§ã§��㧢�¥��Ë�ë�¥��¡¢£ç��㧢�¥��¾� »�¥¿�¥�¾��� §­¢§ã§��㧢�¥���§¢¿»�»¿¤��¥�¢�â�å��»¤¬¤ �§»��� »§®¾­®¤�©����â�§ê»�å§â©�¥¾§ç¥�¾��¼¿¢¬�§¢�­½¢§ã§��¢��㧢�¥���Å�ÇË�í��¤¡¤¢�¤� §¥­¤á¿äî�¦�ᤥ®��­¤��ç�¥��­§�§¡¤¾�ᢣâ©�¡�§����®�â§á¤­½�®¾­®¤�¥®�¿ »§î¤¢¢§ç���¢¤�§ �¥£¾�¤��¾¥¤ã§�»�墧§ê»�å�®�À¼¼¤�§¾©�¾£«å£¾�¤â£¦�»�å­�¡¢£â��­�ã�¢á�â�Ë�§� §�å�¢§©�¡�§�»�å­�¡¢£¤��㧢�¥�£�â§ã¿�����¾�»§¾��½�»�å«­�¡¢£¤� ¿���¾¢¿�»�­¤�§¡¢§ç� ¤»¤á�¡��¥�ã¢�­�©����¢��㧢�¥�£�â§ã¿��§ê­�á��½�¢¤ã���¾¢§ç�¾¢¿«�»¤¢¢¤ç����¾¢§¥�½ä�ð§ê»��¢£¤��㧢�¥�£ñ��­��ê£�½�ò��¦�â�ó�ðò¢¤ç�»�­½¢£â�óñ���ê­§�»§¾��½�¾§åá¤ç¥�¾�¤��㧢�¥�§¾©�¾��§â�¡�¥­¤���§ê»��¢£¦Ë�ô�æ¤�꣭§� §�å�¢§©�¡�§��¢��㧢�¥�£�â§ã¿��¾£«å£¾��½��¢�¤»¢�­�å�¬�ä�»¤¬¤ �§»§¾���¥¢�æ��½��¦�À¥ »¤¥¥�ä�õ�À¼¼¤�£©�§�§»£¤�»�¢½é¤�¥¾®å£¾�«­���§­½§�¥�¾§åá¤ç¥�¾�¤â��㧢�¥�§¾Ë�ৢ¬¤ ¬�®�vgZ_wTZVdeZkU]RdR_WTZ]WT�­�ã�¢á§¾� »¤á«¿¥â��»�¾�¤��¾§åâ§æ¢§¥�½�á�¼¼¤»¤¢¬�»§¾�¢¢§ç����¾�¬��ö�¢ã�ê�»§¾�¢�®�§¢»¤�¢£â�­�ã�¢á§â����¢§¢�¡¤¥�¦� ¿�¤ç�¾¢¿�»�­¤�§¡¢§ç�¥�ã«¢�­�å�¬��©�¢� »�⤻�§ §¥»¤á¿¤â£¦�Á«ê¤­�â�©������¢¤�¢§¢�¡¤¥�¦©����¦©��©�¢� »�⤻©��«��¾�¬�®÷È«�»»¤¥��¢§¾�Å�µ�ÇË�í�á¤ç¥�¾��¤­½¢§¥���ꧭ½é�¢¥�¾§�»¤¬¤ �§»§¾©�¥§ »®æ¤¢¢£¦�¥�Á«ê¤­§â�

Page 12: STPN_2014_(Atypical Antipsychotics. Part 1 + 2)_Extended

����������

���� ������ �������� �����������

������� !"�#�$�% &�' ( ����)��*#'+,�-./012-0.3�4.�5671867�4.9:;252<=>�;403-261.37?4=>�@-7A.557;,�5;B9=;:B58�C71..�?.<�5�7D42<�;2D7<���C.16:EF7/1:547�61:552?.567G�674H7-<:A27447G�<7�

D.12,�;�7350353;22�12/:4D:�-.A.@37-�<7I.3�50J.�53;7;:38�;�4.:632;47G��'+�2�;�:632;47G��'K+�H7-<.��674H7-<:A22+E�L-2�M37<�;�@7@01BA22�-.A.@37-7;,�4:>7DBJ2>5B�4:�@7;.->47532�61.362,�4:C1ND:.35B�D24:<2?.567.�-:;47;.52.,�3E.E�;5./D:�50J.53;0.3�[email protected]:B�H-:6A2B�-.A.@37-7;,�4:>7DBJ2>5B�;�57537B422�:632;47G�674H7-<:A22�D:I.�;�73503�53;2.�:/74253:E�O373�0-7;.48�H747;7G�:632;47532�4:9=;:.35B�PQRSTUTVTUWRQX�YPTUWRQSTZ[�-.A.@�37-7;E�F�M32>�@792A2G�:/74253�B;1B.35B�12/:4D7<,�2<.NJ2<�4:2C718\..�5-7D53;7�6�-.A.@37-0,�4:>7DBJ.<05B�;�57537B422�:632;47G�674H7-<:�A22�2,�;9:2<7D.G53;0B�5�42<,�53:C21292-0.3�./7E]�4:7C7-73,�12/:4D,�;.D0J2G�5.CB�6:6�7C-:34=G�:/74253,�53:C21292-0.3�-.A.@37-�;�57537B422�4.�:632;47G�674H7-<:A22,�542I:B�3.<�5:<=<�0-7;.48�6745323032;47G�:632;47532�;�D:447G�@7@01BA22�-.A.@37-7;E�.6737-=.�12/:4D=�4.�73D:N3�@-.D@7�?3.42B�37G�212�247G�674H7-<:A22E�F:<2�@7�5.C.�3:62.�12/:4D=�4.�5D;2/:N3�D24:<2?.567.�-:;47�;.52.�;�30�212�240N�537-740,�47�@-.@B353;0N3�5;B�9=;:42N�5�-.A.@37-7<�D-0/2>�12/:4D7;,�;=530@:B,�3:62<�7C-:97<,�;�-712�4.G3-:184=>�:43:/742537;E�_:62<�7C-:97<,�;�M37G�<7D.12�;.12?24:�;403-.4�4.G�:632;47532�212�MHH.632;47532�:/74253:a

bcd,�

6712?.53;.447�>:-:63.-290NJ:B�5@757C47538�12/:4D:�:632;2-7;:38�-.A.@37-,�@-.D53:;1B.35B�6:6�/.7<.3-2?.562G�@:-:<.3-,�5773;.353;0NJ2G�7347\.42N�:HH244753.G�D1B�:632;47G�2�4.:632;�

47G�674H7-<:A2GE�F@757C47538�6746-.347/7��*#'�4.9:;252<7�:632;2-7;:38�-:912?4=.���C.162�7Ce�B54B.35B�50J.53;7;:42.<�4.5671862>�:183.-4:32;�4=>�:632;4=>�674H7-<:A2G�-.A.@37-:��'f,�'g�2�3EDE+�5�-:912?4=<�5-7D53;7<�6�-:94=<�32@:<���C.167;�2�5@757C47538N�9:@056:38�5773;.353;0NJ2.�6:56:D=�;403-261.37?4=>�-.:6A2GE�_:6:B�<7D.18�@7530�12-0.3�;79<7I47538�50J.53;7;:42B�12/:4D7;�5�-:912?47G�:HH2447538N�D1B�6:ID7G�6746-.347G�674H7-<:A22�2,�3:62<�7C-:97<,�5@757C4=>�7-2�.432-7;:38�[email protected].�-.A.@37-:�;�4:@-:;1.422�[email protected]=>�6:56:D7;�;403-261.37?47G�@.-.D:?2�52/4:1:�hD1B�C71..�@7D-7C47/7�7C97-:�5<E�i�,���i,��ji,��k�lE�_:62<�7C-:97<,�73D.1847�;9B3=G�12/:4D�<7I.3�@-7B;1B38�:/7429<�;�7347\.422�7D42>�;40�3-261.37?4=>�57C=32G�2�:43:/7429<�;�7347\.422�D-0/2>,�@-2?.<�7312?2385B�73�D-0/2>�12/:4D7;�@7�;403-.44.G�:632;47532�;�7347\.422�6:ID7/7�6746-.347/7�@-7A.55:E�m�<2-7;7G�123.-:30-.�D1B�7C794:?.42B�3:62>�H046A274:1847�n:52<<.3-2?�4=>o�12/:4D7;�[email protected]�3.-<24�p!cq &�%!rc"&,�6737-7<0�;�-05567<�B9=6.�D7;71847�517I47�4:G32�MHH.632;4=G�5<=517;7G�M6;2;:1.43,�794:?:NJ2G�3-7@47538�12/:4D:�6�37<0�212�247<0�MHH.637-47<0�6:56:D0E�F230:A2B�0517I4B.35B�3.<,�?37�D1B�7D47/7�2�37/7�I.�@7D32@:�-.A.@37-7;�;�9:;252<7532�73�2>�:4:37<2?.567G�176:129:A22�<7I.3�C=38�[email protected]�7/-:42?.44=G�[email protected]�;403-261.37?4=>�@03.G�@.-.D:?2�52/4:1:E�:@-2<.-,�57<:37D.4D-234=.�k�st

�u�:037-.A.@37-=,�176:1290NJ2.5B�4:�3.1:>�5.�

-737424.-/2?.562>�4.G-747;�v'w,�[email protected]=�5��x!i�

50Ce.D242A.G���C.16:,�37/D:,�6:6�k�st�u�-.A.@37-=,�

[email protected].<=.�;�/2@@76:<@.,�5;B9=;:N35B�5��x��

50Ce.D242A.GE�m�67-.�2�/2@73:1:<05.�[email protected]�-0N35B�7C:�@7D32@:�50Ce.D242A�h�ijlE�:�0-7;4.�;37-2?4=>�@75-.D4267;�k�st

�u�-.A.@37-�[email protected]

5�24/2C2A2.G�:D.421:3A261:9=�;�/2@@76:<@.,�47�4.�;�v'w,�/D.�74�[email protected]�5�24/2C2-7;:42.<�5243.9:�247923713-2H75H:3:��y*

i+,�?./7,�;�5;7N�7?.-.D8,�

4.�4:C1ND:.35B�;�/2@@76:<@.E�m�67-.�/717;47/7�<79/:�k�st

�u�-.A.@37-�;=9=;:.3�H75H7-212-7;:�

42.�z'{�|���zd��c( %%$%c��q!r"c%�� r$%c� &�}!"cq +,�:�;�

/2@@76:<@.�24/2C2-0.3�./7E�~�kk���B;1B.35B�B-62<�@-2<.-7<�-./274�[email protected]?47/7�:/74253:E�~�kk���B;1B.35B�@714=<�:/742537<,�5.1.632;4=<�;�7347\.�422�67-67;=>�k�st

�u�-.A.@37-7;�2�;�[email protected]<.43:>�

4:�I2;734=>�@7;=\:.3�0-7;.48�67-67;7/7�D7H:<2�4:,�4.�@7D:;1BB�:632;47538�5.-737424.-/2?.562>�4.G-747;�v'w�h�jjlE�_:62<�7C-:97<,�;=-:I.447538�?:532?47/7�:/7429<:�2�@:-:<.3-=�:HH2447532�12�/:4D:�4:�5./7D4B\42G�D.48�4.�B;1BN35B�./7�25?.-�@=;:NJ.G�>:-:63.-253267G,�3:6�6:6�7D24�2�373�I.�12/:4D�;�7347\.422�6746-.347/7�-.A.@37-:�<7I.3�;=530@:38�;�-712�:/74253:,�:43:/74253:�2�7C-:347/7�:/74253:�7D47;-.<.447E��:6�C=17�0@7<B4037�;=�\.,�;�123.-:30-.�<7I47�;53-.3238�6712?.53;.44=.�>:-:63.-253262�;.12?24=�?:532?47/7�:/7429<:�D1B�<47I.53;:�12/:4D7;���;.12?240�;403-.44.G�:632;47532�212�MHH.632;47532���a

bcd,�29<.-B.<0N�

;�@-7A.43:>�@7�7347\.42N�6�53:4D:-347<0�@7147<0�:/742530,�7C=?47�M4D7/.447<0�12/:4D0,�?8B�;40�

���������7D.18�<47I.53;.44=>�:632;4=>�674H7-<:A2G�-.A.@37-:�

2�H046A274:1847G�5.1.632;47532�12/:4D7;�h�jil�

Page 13: STPN_2014_(Atypical Antipsychotics. Part 1 + 2)_Extended

����������

��� � ������ ��������������������� ������

������������ �!"�#�$"%! �!�&����'���"��(������)*�+�"!"�!��������� �!,��!�-!�'�.���/012����� �3�$���/34�%���$� �$������,�&! ��5�!"���'�'4���6��%����*�7��� ��! ���6,�/34�%!��" �(6 ���"��"�/80�9:;<=*�+�" �(��"�>��'�"%�?$���&!�"���#@�A�!����4!%���&�!"�6'�����"&�!"�������6'�'��!?!'�!&��?�%����� �%�A��6� �$������,����� �!"����B!��"���� %���"���!%�A�"� ���!��!&��?�%�����" �3(6 �������?�!%�B��?��C�$"�!,A� !B!���B�?�!%�($����%!B��/80�C�DEFGH/80IG*�J!"�!%#�$�?���6,�'��!?�!&��?�%����!4K$L�"��&��#����� �.���/34�%�! @�!�����&!( !%����!&��?�%��#�-$��.�!��%#�$L�"�%���� 3�!"�#��B!��"��� �!��!M������!������65�/34�%�! *�;���'�!4��(!'@�? ���B!��"���"�!?����! !,�!4K�,� �$������,����� �!"�#L�'!B$��&!3��(�!'$� %���#���� �$����%��!A�6��&�!.�""6*�J!'�'!�"�'�5�/34�%�! @�/012����N��"!&��N��6�

"�"�"��'!,��?�&����65�&�!����! @���(6 ��'65�O3����"����'�*�P&!"!4�!"�#����� ��! ��#�QRRSTUVWXYZ[\]_U � �$����%��!A�!,�"�B��%�(�.���"�,A�"�"A�����"����(� �"�'!,�5��������"���!,�%�B��?�*�P����� �.��,�O3����"���! �" �(6 �L��&�!.�""6�?�"��"���(�.������������%�(�.�����.�&�!�! *�J!'�'!���'�?%���65��%��!A�65�!� ��! @�����/34�%��@�������O3����"���6@����� ��$����(%�A�6��&�!��������(6@�(�&$"��L����"��?6�?!%B! ��'��3�65��('�����,@�����5������('�������>�"&��""���

��.�&�!�! �9"'*���4%*��=@���,�!��!-�A�"��5�-��3�!�! ���"���&��A�"�!,�&%�"��A�!"���D�E�@��abH*�;��@�&!��(��!@�A�!@�"��?��?�$B�5�����&"�5!���! �%�M#��(���&���?!"�! ���!�&! 6M����>�"&��""�L�c����.�&�!�! � �&��-�!���%#�!,��!�����&!?�!��!3

65�"��$��$��5*�J���>�!'@��'��� 6"!�!��"�!?"� !���c

����.�&�!��'@��(���&��@�&!� "�,� �?�'!"��@����

� %���"���5�����B!��"�!'@�&!"�!%#�$��B!�&�!�!B��3�� �!��?�,"� ���4%!���$��"�� �?����'�"�%���� 3�!B!�c

������B!��"���G1d�EEb��D���@���eH*

f!�!M�'�&��'��!'�!�%�A�,� (��'!?�,"� ���"���.�&�!�!'�? $5�%�B��?! �'!N���&!"%$N��#���?� �����""%�?! ����1ghijk�kl�hg*�DEFH@� ��!�!3�!'�&��?&�������&!&6����!&��?�%��#���(%�A���'�N?$���"&���?!�!'����B!�'���4!%��!'�&�%�3&���?!�!'� �5��������� (��'!?�,"� ���"�c

����

F3d8�mn13��.�&�!��'��op]qorst� ��$%#�$����%��!��

1du�91vwxkyk�vhzylki�{|hi}�~kgg=@�>�"&��""��$LK�5��%!���! ���6����.�&�!�6�A�%! ����9"'*���4%*�E=*����� �?�!��(���4%�.6@���"&���?!����&�%�&���?!��&�!� %�%��" !,"� ��!4����65��B!��"�! � �!��!3M�����4!%#M��"� ���""%�?! ���65�>--���!��65�&$��,@�5!�����"���(�!,� �$������,�>--���� �!"�#L*�+�A�"��!"��@�&��'�����%#�!���F3d8

�13��.�&�!��'@�

&�%�&���?!��46%�4!%���>--���� ��@�A�'���"&���3?!�� �!��!M�����"��N����� �$����%��!A�!B!��0

E*�

+�"%$A���F3d8�mn13��.�&�!�! �&�%�&���?!�� �!�3

������������������������������������������������������������������������������Q�QUVRYZQXY]V ¡¢£¢o¤]¥r]£¦§]©©ª«

¬g­�D®wH m �° m2� mG± 1²u �²u°° ²³2°°° u²m 0m²°° ³± 2�G G±2°° µ�0

F3d8�m

¶·F@�� @Fe @a� e@�a e@�E @�e F@� a@�E a@e a@eF F@b b@��

F3d8�¹

F@ @FF @�� a@Fe ¬ ¬ a@a� ¬ a@F� e@�b ¬ b@�F

F3d8�m

¶�F@�� @�� ��@�F @Eb @�F @ab @ b@� a@� b@ab b@F b@F�

F3d8�¹

e@b b@Fb b@eF @eb ¬ ¬ @�� ¬ e@EE e@bb ¬ b@�

F3d8�1

¶�F@�� e@FF ��@�a @Fa e@Ee a@E @�� e@E� F@b @�e b@�F b@��

F3d8Fm

¶�F@�� a@�F @� e@a� ¬ ¬ e@�� ¬ F@e� e@�E ¬ F@bF

F3d8a

F@� a@a� b@a� @�F e@�� ¬ @�b ¬ F@a� F@aa b@�E a@e

F3d8e

@� e@�a b@b� @�b a@bF b@E� e@�E @� e@�F b@�E e@ba @a�

c�

¶�F@�� a@�b @F e@a� a@ae a@F e@bE a@�b a@e� e@a a@�b @�F

c�²

@F @b� @b� a@e e@ae @ee e@ae @E� a@E @�� @�F @�b

c�G

@F @b� @� a@� ¬ @ee e@F @E� a@E� @�e @�F e@bb

cE

@F @F b@E a@aa @�� ¬ e@�a @�a a@�� @�a @�� @EF

c�

F@a a@b @bF e@EE e@a� ¬ e@eF e@F� F@F @�� e@a e@EE

º�m

¶�F@�� a@�b @bE e@b� @Ea e@E� e@aF @� e@�b @�b @F e@�

º�m

F@b e@�a @b e@F� a@eb e@Eb a@E e@�b a@�F @�b a@� a@Fb

º�¹

¶�F@�� a@e� b@�b e@FF a@eb ¬ a@� ¬ e@� @�� a@EF a@a�

º�1

¶�F@�� e@bE @b� @� e@eb e@be e@Eb ¬ e@�� @e� a@EF e@E

d�

¶�F@�� e@ab b@�� @ea a@Ea ¶�F@�� @�e e@�b e@ba e@�b a@�b a@b

�¶�F@�� F@�� F@�b @�b F@E� ¶�F@�� e@b� F@�F a@FF �@Fe a@F ¶�F@��

»]¼½½£¾]¥r]£¦§¿]©©ª§»»]À¥stq¥ÁÂo]¥r]£¦§¿]©ÃÄ]Å]¡¥s¤t¦¥Ár]ÆÇÇoÁo£¦]ÈsÉÊ]ËpÇt]�Ìȼ«§»»»]Í£s£Îo]¥r]Ïoq£¿]©Ãħ

shagiakhmetov
Пишущая машинка
Page 14: STPN_2014_(Atypical Antipsychotics. Part 1 + 2)_Extended

����������

���� ������ �������� �����������

�������� !�"��#$�%�&'($�)%*+(,(�--%.%$�#��/�0�)$1&��$/�0*�&(/�+(-�$��2+*0'%**�3�'%4�%0/('(-�-�'�5��)$1&�*/'6+/6'�&�789�:�;<=�;>?�

@AB CD@ EFA GHB IDC

J4KLMN�OPQRST

U;;�V U<W�V U<��V U�X�V U�<�V

J4KLMN�OYZ[[Q\PS][T

U�<�V ^ ^ ^ ^

J4KL N�OPQRST

=�X�V =���V =���V =���V =<��V

<\_ �I ^ =;��V ^ ^ =;��V

aM�OPQRST

U�W�V ^ ^ ^ ^

aMObcRZScd]T

U<<�V ^ ^ ^ ^

a OPQRST

U<<�V UWX�V U;��V ^ UW��V

a ObcRZScd]T

U���V U���V U�<�V ^ ^

efgfhifjhklmnop

��������q!�r,($�5s����$/�,($�5s�'�*0%'�.($����0���0%'�.($��-�(/$(t%$���J4KL

Nuv4���a

4

'%�%0/('(-w�xy]z{z{Zz�Qc{QbZcz|}{Q�~kjk��ho��PQ{bcZcdcZ�{Q��SPcZ�{QbcZ�OV�Qc�Zb�Q�{Q���z|Z\�Z{�T

<\_�I

EFA �@D

F�;

=W� =��

@@ =�� ��

BE� =�< =�<

�\SRRzbcZ{ =�� =��

�z{bZcZyS�Z��F�� U�< U�<�

�z{bZcZyS�Z��BE� U<X� U�;;

<\_�@

F�;

=�; =;>

@@ =�X ��

BE� =;� =;�

�\SRRzbcZ{� U�>X U�W<

�z{bZcZyS�Z��F�;

U;� U;�

�z{bZcZyS�Z��BE� =��� =��W

��

�@�� U��� UW��

BE� =�� =;<

�\SRRzbcZ{� �� ��

:;_?\RSP|Q[RZ� U<� U�>

�����f�f����

|Z�Zz�Qc�RZb[zRZ�Q{S���Q�QZ��b|d�S����z|�bz���PSP�{z�cRS|}{���S{cSYQ{Zbc���Qc{Q�z{ZZ�[RQ�dP�ZZ�SRS�Z�Q{Q�Q��PZb|Qc��O@@Tw�S[Q�Q�Zz�cQYQ �PSP��Qy�z�bc�Zz�SYQ{ZbcS���y��Szc��zbz{bZcZyS�Z¡ �PQ{bcZcdcZ�{S��SPcZ�{Qbc}�Rz�z[cQRQ����y��S\zc�¢oh£¤m¤¥¤m¦h¥§fi£ih£m¤mjk©m§�:�� ����?w�ªSPZ]�Q�RSyQ] ��Qy�z�bc�Zz�Q�RSc{QYQ�SYQ{ZbcS �b{Z«S¡¬zz�dRQ�z{}�PQ{bcZcdcZ�{Q��SPcZ�{QbcZ���[Q[d|��ZZ�Rz�z[cQRQ� ���y��Szc�Q�RSc{��[RQ�zbb�­�b{Z«z{Zz�Z�PQ{bcZcdcZ�{Q���zbz{bZcZ\yS�ZZ�­�£ih£m¤mjk©m§f®i©i¤o®o¦w�ªSPS��bz{bZcZ\yS�Z��]Q«zc�[RQZb�Q�Zc}�PSP�yS�b�zc�[Q���z{Z��[|Qc{QbcZ�OPQ|Z�zbc�ST�°Pb[RzbbZZ�Rz�z[cQRQ���b|z�bc�Zz�d]z{}�z{Z��¢oh£¤m¤¥¤m¦ho�fmh¤i®�hk�mjk©mm�:�W�? �cSP�Z�yS�b�zc�[Q���z{Z��°±±zP\cZ�{QbcZ�Rz�z[cQR\°±±zPcQR{QYQ�bQ[R�«z{Z��:��?w�²³fµ¶·�bz{bZcZyS�Z��]Q«zc���c}�Q[Rz�z|z{S�PSP�dbZ|z{Zz�Qc�zcS�{S��Qy�z�bc�Zz�SYQ{ZbcSw�¹��S{\{Q]�b|d�Sz�[RZ]z{�|b��<\_

�@ºI\SYQ{Zbc��CF�[Qb|z�

��\�SbQ�Q��°Pb[QyZ�ZZ�I_C�P|zcQP�RZb[zRZ�Q{d�Z�[S|Z[zRZ�Q{dw�»¡�Q[�c{Q ��cQ�PSP�RZb[zRZ�Q{ �cSP�Z�[S|Z[zRZ�Q{�[RQ��|�|Z�b�Q�bc�S�b|S����SYQ{ZbcQ����Qc{Q�z{ZZ�SRRzbcZ{Q�QYQ�[dcZ�Z�bz{\bZcZyS�ZZ�BE��<\_

�@\Rz�z[cQRQ�w�¼PcZ�S�Z���

�\

Rz�z[cQRS�bQ[RQ�Q«�Szcb��SPcZ�S�Zz��½¾�bz]z�bc�S�

Z{YZ�ZcQR{���½\�z|PQ��Z�]Q«zc���c}�Q[Rz�z|z{S�µ³fµ¶·�[Q�Z{YZ�ZRQ�S{Z¡�[RQ�dP�ZZ��¼¿À�O�@��T�±QRbPQ|Z{\bcZ]d|ZRQ�S{{Q��S�z{Z|Sc�ZP|SyQ�w�Á�RSc{�z�SYQ{Zbc����bQQc�zcbc�ZZ�b�°cZ]��d�dc�[Q���Sc}�dRQ�z{}��@��w�¹Qy�z�bc�Zz�RZb[zRZ�Q{S�Z�[S|Z[zRZ�Q{S�cSP«z�[RQ��|�|Qb}�d�z|Z�z{Zz]�PQ|Z�zbc�S��

�\Rz�z[cQRQ��{S�[Q�zR�{QbcZ�P|zcQP�

Z�Q[Rz�z|�|Qb}�[Q�d�z|Z�z{Z¡�b��y��S{Z��RS�ZQ\|ZYS{�S�:;_?\RSP|Q[RZ�S�:;<?w�Â�bQ«S|z{Z¡ �[QPS�b|Q«{Q�°PbcRS[Q|ZRQ�Sc}�°cZ��S{{�z�{S�P|Z{Z�z\bPZz�RSy|Z�Z����°±±zPcS��RSZb[zRZ�Q{S�Z�[S|Z\[zRZ�Q{Sw�ÃQc��[Q�Rzyd|}cScS]�b�Q�{QYQ�S{S|ZyS��zbcZ�RS{�Q]ZyZRQ�S{{�� �[|S�z�Q\PQ{cRQ|ZRd\z]���PRScPQbRQ�{���Zbb|z�Q�S{Z��[S|Z[zRZ�Q{�QPSyS|b��°±±zPcZ�{zz�RZb[zRZ�Q{S�[Q��PS|z��@ÄAA�Z�|d��z�[zRz{QbZ|b��:��X? �°cZ��S{{�z�b|z�dzc�Z{czR[RzcZRQ�Sc}�b�QbcQRQ«{Qbc}¡ �[QbPQ|}Pd�bRS�{Z�S|Zb}�RSy{�z�|zPSRbc�z{{�z�±QR]��[Rz\[SRScQ��­�±QR]S�{z]z�|z{{QYQ���b�Q�Q«�z{Z��RZb[zRZ�Q{S�Z�yS]z�|z{{QYQ���b�Q�Q«�z{Z��[S|Z\[zRZ�Q{Sw�¹�cQ�«z��Rz]��Zbb|z�Q�S{Z��[RQ|Q{YZRQ\�S{{���Z{ÅzP�ZQ{{���±QR]�Q�QZ��[Rz[SRScQ���S|Z�[RQcZ�QRz�Z��z�Rzyd|}cSc��:<< ���X?w¹�cS�|w���[RZ�z�z{Q�RS{«ZRQ�S{Zz�S{cZ[bZ�QcZ\

PQ��[Q�bcz[z{Z�RZbPS��Qy{ZP{Q�z{Z��]zcS�Q|Z�zbPZ��{SRd�z{Z�w��Rz�Z�[RQ�Z� �<\_

�I\Rz�z[cQR� �[Q\

�Z�Z]Q]d �ZYRS¡c��z{cRS|}{d¡�RQ|}���RzYd|��ZZ�[Z¬z�QYQ�[Q�z�z{Z��Z�b��yS{��b�]zcS�Q|Z�zbPZ]Z�Qb|Q«{z{Z�]Z�S{cZ[bZ�QcZ�zbPQ��czRS[ZZw�ÆQPSyS\{Q ��cQ�d�]��z��b���P|¡�z{{�]�OÇÈÉ�ÇÉÊËT�Yz{Q]�<\_

�I\Rz�z[cQRQ��RSy�Z�Szcb��YZ[zR±SYZ� �Q«ZRz\

{Zz�Z��RQ{Z�zbPS��YZ[QZ{bd|Z{z]Z��:�<�?w�ÃQc��{z�Q�{SRd«z{Q�PQRRz|��ZZ���RS«z{{QbcZ�°cZ��{z«z|S\cz|}{�����|z{Z��{Z�b�bz|zPcZ�{Qbc}¡ �{Z�bQ�b[QbQ�\{Qbc}¡�S{cZ[bZ�QcZPS���bcd[Sc}���RQ|Z�Q�RSc{QYQ�SYQ{ZbcS�<\_

�I\Rz�z[cQRQ� �Q�{Q�Q�bcQ�cz|}bc�Q�

Page 15: STPN_2014_(Atypical Antipsychotics. Part 1 + 2)_Extended

����������

��� � ������ ��������������������� ������

������������ !�"��#�$�� ��%"&���� �'�((��"&�%)�((��*"�+����$"%�,���#�"�(%(��-.�#�/��"�#�����#,��%"%��)�",0� %'��1%.�(,#23�(%45�60(,#2��(�7�'"��"� &1��$�,�8897��" %',:;%.�!�(,%0� &3�4��"���(&:�#%�1,�",1%.��� ��(�(%4�<�1 ��,�%(�%�� ,(�,�%(7��(%�,:"�*1��#���%:�=>?@

�A>#�/��"�#���

��BCD�E�FGH�I�)5�",0 5��J5�K�7�'"���(%��(%��*1��#��>�%%�=>?@

�A>#�/��"�#���)���"���#�$� !"&�0� &3%4�

#%�1�)�",0� %'��1%.�(,#23�(%4��#%�"�#,�%%�*"%)%�$�2)!�,("%��%.�"%1,)%7���1,� %3&��#�$�� ���(%�7�"�)�(��)�(���*"%�$,((-����%$�"� &�"�2:"���+ 20�1%.�#,� %'%!.�)��$2�(%)%�%�$#2+%)%�889���.,#,1"�#����,%)�$�4�"�%!���=>?@

�A>#�/��"�#�)�E�GGH5

L�M�EMNOPH>�%�L

�Q�EQRNSTH>#�/��"�#-�<��#�$21"-�

, &"�#(,"%�(�+���� ,4�%(+,��$%(�+��+�(,�L��$�>

U,)%(���+��#�/��"�#,5�L�M�<�+ ,�(,!�%��U�#),�

VWXYXZ[\VYZ]X_Z�L�>#�/��"�#��5�L

�Q� �1, %�2:">

�!��#�%)2;��"��((��VaXZ[\VYZ]X_Z�%�!� !:"�!�%(+%0%"�#(-)%�,2"�#�/��"�#,)%5�81"%�,/%!�L

�Q>

#�/��"�#����#%��$%"�1�b>0� �1�����#�$��,((�4�,1"%�,/%%�cd�"�1,�%�%(+%0%#��,(%:�,$�(% ,"/%>1 ,�-7�� �$�"�%�)�'�+��!� !�"�!�%(+%0%#��,(%��YZaWeZ[fZgaW_XZh\ei7�!� !:;�4�!�1 :'��-)�U�#>)�("�)��%("��,�$�U,)%(,7�2)�(&3�(%���-���0��>$�(%!�%�2�� %'�(%���0#,"(�+���,.�,",�$�U,)%(,5�L�Q>#�/��"�#-��(,'%"� &(��0� ���'2��"�%"� &(-�1�

$�U,)%(27�'�)�L�M7�%�,1"%�%#2:"�!���$����$�4�"�%>

�)�0� ���(%�1%.��+��1�(/�("#,/%4����%(,�"%'��1�4�;� %5�8("%��%.�"%1�,#%�%�#,�� �#,�#,0,"-�, �!�1,1��� �1"%�(-4�,+�(%�"�L

�Q>#�/��"�#��7�1�"�#-4�

02$�"�2)�(&3,"&��-���0��$�(%��$�U,)%(,�%���#��%(,�"%'��1�+���1�(',(%!�%��#%�*"�)�02$�"��#�!� !"&����4�"�,�',�"%'(�+��,+�(%�",����"(�3�>(%%�L

�M>#�/��"�#��7��0����'%�,!�)%(%), &(2:�%.�

,1"%�,/%:7�(��0.�$%)2:�$ !�"�+�7�'"�0-�%�0��,"&�(��� ,"� &(-.�*1�"#,�%#,)%$(-.��%)�"�)��7����>(%1,:;%.���$�$�4�"�%�)��0#,"(-.�,+�(%�"���E�jFH5�k,1�0- ���1,�,(���-3�7�*1�"#,�%#,)%$(-����0�'>(-��*UU�1"-�"%�%'(-.�,("%��%.�"%1������(%1,:"��#%���!�-�,(%%�0� ���l��m�L

�>#�/��"�#������"#%,>

"2)�5�9�1,�,(�7�'"����$%,�,��(��1 %(%'��1%��#%>)�(!�)-.�$���,#%�%�#,�� ��112�%#2�"�0� ���G��m�L�M>#�/��"�#������"#%,"2)�7�'"�7��$(,1�7�(�����#���>

�$,�"�!�2�� %'�(%�)�',�"�"-�n9D5�n"��1 %(%'��1���$��"�%(�"���,#%�%�#,�� ,�(����!�,(�����+��,1"%�(�>�"&:����"(�3�(%%�=>?@

�op�o>#�/��"�#���E�FqH5�r(2>

"#�((!!�*UU�1"%�(��"&�,#%�%�#,�� ,����"(�3�(%%�,1"%�,/%%�b>0� 1���L

�M>#�/��"�#,����$,((-)�EF=QH

b@stQ�,(, %�,�uvwxuyz{����",� !�"�d=7=�m7���"���#�)!�1,1�|

}~���2 &�%#%$,����q=�m7�|

}~��+, ���#%$� ,���

�lF�m7�|}~��1 ��,�%(,����lq�m�%�|

}~��#%���#%$�(,���

�G��m�E��FH5�K,1%)��0#,��)7�,#%�%�#,�� �!� !�"�!�'#���-',4(��� ,0-)�',�"%'(-)�,+�(%�"�)�b

�������>

#�$��,((�+��%(+%0%#��,(%!�,$�(% ,"/%1 ,�-7�,�",1���',�"%'(-)�,+�(%�"�)��>,##��"%(,>��%�'%�"-)�(�4"#, &(-)�,(",+�(%�"�)�b

�t>,1"%�,/%%�b��c�1,>

(, ���Ib��SNT��O>�N�������O�~S���>S��T����OP��NT~����}��R~OO��J7����#!��((-.���L

�M>#�/��"�#�)�E�7���FH5�

��4�"�2!�(,�L�Q>#�/��"�#-7�,#%�%�#,�� ��-�"2�,�"�

��#� %��� (�+��,+�(%�",7�*UU�1"%�(��%(+%0%#2!��#��%(,�"%'��12:�"%#��%(+%$#�1�% ,�2�E���H�%���#� %�',�"%'(�+��,+�(%�",�<�,1"%�%#2!��>,##��"%(>��EFlH5�r�$�4�"�%"� &(��"%��"� &�(%�1,!��(2"#�((!!�,+�(%�"%'��1,!�,1"%�(��"&�,#%�%�#,�� ,����"(�>3�(%%�,1"%�,/%%����"�%(,�"%'��1%.�b

�>0� 1���(��

)���"��0�!�(%"&����.�1 %(%'��1%.����0�((��"�4��+����,%)�$�4�"�%!���L

�M>#�/��"�#�)5��,((�����>

���(%��",1�����$"��#�$,�"�!�%���*1���#%)�(",.�uvwxux{5��(% ,"�#, &(������#��$�(%��$�U,)%(�#+%>'��1�4��%�"�)-�(�4#�"�1�%(�)�q>+%$#�1�%$�U,)%>(�)�!� !�"�!�'#���-',4(��'2��"�%"� &(�4�)�$� &:�$ !��-!� �(%!�',�"%'(-.�,+�(%�"���L

�>#�/��"�#��5�

K,1���$,((,!�)�$� &�%(�+$,�%��� &�2�"�!�$ !�)�>$� %#��,(%!�0� ��(%�9,#1%(��(,�2�1#-�5������"(�7�'"��*UU�1"�',�"%'(�+��,+�(%�",��,�%�%"��"�� �">(��"%�*1��#���%%�I1� %'��"�,J�%�'2��"�%"� &(��"%�#�/��"�#���(,�����#.(��"%�1 �"1%5�r� �$�"�%��$�U,)%(�#+%'��1�4�$�(�#�,/%%���$,((�4�)�$� %����(%1,�"�$�U,)%(�#+%'��1,!�+%��#'2��"�%"� &>(��"&�(�4#�(����"#%,"2),�(,��"�#�(����#,��(%!5�r��$�(%��1,1��� (-.7�",1�%�',�"%'(-.�L

�>,+�(%�"���

�-�-�,�"�1#2+��-��$�%��(%!��%��"(�+�����"�#�(27��#�"%���� ��(2:��',+2���#,��(%!7�"5�5�����#�"�� �����#%����#��$�(%%��#,��+��(%+#��"#%,#(�+���2"%�E��GH5��� %�0-�,#%�%�#,�� �0- �1 ,��%'��1%)�',�"%'(-)�L

�>,+�(%�"�)7��+�����$�(%���-�-�, ��

0-�1�("# ,"�#, &(����#,;�(%�7�(��*"�+��(��(,0 :>$, ��&7�0� ���"�+�7��(�*UU�1"%�(���#�$�"�#,;, �,(, �+%'(���$�4�"�%��L

�>,+�(%�"���E���H5�K,1%)�

�0#,��)7�,#%�%�#,�� ��� ���0!�1,1�'%�"-4�,(",+�>(%�"����%�"�)����'#���-',4(��(%�1%)�2#��(�)�$�U,>)%(�#+%'��1�4�(�4#�"#,(�)%��%%5�r�$,((�4���!�%�%("�#��(���0#,"%"&��(%),(%��(,�� �$2:;%��1 %(%>'��1%��(,0 :$�(%!5���)(�+%.��,/%�("��7��"#,$,:>;%.�0� ��(&:�9,#1%(��(,7��� 2',:;%.�"�#,�%:��#��,#,",)%� ���$��-7�#,��%�,:"�!���%.�"%'��1%�����"�!(%!��� �$�"�%���"#%,#(�4�+%��#,1"%�,/%%�L�>#�/��"�#��5�k ��,�%(�%�1��"%,�%(�$��� &(��

*UU�1"%�(-��� �'�(%%�",1%.����"�!(%4�%���(%�1%.�$��,.�(��2.2$3,:"�*1�"#,�%#,)%$(2:��%)�"�),>"%125���+%'(���#�$�� ��%"&7�'"��,#%�%�#,�� 7�%�0���"�+���" %',:;%4�!�(%�1�4�',�"�"�4�*1�"#,�%>#,)%$(-.�(,#23�(%47�0- �0-��;��0� ����#�$��>'"%"� �(���$,((�4��%"2,/%%5�r�$�4�"�%"� &(��"%�

����������� �¡¢�£¤¥¦�¢¦¤£§¦��©§ª��¤��«§¡¢�¬�¦�­® §¦�°�£�¡£¥��¡�ª§­�±�§°��¦ª�±¡�¬¤ª�¢�²©��I\g\VYZaW³\[WwZewµ¶·w{z¹wµº»¼½u¾yz»w¿ÀÁÁJ

8("%��%.�"%1 Â%�1

AMÃÃMo

r-��1%4

ÄÅÆ��Q

�)�#�((-4

oÇ��MÃQÆ�

C��-��1%4

oQÆo��MÅ�È�s

C%�1%4

Page 16: STPN_2014_(Atypical Antipsychotics. Part 1 + 2)_Extended

����������

���� ������ �������� �����������

������������ !�"��#$���$����%&� !'((!$"�)! �)�$*����)� ���"�$�+�,!-�$�,! "�� .+��%�+���)/� ����*+*-0���,�"�� .!�(* $1���23456�7"��-� .!�8��#0!�%�9��%*:"%&�%�$� 1!�1�!;�(* $1�� ��# �;�%!�!$"�) �%"�/�<!,�%���!-%"�)�! �&,���8���������=���!�$�$���$��%%�<!%$�,��9� �%"!�>

�=�!1!�"���)6�

?��# !;0�!��%%�!-�)� �&�(* $1�� ��# �;�%!�!$="�) �%"��,�-�(�$�1�;�,��!$*�.�����������������)!���$�%��-� �:� !%$��#$�+������)�- .+/����&)�&:@�+��%$�:<�"!�# *:�%!�!$"�) �%"#�)��" �0! ����$"�)�1���A=���!%"� =�/�B�CDE44F3���CDE444��2�/�G�56�H��%%�!-�)� �&+�IJJKL�KM�NJ6�2�5�-� .!�%�!-� ! �&� !��8 ��*O�)���� �$�$�+����=� �$�)��9� ��,��)��" �0! ���P

Q=���%�!-*!,�9��

�*"���!�!-�<��%�9 ����)��"��<�!��"�������������RSTRUSVWX6�Y8��-�&� *�!)�;�) *"�! !;��$"�) �%"#:�)��" �0! ���P

Q=�*"�/�CDE44F3���CDE444��&)�&:"%&�

!9�� !;"���# .,��� "�9� �%"�,�6�H��" �0! ����$"�)�1���AZ���!%"� �=��[

\N]��������������%�%"�)=

�&���FG�/�[\N]�CDE44F3�B��G����[

\N]�CDE444��B�4��

^6�_ "!�!% �/�<"�/�+�"&������������/�CDE44F3���CDE444��&)�&:"%&��9� �%"�,�����!%"� �)�9���*"�/�� �� !�).�.)����� "!� �����1�:�>

�=�!1!�"���)6�

��,!�"�9�/�STRUSUX�$�$������������/�"�$���!9�����=��)�- .!�'((!$"�) ����-�)�&���9��!���$�,�1�:/�).�)� *:�>=�,(!"�,� �,���aEa6�_ "!�!% ��"�$O!/�<"���+�� "��%�+�"�<!%$�&��$"�) �%"#�8.���� �<�="!�# ��% �O! ��*�,.0!;�%�).$�:<! .,�bcLdecdfMg�9! �,�A=���!%"� �=�6�h�$O!�8.�����$��� �/�<"��"�$�&�9! !"�<!%$�&�,�-�(�$�1�&�% �O������-)!�=O! �%"#�,.0!;�9��!���$�,�1��/�).�.)�!,�;���&,.,�>

�=�9� �%"�,����,��(� �,����� !��&=

,.,�B�>=�,(!"�,� �,6���,!�"�9�/�)��"��<�!��"��"���< .+�� "��%�+�"�$�)/�)$�:<�&���%�,������=������/�CDE44F3���CDE444���8 ��*O�)����% �=O! *:�� "��%�+�"�<!%$*:��$"�) �%"#�*�,.0!;/� !�'$%��!%%��*:@�+iA=���!%"� =�6�H%!�"���< .!���, �9�!��"���< .!�� "��%�+�"�$�/����,! &!,.!�)�$�� �<!%$�;����$"�$!/�&)�&:"%&�� "�9� �%"�,��$�$�P

Q=���%�!-*!,�9�/�"�$���A=���!%"� �)�9���*"��

�!�!-�<��%�9 ���/�%���&O! �9��%�>�j=�!1!�"���,�

2�/����56�k:8��." �/�<"�� �������������/� ��!9�������)�- .!�)��%%�!-�)� ���IJJKL�KM�NJ6�2�5� !�).�.)����$�"��!�%���)�-���+/� !�8+�-�,.+�-�&����)�"�&�� "��%�+�"�<!%$�9��-!;%")�&�*�,.0!;�-�$�9��"���6�l�,.0!;�O!�%�� �$"�)���)� .,�9!= �,�A=���!%"� �=�����$�"��!�"�9! �;��$"�) �%"��CDE44F3���CDE444��,����<!,��"��<���%#��"�9����!=��-���6�m����������/���=)�-�,�,*/�))�-*�%)�!9��P

Q�

�9� ��,��)��8@!� !�).�.)���$�"��!�%���*�,.0!;6�h�$�&�%��%�8 �%"#�CDE44F3���CDE444��).�.)�"#�'$%"������,�- .!� ��*0! �&������ �$"�)�1������!%"� �)�9���*"��%)�-!"!�#%")*!"� !�"��#$����"�,/�<"��'"��-!��)�".���������������$"�)��*:"�%���&=O! .;�%�>

�=�!1!�"���,iAZ���!%"� =��STRUSUX/� ������

"�,/�<"��!9���$"�)�1�&�,�O!"����"�)�-!;%")�)�"#����)�"�:�$�"��!�%�����-�*9�+�'$%"������,�- .+� ��*0! �;/�).�)� .+�� "�9� ��,�,n�8��" .,��9� ��,�,�)��" �0! ���P

Q=���%�!-*!,�;�%�9 �=

����1��6�h�$�,��8����,/��%%�!-�)� �&�IJJKL�KM�NJ6�2�5���!-����9�:"/�<"��� "��%�+�"�<!%$�!�-!;%")�!�

"���< .+����"���< .+�� "��%�+�"�$�)�%)&�� ��%��+�� "�9� ��,�,n�8��" .,��9� ��,�,�)��" �0! ���PQ����%�!-*!,�;��!�!-�<��%�9 ���/�"�9-��$�$�P

Q=

!��)�%�,�&��$"�)�1�&iA=���!%"� �=�����%�!-*!"�$�$�� "��%�+�"�<!%$�!/�"�$���� "�$�"��!�"�9! �!�-!;%")�!6�h�$�,��8����,/����)!-! .!�-� .!/�%)�-!=

"!�#%")*:@�!���%��O �%"����, �9�*��) !)�%"��)���,�-!;%")�&�(��,�$���9�<!%$�+��9! "�)�%�1! "���# �;� !�) �;�%�%"!,�;/�-�:"��% �)� �!�����9�"#/�<"��8��!!�9�*8�$�!��� �,� �!�,!+� ��,��-!;%")�&����,! &!,.+�)�$�� �<!%$�;����$"�$!���!����"�)�8*-!"�%��%�8%")�)�"#�).&)�! �:�$��= �<!%$�+�$���!�&"�)�,�-*�&1����$"�) �%"���"-!�#= ��)�&".+��!1!�"���)���) *"��$�!"�< .+�$�%$�-�)/�� -�)�-*�����1���"!��������)�8*-*@!,����)!-!"�$�%��-� �:��!$��%")! .+�%�!-%")�%�*�*<0! �;��!�! �%�,�%"#:���'((!$"�) �%"#:6�

opqrstRuqvwxyvzx{r|}R~yRry�vwR�VV�����X�X��W���}W���V�T

�����������������������������������������������������������������������������������������������������������������������������

�}� }R��¡�S¡¢�£�VXUR��¤�W¡�R�V¡V�R¥�¤��V¡W¦R§T�VSV�VSXTR¡VSXT¡�R

�©S�TVSªS©R«�TV�WRXªR¡W©X�X�¦

I\dL¬�M­K�NM®QeNJ�NLMQ°®e­dMQe°/�M­K�±d²J³°�\d°M�±Q³KJ®�f°K³����N²Kµ�²dMdM®QeNJ�NM®QeNJ�NLMQ°®e­dMQe�eJd¶NQLK/�N²QQ²N¶dJK/�N\Q°fJ²Q³K/�N°KLNQLK/�¶Q²N=°Q³dLK/�QJdK²Q³dLK/�·fKMQNQLK/�Jf²N°Q³dLK/�dJNL¶NQLK/�NJQK²Q³dLK/�²Q°K²Q³dLK�NL³�°K²MQL³dJK6�EdLMK\ d²N²®�eJQLQeNJ�°Mf³QK°�³d�LdM�NJJd±�Q³KLMQ®QL¬�N�³Q°MQLeMQ¹K�KNMf²K�d�°®e­dM²dQe�NeMQ¹QM®�°KeM²f\�d�KNe­�°KeQQe�NLMQ°®e­dMQe6�ºd±K¹K²/�QL�²NeMQeK�±K�eNL�dMKL�d»°K²¹K�N�N²MQefJN²�KQeQKLe®�d�N�eK²MNQL�NLMQ°®e­dMQe�³²f¬�d²�N�N²MQefJN²�NMQKLM6�¼L�M­Q°�M­Kd²KMQeNJ�°Mf³®�±K�NMMK\ M�Md�°KeQ®�M­K�d°°Q»JK�²dJK�d�ed\\dL�­N²\NedJd¬QeNJ�MN²¬KM°�d�NM®QeNJ�NLMQ°®e­dMQe°�±QM­�²K°KeM�Md�M­K�N¹NQJ=N»JK�³NMN�dL�M­K�NM­d¬KLK°Q°�d�°e­Q¶d­²KLQN6�a²KeJQLQeNJ�³NMN�²d\�NLQ\NJ�\d³KJ°�d�°e­Q¶d­²KLQN/�³K\dL°M²NMK�M­NM�NLMQ°®e­dMQe�½NM®QeNJQM®¾�\N®�LdM�dLJ®�NMM²Q»fMK�Md�3=º¿

�I�²KeKMd²�NLMN¬dLQ°\/�»fM�²NM­K²�Md�M­K�N»QJQM®�d�

M­K°K�³²f¬°�Md�NeM�N°�N�³Q²KeM�3=º¿�I�²KeKMd²�N¬dLQ°M°�NL³�

3=º¿�E/�3=º¿

À/�3=º¿

F�NL³�8

��N³²KLK²¬Qe�²KeKMd²°�dMKLM�

NLMN¬dLQ°M°nQL¹K²°K�N¬dLQ°M°6�¿­K°K�²KeKMd²°�N²K�QL¹dJ¹K³�QL�²K¬fJNMQdL�d�³dN\QLK�NL³�Ld²KQLK­²QLK�²KJKN°K�QL�²K²dLMNJ�ed²MK]�NL³�M­f°�JN®°�N�e²QMQeNJ�²dJK�QL�ed¬LQMQ¹K�K²d²\NLeK/�\dMQ¹NMQdL�NL³�\dd³6�ÁKeKLM�°Mf³QK°�­N¹K�NJ°d�²K¹KNJK³�M­NM�³QK²KLeK°�QL�­N²\NedJd¬QeNJ�NeMQ¹QM®�\N®�NJ°d�NMM²Q»fMK�Md�M­K�³²f¬°�N»QJQM®�Md�NKeM�M­K�°KedL³�\K°°KL¬K²�°®°MK\6�¿­K�K]Q°MKLeK�d�\fJMQJK�NeMQ¹K�edL=d²\NMQdL°�d�N�²KeKMd²/�edfJK³�±QM­�M­K�NeMQ¹NMQdL�d�³QK²KLM�P=²dMKQL�NL³�)=N²²K°MQL�d°MfJNMK°�M­K�d°°Q»QJQM®�d�JQ¬NL³�Md�QL³KKL³KLMJ®�²K¬fJNMK�³QK²KLM�QLM²NeKJJf=JN²�eN°eN³K°6�¿­K°K�JQ¬NL³°�eNL�NJ°d�³QK²�QL�M­K�³K¬²KK�d�QLM²QL°Qe�KQeNe®�bÂ

\N]g�d²�KNe­�°KeQQe�QLM²NeKJJfJN²�

°Q¬LNJQL¬�NM­±N®6

Ã���Ä������NM®QeNJ�NLMQ°®e­dMQe°/�Å=d°eQJJNMQdL/�DÆ>I/�>

�/�>

�j/�>

�Ç/�3=º¿

�/�3=º¿

À/�3=º¿

F/�È�/�²KeKMd²�

NQLQM®�²dQJK/�QLM²QL°Qe�KQeNe®/�fLeMQdLNJ�°KJKeMQ¹QM®/�PaEÁ/�2G3Ç5P¿aÅÇ/�A=N²²K°MQL/�ÂÁÉ6

Page 17: STPN_2014_(Atypical Antipsychotics. Part 1 + 2)_Extended

СПИСОК ЛИТЕРАТУРЫ

1. Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL (2009) Amisulpride is a

potent 5-HT7 antagonist: relevance for antidepressant actions in vivo.

Psychopharmacology 205(1):119–128

2. Abdul-Monim Z, Neill JC, Reynolds GP (2007) Sub-chronic psychotomimetic

phencyclidine induces deficits in reversal learning and alterations in parvalbumin-

immunoreactive expression in the rat. J Psychopharmacol 21:198–205

3. Abi-Dargham A, Moore H. Prefrontal DA transmission at D1 receptors and the

pathology of schizophrenia. Neuroscientist 2003; 9: 404-16.

4. Allen JA, Yost JM, Setola V, Chen X, Sassano MF, Chen M, Peterson S. Discovery of β-

Arrestin–Biased Dopamine D2 Ligands for Probing Signal Transduction Pathways

Essential for Antipsychotic Efficacy. PNAS, November 8, 2011, vol. 108, no. 45. 18488–

93

5. Amargós-Bosch M, López-Gil X, Artigas F, Adell A. Clozapine and olanzapine, but not

haloperidol, suppress serotonin efflux in the medial prefrontal cortex elicited by

phencyclidine and ketamine. Int J Neuropsychopharmacol 2006; 9: 565-73.

6. Andersson JL, Nomikos GG, Marcus M, Hertel P, Matheґ JM, Svensson TH. 1995.

Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and

dopamine release selectivity in the mesolimbic dopaminergic system. Naunyn

Schmiedebergs Arch Pharmacol 352:374–385.

7. Assié MB, Ravailhe V, Faucillon V, Newman-Tancredi A (2005) Contrasting contribution

of 5-hydroxytryptamine 1a receptor activation to neurochemical profile of novel

antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat

brain. J Pharmacol Exp Ther 315(1):265–272

8. Baddeley A. Working memory. Curr Biol 2010;20:R136–R140.

9. Barnhart WJ, Makela EH, Latocha MJ. SSRI-induced apathy syndrome: a clinical review.

J Psychiatric Pract. 2004;10:196–199.

10. Bartos M, Vida I, Jonas P. Synaptic mechanisms of synchronized gamma oscillations in

inhibitory interneuron networks. Nat Rev Neurosci 2007;8:45–56.

11. Beaulieu J-M, Gainetdinov RR. The Physiology, Signaling, and Pharmacology of

Dopamine Receptors. Pharmacol Rev 63:182–217, 2011

12. Berg KA, Stout BD, Cropper JD, Maayani S, Clarke WP (1999). Novel actions of inverse

agonists on 5-HT2C receptor systems. Mol Pharmacol 55: 863–872.

13. Berk M, Ichim C, Brook S. 2001. Efficacy of mirtazapine add on therapy to haloperidol

in the treatment of the negative symptoms of schizophrenia: a double-blind

randomized placebo-controlled study. Int Clin Psychopharmacol 16:87–92.

14. Boer SF, Koolhaas JM (2005). "5-HT1A and 5-HT1B receptor agonists and aggression: a

pharmacological challenge of the serotonin deficiency hypothesis". Eur J Pharmacol.

526 (1–3): 125–39.

15. Bolling MY, Kohlenberg RJ. Reasons for quitting serotonin reuptake inhibitor therapy:

paradoxical psychological side effects and patient satisfaction. Psychother Psychosom.

2004;73:380–385.

16. Bubar MJ, Cunningham KA. Distribution of serotonin 5-HT2C receptors in the ventral

tegmental area. Neuroscience. 2007 Apr 25;146(1):286-97

17. Bubeníková-Valesová V, Horácek J, Vrajová M, Höschl C (2008) Models of

schizophrenia in humans and animals based on inhibition of NMDA receptors.

Neurosci Biobehav Rev 32 (5):1014–1023

18. Burnet PW, Eastwood SL, Harrison PJ (1996) 5-HT1A and 5-HT2A receptor mRNAs and

binding site densities are differentially altered in schizophrenia.

Neuropsychopharmacology 15(5):442–455

19. Burnet PW, Eastwood SL, Harrison PJ (1997) [3H]WAY-100635 for 5-HT1A receptor

autoradiography in human brain: a comparison with [3H]8-OH-DPAT and

demonstration of increased binding in the frontal cortex in schizophrenia. Neurochem

Int 30(6):565–574

20. Cai JX, Arnsten AF. Dose-dependent effect of dopamine D1 receptor agonists A77636

or SKF81297 on spatial working memory in aged monkeys. J of Pharmacol and Exp

Ther 1997;283(1):183-9

21. Carle´n M, Meletis K, Siegle JH, Cardin JA, Futai1 K, Vierling-ClaassenD, Ru¨hlmann C,

Jones SR, Deisseroth K, Sheng M, Moore CI, Tsai L-H. A critical role for NMDA receptors

in parvalbumin interneurons for gamma rhythm induction and behavior. Molecular

Psychiatry (2011), 1–12

22. Carlsson A (1978) Antipsychotic drugs, neurotransmitters, and schizophrenia. Am J

Psychiatry 135:165–173

23. Carlsson M, Carlsson A (1989) The NMDA antagonist MK-801 causes marked

locomotor stimulation in monoamine-depleted Mice. J Neural Transm 75:221–226

24. Carlsson ML, Martin P, Nilsson M, Sorenson SM, Carlsson A, Waters S, Waters N (1999)

The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA

antagonist- than dopamine agonist-induced hyperactivity in mice. J Neural Transm

106:123–129

25. Castner SA, Williams GV, Goldman-Rakic PS (2000) Reversal of antipsychotic-induced

working memory deficits by short-term dopamine D1 receptor stimulation. Science

287:2020–2022

26. Celada P, Bortolozzi A, Artigas F. Serotonin 5-HT1A Receptors as Targets for Agents to

Treat Psychiatric Disorders: Rationale and Current Status of Research. CNS Drugs

(2013) 27:703–716

27. Celada P, Puig MV, Artigas F. Serotonin modulation of cortical neurons and networks.

Frontiers in Integrative Neuroscience, April 2013, Volume7, Article 25

28. Cerovecki A, Musil R, Klimke A, Seemuller F, Haen E, Schennach R, Kuhn K, Volz H,

Riedel M. Withdrawal Symptoms and Rebound Syndromes Associated with Switching

and Discontinuing Atypical Antipsychotics: Theoretical Background and Practical

Recommendations. CNS Drugs (2013) 27:545–572

29. Chen L, Yang CR. 2002. Interaction of dopamine D1 and NMDA receptors mediates

acute clozapine potentiation of glutamate EPSPs in rat prefrontal cortex. J

Neurophysiol 87:2324–2336.

30. Chen X, Sassano MF, Zheng L, Setola V, Chen M, Bai X, Frye SV, Wetsel WC, Roth BL, Jin

J. Structure-functional selectivity relationship studies of β-arrestin-biased dopamine D₂

receptor agonists. J Med Chem. 2012 Aug 23;55(16):7141-53.

31. Cho RY, Konecky RO, Carter CS. Impairments in frontal cortical gamma synchrony and

cognitive control in schizophrenia. Proc Natl Acad Sci U S A 2006;103:19878–19883

32. Choi YK, Snigdha S, Shahid M, Neill JC, Tarazi FI (2009) Subchronic effects of

phencyclidine on dopamine and serotonin receptors: implications for schizophrenia. J

Mol Neurosci 38(3):227–235

33. Clark RE, Squire LR (2010) An animal model of recognition memory and medial

temporal lobe amnesia: History and current issues. Neuropsychologia 48:2234–2244

34. Clarke WP (2005). What’s for lunch at the conformational cafeteria? Mol Pharmacol

67: 1819–1821.

35. Clarke WP, Chavera TA, Silva M, Sullivan LC and Berg KA. Signalling profile differences:

paliperidone versus risperidone British Journal of Pharmacology (2013) 170 532–545

36. Codony X, Vela JM and Ramirez MJ (2011) 5-HT(6) receptor and cognition. Curr Opin

Pharmacol 11: 94–100.

37. Cowen P, Sherwood AC. The role of serotonin in cognitive function: evidence from

recent studies and implications for understanding depression. J Psychopharmacol.

2013 Jul;27(7):575-83.

38. Klewe IV , Nielsen SM , Tarpø L et al . Recruitment of b -arrestin2 to the dopamine D2

receptor: insights into anti-psychotic and anti-parkinsonian drug receptor signaling .

Neuropharmacology 2008 ; 54 : 1215 – 22

39. Da Silva CV, Duchatelle P, Boulouard M, Dauphin F (2009) Selective 5-HT6 receptor

blockade improves spatial recognition memory and reverses age-related deficits in

spatial recognition memory in the mouse. Neuropsychopharmacology 34(2):488–500

40. Deeks ED, Keating GM. Olanzapine/fluoxetine: a review of its use in the treatment of

acute bipolar depression. Drugs 2008;68:1115–1137.

41. Deutch AY, Cameron DS (1992) Pharmacological characterization of dopamine systems

in the nucleus accumbens core and shell. Neuroscience 46:49–56

42. Deutch AY, Lee MC, Iadarola MJ (1992) Regionally specific effects of atypical

antipsychotic drugs on striatal fos expression: The nucleus accumbens shell as a locus

of antipsychotic action. Mol Cell Neurosci 46:49–56

43. Devoto P, Flore G, Pani L, Gessa GL. 2001. Evidence for co-release of noradrenaline and

dopamine from noradrenergic neurons in the cerebral cortex. Mol Psychiatry 6:657–

664.

44. Devoto P, Flore G, Longu G, Pira L, Gessa GL. 2003. Origin of extracellular dopamine

from dopamine and noradrenaline neurons in the medial prefrontal and occipital

cortex. Synapse 50:200–205.

45. Devoto P, Flore G, Pira L, Longu G, Gessa GL. 2004. Alpha2-adrenoceptor mediated co-

release of dopamine and noradrenaline from noradrenergic neurons in the cerebral

cortex. J Neurochem 88:1003–1009.

46. Dogterom P, Timmer C, Greef R, Spaans E, Vries D, Vliet A, Peeters P. Asenapine

Safety, Tolerability, and Pharmacokinetics After Single and Multiple Doses in Healthy

Volunteers. Clinical Pharmacology in Drug Development October 2012 vol. 1 no. 4 131-

143

47. Dremencov E, Mansari M, Blier P. Effects of sustained serotonin reuptake inhibition on

the firing of dopamine neurons in the rat ventral tegmental area. J Psychiatry Neurosci

2009;34(3)

48. Ebenezer IS, Arkle MJ, Tite RM (1998). "8-Hydroxy-2-(di-n-propylamino)-tetralin

inhibits food intake in fasted rats by an action at 5-HT1A receptors". Methods Find Exp

Clin Pharmacol. 29 (4): 269–72.

49. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE, Goldman D,

Weinberger DR (2001) Effect of COMT Val108/158 Met genotype on frontal lobe

function and risk for schizophrenia. Proc Natl Acad Sci USA 98:6917–6922

50. Eggers AE. A serotonin hypothesis of schizophrenia. Med Hypotheses. 2013

Jun;80(6):791-4.

51. Eltayb A, Wadenberg ML, Svensson TH (2005) Enhanced cortical dopamine output and

antipsychotic-like effect of raclopride with adjunctive low-dose L-dopa. Biol Psychiatry

58:337–343

52. Emamian ES, Karayiorgou M, Gogos JA (2004) Decreased phosphorylation of NMDA

receptor type 1 at serine 897 in brains of patients with Schizophrenia. J Neurosci

24:1561–1564

53. Farde L, Wiesel FA, Halldin C, Sedvall G (1988) Central D2-dopamine receptor

occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen

Psychiatry 45:71–76

54. Fava M, Graves LM, Benazzi F, Scalia MJ, Iosifescu DV, Alpert JE, et al. A cross-sectional

study of the prevalence of cognitive and physical symptoms during long-term

antidepressant treatment. Journal of Clinical Psychiatry 2006;67: 1754e9.

Page 18: STPN_2014_(Atypical Antipsychotics. Part 1 + 2)_Extended

55. Fleischhacker W, Gopal S, Lane R, Gassmann-Mayer C, Lim R, Hough D et al. (2011). A

randomized trial of paliperidone palmitate and risperidone long-acting injectable in

schizophrenia. Int J Neuropsychopharmacol 15: 107–118.

56. Franberg O, Marcus MM, Ivanov V, SchilstroЁm B, Shahid M, Svensson TH. 2009.

Asenapine elevates cortical dopamine, noradrenaline and serotonin release. Evidence

for activation of cortical and subcortical dopamine systems by different mechanisms.

Psychopharmacology (Berl) 204:251–264.

57. Franberg O, Wiker C, Marcus MM, Konradsson A, Jardemark K, SchilstroЁm B, Shahid

M, Wong EH, Svensson TH. 2008. Asenapine, a novel psychopharmacologic agent:

preclinical evidence for clinical effects in schizophrenia. Psychopharmacology (Berl)

196:417–429.

58. Frassetto A, Zhang J, Lao JZ, et al. (October 2008). "Reduced sensitivity to diet-induced

obesity in mice carrying a mutant 5-HT6 receptor". Brain Research 1236: 140–4

59. Friedman JH, Berman RM, Goetz CG, Factor SA, Ondo WG, Wojcieszek J, et al. Open-

label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in

patients with psychosis associated with Parkinson's disease. Mov Disord 2006; 21:

2078-81.

60. Furchgott, R. F. The use of haloalkylamines in the differentiation of receptors and in

the determination of dissociation constants of agonist-receptor complexes. Advances

in Drug Research; Harper, N.; Simmonds, A., Eds.; Academic Press: New York, 1966;

Vol. 3, pp 21−55.

61. Gabbott PL, Warner TA, Jays PR, Salway P, Busby SJ. Prefrontal cortex in the rat:

projections to subcortical autonomic, motor, and limbic centers. J Comp Neurol 2005;

492: 145-177.

62. Galici R, Boggs JD, Miller KL, Bonaventure P, Atack JR (2008) Effects of SB-269970, a 5-

HT7 receptor antagonist, in mouse models predictive of antipsychotic-like activity.

Behav Pharmacol 19(2):153–159

63. Giovanni G, Di Matteo V, Pierucci M, Esposito E. Serotonin-dopamine interaction:

electrophysiological evidence. Prog Brain Res. 2008;172:45-71.

64. Glausier JR, Khan ZU, Muly EC. Dopamine D1 and D5 receptors are localized to discrete

populations of interneurons in primate prefrontal cortex. Cereb Cortex 2009; 19: 1820-

34.

65. Gleason SD, Shannon HE (1997) Blockade of phencyclidine-induced hyperlocomotion

by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice.

Psychopharmacol 129:79–84

66. Goff DC, Midha KK, Brotman AW, McCormick S, Waites M, Amico ET. An open trial of

buspirone added to neuroleptics in schizophrenic patients. J Clin Psychopharmacol

1991; 11: 193-7.

67. Goldman-Rakic PS, Muly EC, Williams GV (2000) D(1) receptors in prefrontal cells and

circuits. Brain Res Brain Res Rev 31:295–301

68. Goldman-Rakic PS, Castner SA, Svensson TH, Siever LJ, Williams GV. Targeting the

dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction.

Psychopharmacology 2004; 174: 3-16.

69. Gonzalez-Burgos G, Lewis DA. NMDA Receptor Hypofunction, Parvalbumin-Positive

Neurons and Cortical Gamma Oscillations in Schizophrenia. Schizophrenia Bulletin

Advance Access published May 24, 2012

70. Gonzalez-Burgos G, Lewis DA, Hashimoto T. Alterations of Cortical GABA Neurons and

Network Oscillations in Schizophrenia. Curr Psychiatry Rep. 2010 August ; 12(4): 335–

344.

71. Gonzalez-Burgos G, Lewis DA. GABA neurons and the mechanisms of network

oscillations: implications for understanding cortical dysfunction in schizophrenia.

Schizophr Bull 2008; 34: 944-61.

72. Grayson BI, Idris NF, Neill JC (2007) Atypical antipsychotics attenuate a sub-chronic

PCP-induced cognitive deficit in the novel object recognition task in the rat. Behav

Brain Res 184 (1):31–38

73. Gresch PJ, Sved AF, Zigmond MJ, Finlay JM. 1995. Local influence of endogenous

norepinephrine on extracellular dopamine in rat medial prefrontal cortex. J

Neurochem 65:111–116.

74. Grinshpoon A, Valevski A, Moskowitz M, Weizman A. 2000. Beneficial effect of the

addition of the 5-HT 2A/2C and alpha2 antagonist mianserin to ongoing haloperidol

treatment in drug-resistant chronically hospitalized schizophrenic patients. Eur

Psychiatry 15:388–390.

75. Grunze HC, Rainnie DG, Hasselmo ME, Barkai E, Hearn EF, McCarley RW, et al. NMDA-

dependent modulation of CA1 local circuit inhibition. J Neurosci 1996; 16: 2034-43

76. Gu H, Wall SC, Rudnick G. 1994. Stable expression of biogenic amine transporters

reveals differences in inhibitor sensitivity, kinetics, and ion dependence. J Biol Chem

269:7124–7130

77. Guiard BP, El Mansari M, Merali Z, Blier P. Functional interactions between dopamine,

serotonin and norepinephrine neurons: an in-vivo electrophysiological study in rats

with monoaminergic lesions. Int J Neuropsychopharmacol. 2008 Aug;11(5):625-39.

Epub 2008 Jan 21.

78. Gurevich EV, Joyce JN (1997) Alterations in the cortical serotonergic system in

schizophrenia: a postmortem study. Biol Psychiatry 42 (7):529–545

79. Haenschel C, Bittner RA, Waltz J, et al. Cortical oscillatory activity is critical for working

memory as revealed by deficits in early-onset schizophrenia. J Neurosci 2009;29:9481–

9489.

80. Haensel SM, Slob AK (July 1997). "Flesinoxan: a prosexual drug for male rats".

European Journal of Pharmacology 330 (1): 1–9

81. Hagiwara H, Fujita Y, Ishima T, Kunitachi S, Shirayama Y, Iyo M, Hashimoto K (2008)

Phencyclidine-induced cognitive deficits in mice are improved by subsequent

subchronic administration of the antipsychotic drug perospirone: role of serotonin 5-

HT1A receptors. Eur Neuropsychopharmacol 18(6):448–454

82. Hajós M. Targeting information-processing deficit in schizophrenia: a novel approach

to psychotherapeutic drug discovery. Trends Pharmacol Sci 2006; 27: 391-8.

83. Hashimoto K, Fujita Y, Shimizu E, Iyo M (2005) Phencyclidine-induced cognitive deficits

in mice are improved by subsequent sub-chronic administration of clozapine, but not

haloperidol. Eur J Pharmacol 519:114–117

84. Hashimoto T, Nishino N, Nakai H, Tanaka C (1991) Increase in serotonin 5-HT1A

receptors in prefrontal and temporal cortices of brains from patients with chronic

schizophrenia. Life Sci 48 (4):355–363

85. Heal DJ, Smith SL, Fisas A, Codony X, Buschmann H (February 2008). "Selective 5-HT6

receptor ligands: progress in the development of a novel pharmacological approach to

the treatment of obesity and related metabolic disorders". Pharmacology &

Therapeutics 117 (2): 207–31.

86. Hedlund PB (2009) The 5-HT7 receptor and disorders of the nervous system: an

overview. Psychopharmacology 206(3):345–354

87. Hedlund PB, Sutcliffe JG (2004) Functional, molecular and pharmacological advances in

5-HT7 receptor research. Trends Pharmacol Sci 25(9):481–486

88. Herrick-Davis K, Grinde E, Teitler M. Inverse agonist activity of atypical antipsychotic

drugs at human 5-hydroxytryptamine2C receptors. J Pharmacol Exp Ther. 2000 Oct;

295(1):226-32.

89. Hertel P, Fagerquist MV, Svensson TH. 1999a. Enhanced cortical dopamine output and

antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade. Science

286:105–107.

90. Hertel P, Nomikos GG, Svensson TH. 1999b. Idazoxan preferentially increases

dopamine output in the rat medial prefrontal cortex at the nerve terminal level. Eur J

Pharmacol 371:153–158.

91. Hertel P, Nomikos GG, Svensson TH. 1999c. The antipsychotic drug risperidone

interacts with auto- and hetero-receptors regulating serotonin output in the rat frontal

cortex. Neuropharmacology 38:1175–1184.

92. Hoehn-Saric R, Harris GJ, Pearlson GD, Cox CS, Machlin SR, Camargo EE. A fluoxetine-

induced frontal lobe syndrome in an obsessive compulsive patient.J Clin Psychiatry.

1991 Mar;52(3):131-3.

93. Homayoun H, Moghaddam B. NMDA receptor hypofunction produces opposite effects

on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 2007; 27: 11496-

500.

94. Horiguchi M, Meltzer HY. Blonanserin reverses the phencyclidine (PCP)-induced

impairment in novel object recognition (NOR) in rats: role of indirect 5-HT(1A) partial

agonism. Behav Brain Res. 2013 Jun 15;247:158-64.

95. Horiguchi M, Hannaway KE, Adelekun AE, Huang M, Jayathilake K,Meltzera HY. D1

receptor agonists reverse the subchronic phencyclidine (PCP)-induced novel object

recognition (NOR) deficit in female rats. Behavioural Brain Research 238 (2013) 36– 43

96. Howard MW, Rizzu DS, Caplan JB, et al. Gamma oscillations correlate with working

memory load in humans. Cereb Cortex 2003;13:1369–1374.

97. Huanga M, Horiguchia M, Felixb AR, Meltzer HY. 5-HT1A and 5-HT7 receptors

contribute to lurasidone-induced dopamine efflux. NeuroReport 23:436–440 (2012).

98. Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O’Laughlin IA, Meltzer HY (2001) 5-HT(2A)

and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor

activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine

release. J Neurochem 76(5):1521–1531

99. Ichikawa J, Li Z, Dai J, Meltzer HY (2002) Atypical antipsychotic drugs, quetiapine,

iloperidone, and melperone, preferentially increase dopamine and acetylcholine

release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res

956(2):349–357

100. Irifune M, Shimizu T, Nomoto M (1991) Ketamine-induced hyperlocomotion associated

with alteration of presynaptic components of dopamine neurons in the nucleus

accumbens of mice. Pharmacol Biochem Behav 40(2):399–407

101. Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R, Matsumoto K,

Nishikawa H, Ueda Y, Toma S, Oki H, Tanno N, Saji I, Ito A, Ohno Y, Nakamura M.

Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-

hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010

Jul;334(1):171-81.

102. Jardemark K, Marcus MM, Shahid M, Svensson TH. 2010. Effects of asenapine on

prefrontal N-methyl-D-aspartate receptor-mediated transmission: Involvement of

dopamine D1 receptors. Synapse 64:870–874.

103. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J

Psychiatry 1991; 148: 1301-8.

104. Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB, Roth BL. N-

desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A

agonist, as a putative mediator of quetiapine's antidepressant activity.

Neuropsychopharmacology. 2008 Sep;33(10):2303-12.

105. Jensen NH, Cremers TI and Sotty F (2010) Therapeutic potential of 5-HT2C receptor

ligands. ScientificWorldJournal 10: 1870–1885.

106. Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine: from NMDA

receptor hypofunction to the dopamine hypothesis of schizophrenia.

Neuropsychopharmacology 1999; 20: 201-25.

Page 19: STPN_2014_(Atypical Antipsychotics. Part 1 + 2)_Extended

107. Joffe G, Terevnikov V, Joffe M, Stenberg JH, Burkin M, Tiihonen J. 2009. Add-on

mirtazapine enhances antipsychotic effect of first generation antipsychotics in

schizophrenia: A double-blind, randomized, placebo-controlled trial. Schizophr Res

108:245–251.

108. Johnson CN, Ahmed M, Miller ND. 5-HT6 receptor antagonists: prospects for the

treatment of cognitive disorders including dementia. Curr Opin Drug Discov Devel.

2008; 11:642–654.

109. Julien RM (2004). A Primer Of Drug Action: A Comprehensive Guide To The Actions,

Uses, And Side Effects Of Psychoactive Drugs. Macmillan. pp. 286. ISBN 978-0-7167-

0615-1.

110. Kargieman L, Santana N, Mengod G, Celada P, Artigas F. Antipsychotic drugs reverse

the disruption in prefrontal cortex function produced by NMDA receptor blockade

with phencyclidine. Proc Natl Acad Sci USA 2007; 104: 14843-8.

111. Kasper S, Tauscher J, Willeit M, Stamenkovic M, Neumeister A, Küfferle B, Barnas C,

Stastny J, Praschak-Rieder N, Pezawas L, de Zwaan M, Quiner S, Pirker W, Asenbaum S,

Podreka I, Brücke T (2002) Receptor and transporter imaging studies in schizophrenia,

depression, bulimia and Tourette’s disorder— implications for psychopharmacology.

World J Biol Psychiatry 3 (3):133–146

112. Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled,

duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu

AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol.

2012 Jul;27(4):215-23.

113. Kenakin T (2011). Functional selectivity and biased receptor signaling. J Pharmacol Exp

Ther 336: 296–302.

114. Kikuchi T, Tottori K, Uwahodo Y, Hirose T, Miwa T, Oshiro Y, et al. 7-(4-[4-(2,3-

Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4– dihydro-2(1H)-qui nolinone (OPC-14597),

a new putative antipsychotic drug with both presynaptic dopamine autoreceptor

agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp

Ther 1995; 274: 329-36.

115. Kodela S, Venkata PD. Antidepressant induced apathy responsive to dose reduction.

Psychopharmacol Bull. 2010;43(4):76-9.

116. Kosaka J, Takahashi H, ItoH, Takano A, Fujimura Y, Matsumoto R et al. Decreased

binding of [11C]NNC112 and [11C]SCH23390 in patients with chronic schizophrenia.

Life Sciences 2010;86(21-22):814-8.

117. Krystal JH, D'Souza DC, Mathalon D, Perry E, Belger A, Hoffman R. NMDA receptor

antagonist effects, cortical glutamatergic function, and schizophrenia: toward a

paradigm shift in medication development. Psychopharmacology 2003; 169: 215-33.

118. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al.

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans.

Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen

Psychiatry 1994; 51: 199-214.

119. Kuroki T, Meltzer HY, Ichikawa J (1999) Effects of antipsychotic drugs on extracellular

dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol

Exp Ther 288:774–781

120. Kvachnina E, Liu G, Dityatev A, Renner U, Dumuis A, Richter DW, Dityateva G,

Schachner M, Voyno-Yasenetskaya TA, Ponimaskin EG. 5-HT7 receptor is coupled to G

alpha subunits of heterotrimeric G12-protein to regulate gene transcription and

neuronal morphology. J Neurosci 2005;25:7821–7830.

121. Lahti AC, Koffel B, LaPorte D, Tamminga CA (1995) Subanesthetic doses of ketamine

stimulate psychosis in schizophrenia. Neuropharmacol 13:9–19

122. Lee SI, Keltner NL. Antidepressant apathy syndrome. Perspect Psychiatr Care.

2005;41:188–192.

123. Lecrubier Y, Boyer P, Turjanski S, Rein W. Amisulpride versus imipramine and placebo

in dysthymia and major depression. Amisulpride Study Group. J Affect Disord

1997;43:95–103.

124. Li Q, Clark S, Lewis DV, Wilson WA. NMDA receptor antagonists disinhibit rat posterior

cingulate and retrosplenial cortices: a potential mechanism of neurotoxicity. J Neurosci

2002; 22: 3070-80.

125. Lieґgeois JF, Ichikawa J, Meltzer HY. 2002. 5-HT(2A) receptor antagonism potentiates

haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that

in the nucleus accumbens in a dose-dependent manner. Brain Res 947:157–165.

126. Linnér L, Wiker C, Wadenberg ML, Schalling M, Svensson TH. Noradrenaline reuptake

inhibition enhances the antipsychotic-like effect of raclopride and potentiates D2-

blockage-induced dopamine release in the medial prefrontal cortex of the rat.

Neuropsychopharmacology. 2002 Nov;27(5):691-8.)

127. Litman RE, Hong WW, Weissman EM, Su TP, Potter WZ, Pickar D. 1993. Idazoxan, an

alpha 2 antagonist, augments fluphenazine in schizophrenic patients : a pilot study. J

Clin Psychopharmacol 13:264–267.

128. Litman RE, Su TP, Potter WZ, Hong WW, Pickar D. 1996. Idazoxan and response to

typical neuroleptics in treatment-resistant schizophrenia. Comparison with the

atypical neuroleptic, clozapine. Br J Psychiatry 168:571–579.

129. López-Gil X, Artigas F, Adell. Unraveling Monoamine Receptors Involved in the Action

of Typical and Atypical Antipsychotics on Glutamatergic and Serotonergic Transmission

in Prefrontal Cortex. Current Pharmaceutical Design, 2010, 16, 502-515

130. Lorrain DS, Baccei CS, Bristow LJ, Anderson JJ, Varney MA. Effects of ketamine and N-

methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex:

modulation by a group II selective metabotropic glutamate receptor agonist LY379268.

Neuroscience 2003; 117: 697-706.

131. Löscher W, Annies R, Hönack D (1991) The N-methyl-D-aspartate receptor antagonist

MK-801 induces increases in dopamine and serotonin metabolism in several brain

regions of rats. Neurosci Lett 128:4–191

132. Lymperopoulos A. Beta-arrestin Biased Agonism/Antagonism at Cardiovascular Seven

Transmembrane-spanning Receptors. Current Pharmaceutical Design, 2012, 18, 192-

198

133. Mailman RB, Murthy V. Third Generation Antipsychotic Drugs: Partial Agonism or

Receptor Functional Selectivity? Current Pharmaceutical Design, 2010, Vol. 16, No. 5

134. Malhotra AK, Adler CM, Kennison SD, Elman I, Pickar D, Breier A (1997a) Clozapine

blunts N-methyl-D-aspartate antagonistinduced psychosis: a study with ketamine. Biol

Psychiatry 42 (8):664–668

135. Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D, Breier A (1997b)

Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in

neuroleptic-free schizophrenics. Neuropsychopharmacology 17:141–150

136. Mamo D, Graff A, Mizrahi R, Shammi CM, Romeyer F, Kapur S. Differential effects of

aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with

schizophrenia: a triple tracer PET study. Am J Psychiatry. 2007 Sep;164(9):1411-7.

137. Mannoury la Cour C, El Mestikawy S, Hanoun N, Hamon M, Lanfumey L(2006) Regional

differences in the coupling of 5-hydroxytryptamine-1A receptors to G proteins in the

rat brain. Mol Pharmacol 70:1013–1021.

138. Marcus MM, Wiker C, Frånberg O, Konradsson-Geuken A, Langlois X, Jardemark K,

Svensson TH. Adjunctive alpha2-adrenoceptor blockade enhances the antipsychotic-

like effect of risperidone and facilitates cortical dopaminergic and glutamatergic,

NMDA receptor-mediated transmission. Int J Neuropsychopharmacol. 2010

Aug;13(7):891-903.

139. Marcus MM, Jardemark KE, Wadenberg ML, Langlois X, Hertel P, Svensson TH. 2005.

Combined alpha2 and D2/3 receptor blockade enhances cortical glutamatergic

transmission and reverses cognitive impairment in the rat. Int J

Neuropsychopharmacol 8:315–327.

140. Marcus MM, Jardemark K, Malmerfelt A, Björkholm C, Svensson TH. Reboxetine

Enhances the Olanzapine-Induced Antipsychotic-Like Effect, Cortical Dopamine

Outflow and NMDA Receptor-Mediated Transmission. Neuropsychopharmacology.

2010 August; 35(9): 1952–1961.

141. Marion S, Weiner DM, Caron MG (2004). RNA editing induces variation in

desensitization and trafficking of 5-hydroxytryptamine 2C receptor isoforms. J Biol

Chem 279: 2945–2954.

142. Martin P, Waters N, Carlsson A, Carlsson ML (1997) The apparent antipsychotic action

of the 5-HT2A receptor antagonist M100907 302 Psychopharmacology (2011)

213:289–305 in a mouse model of schizophrenia is counteracted by ritanserin. J Neural

Transm 104(4–5):561–564

143. Martin P, Waters N, Schmidt CJ, Carlsson A, Carlsson ML (1998) Rodent data and

general hypothesis: antipsychotic action exerted through 5-HT2A receptor antagonism

is dependent on increased serotonergic tone. J Neural Transm 105(4–5):365–396

144. Mata I, Arranz MJ, Staddon S, Lopez-Ilundain JM, Tabares-Seisdedos R, Murray RM.

The high-activity Val allele of the catechol-O-methyltransferase gene predicts greater

cognitive deterioration in patients with psychosis. Psychiatr Genet. 2006

Oct;16(5):213-6.

145. Masana M, Bortolozzi A, Artigas F. 2011. Selective enhacement of mesocortical

dopaminergic transmission by noradrenergic drugs: therapeutic opportunities in

schizophrenia. Int J Neuropsychopharmacol 14:53–68.

146. Martín-Cora FJ, Pazos A (2004) Autoradiographic distribution of 5-HT7 receptors in the

human brain using [3H]mesulergine: comparison to other mammalian species. Br J

Pharmacol 141 (1):92–104

147. Maurel-Remy S, Bervoets K, Millan MJ (1995) Blockade of phencyclidine-induced

hyperlocomotion by MDL100, 907 in rats reflects antagonism of 5-HT2A receptors. Eur

J Pharmacol 280: R9–R11

148. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine versus

olanzapine in acute mania: a double-blind extension study. Bipolar Disord. 2009 Dec;

11(8):815-26.

149. McKibben CE, Jenkins TA, Adams HN, Harte MK, Reynolds GP (2010) Effect of

pretreatment with risperidone on phencyclidine-induced disruptions in object

recognition memory and prefrontal cortex parvalbumin immunoreactivity in the rat.

Behav Brain Res 208(1):132–136

150. McLean SL, Idris NF, Woolley ML, Neill JC (2009a) D(1)-like receptor activation

improves PCP-induced cognitive deficits in animal models: implications for

mechanisms of improved cognitive function in chizophrenia. Eur

Neuropsychopharmacol 19:440–450

151. McLean SL, Woolley ML, Thomas D, Neill JC (2009b) Role of 5-HT receptor mechanisms

in sub-chronic PCP-induced reversal learning deficits in the rat. Psychopharmacology

206(3):403–414

152. Meier U, Gressner AM. Review Endocrine regulation of energy metabolism: review of

pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and

resistin. Clin Chem. 2004 Sep; 50(9):1511-25.

153. Meneses A (2002) Involvement of 5-HT(2A/2B/2C) receptors on memory formation:

simple agonism, antagonism, or inverse agonism? Cell Mol Neurobiol 22(5–6):675–688

154. Meltzer HY, Massey BW. The role of serotonin receptors in the action of atypical

antipsychotic drugs. Curr Opin Pharmacol. 2011 Feb;11(1):59-67.

Page 20: STPN_2014_(Atypical Antipsychotics. Part 1 + 2)_Extended

155. Meltzer HY, Horiguchi M, Massey BW. The role of serotonin in the NMDA receptor

antagonist models of psychosis and cognitive impairment. Psychopharmacology (2011)

213:289–305

156. Meltzer HY (1999) The role of serotonin in antipsychotic drug action.

Neuropsychopharmacology 21(2 Suppl):106S–115S

157. Meltzer HY, McGurk SR (1999) The effects of clozapine, risperidone, and olanzapine on

cognitive function in schizophrenia. Schizophr Bull 25:233–255

158. Meltzer HY, Arvanitis L, Bauer D, Rein W, Meta-Trial Study Group (2004) Placebo-

controlled evaluation of four novel compounds for the treatment of schizophrenia and

schizoaffective disorder. Am J Psychiatry 161(6):975–984

159. Meltzer HY, Huang M (2008) In vivo actions of atypical antipsychotic drug on

serotonergic and dopaminergic systems. Prog Brain Res 172:177–197

160. Millan MJ, Brocco M, Gobert A, Joly F, Bervoets K, Rivet JM, Newman-Tancredi A,

Audinot V, Maurel S (1999) Contrasting mechanisms of action and sensitivity to

antipsychotics of phencyclidine versus amphetamine: importance of nucleus

accumbens 5-HT2A site for PCP-induced locomotion in the rat. Eur J Neurosci 11:4419–

4432

161. Milligan G, Bond RA (1997). Inverse agonism and the regulation of receptor number.

Trends Pharmacol Sci 18: 468–474.

162. Miner LH, Schroeter S, Blakely RD, Sesack SR. 2003. Ultrastructural localization of the

norepinephrine transporter in superficial and deep layers of the rat prelimbic

prefrontal cortex and its spatial relationship to probable dopamine terminals. J Comp

Neurol 466:478–494.

163. Mizuki Y, Kajimura N, Imai T, Suetsugi M, Kai S, Kaneyuki H, Yamada M. 1990. Effects of

mianserin on negative symptoms in schizophrenia. Int Clin Psychopharmacol 5:83–95.

164. Mizuki Y, Kajimura N, Kai S, Suetsugi M, Ushijima I, Yamada M. 1992. Effects of

mianserin in chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry

16:517–528.

165. Moghaddam B, Bunney BS (1990) Acute effects of typical and atypical antipsychotic

drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and

striatum of the rat: an in vivo microdialysis study. J Neurochem 54:1755–1760

166. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic

neurotransmission by ketamine: a novel step in the pathway from NMDA receptor

blockade to dopaminergic and cognitive disruptions associated with the prefrontal

cortex. J Neurosci 1997; 17: 2921-7.

167. Mohn AR, Gainetdinov RR, Caron MG, Koller BH (1999) Mice with reduced NMDA

receptor expression display behaviors related to schizophrenia. Cell 98:427–436

168. Montgomery SA. Dopaminergic deficit and the role of amisulpride in the treatment of

mood disorders. Int Clin Psychopharmacol 2002;17:S9–S15. discussion S16-7.

169. Moron JA, Brockington A, Wise RA, Rocha BA, Hope BT. 2002. Dopamine uptake

through the norepinephrine transporter in brain regions with low levels of the

dopamine transporter: Evidence from knock-out mouse lines. J Neurosci 22:389–395.

170. Mortimer AM, Joyce E, Balasubramaniam K, Choudhary PC, Saleem PT. Treatment with

amisulpride and olanzapine improve neuropsychological function in schizophrenia.

Hum Psychopharmacol 2007;22:445–454.

171. Nagai T, Murai R, Matsui K, Kamei H, Noda Y, Furukawa H, Nabeshima T (2009)

Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory

through dopamine D1 and serotonin 5-HT1A receptors. Psychopharmacology 202 (1–

3):315–328

172. Nberg OF, Marcus MM, Svensson TH. Involvement of 5-HT2A Receptor and a2-

Adrenoceptor Blockade in the Asenapine-Induced Elevation of Prefrontal Cortical

Monoamine Outflow. Synapse 66:650–660 (2012)

173. Neve KA. FUNCTIONAL SELECTIVITY OF G PROTEIN-COUPLED RECEPTOR LIGANDS New

Opportunities for Drug Discovery. Humana Press, a part of Springer Science+Business

Media, LLC 2009 ISBN 978-1-60327-334-3

174. Newcomer JW, Farber NB, Jevtovic-Todorovic V, Selke G, Melson AK, Hershey T, Craft

S, Olney JW (1999) Ketamine-induced NMDA receptor hypofunction as a model of

memory impairment and psychosis. Neuropsychopharmacology 20:18–106

175. Newman-Tancredi A, Gavaudan S, Conte C, Chaput C, Touzard M, Verrièle L, Audinot V,

Millan MJ (1998) Agonist and antagonist actions of antipsychotic agents at 5-HT1A

receptors: a [35S] GTPgammaS binding study. Eur J Pharmacol 355(2–3):245–256

176. Newman-Tancredi A, Verrièle L, Touzard M, Millan MJ. (2001) Efficacy of antipsychotic

agents at human 5-HT(1A) receptors determined by [3H]WAY100,635 binding affinity

ratios: relationship to efficacy for G-protein activation. Eur J Pharmacol. 2001 Oct

5;428(2):177-84.

177. Newman-Tancredi A, Martel JC, Assié MB, Buritova J, Lauressergues E, Cosi C, Heusler

P, Bruins Slot L, Colpaert FC, Vacher B, Cussac D. Signal transduction and functional

selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonist. Br J

Pharmacol. 2009 Jan;156(2):338-53.

178. Newman-Tancredi A (2010) The importance of 5-HT1A receptor agonism in

antipsychotic drug action: rationale and perspectives. Curr Opin Investig Drugs

11(7):802–812

179. Nikiforuk A, Popik P.Amisulpride promotes cognitive flexibility in rats: The role of 5-

HT7 receptors. Behavioural Brain Research 248 (2013) 136– 140

180. Ninan I, Jardemark KE, Wang RY (2003) Differential effects of atypical and typical

antipsychotic drugs on N-methyl-D-aspartateand electrically evoked responses in the

pyramidal cells of the rat medial prefrontal cortex. Synapse 48:66–79

181. Ninan I, Wang RY. 2003. Modulation of the ability of clozapine to facilitate NMDA- and

electrically evoked responses in pyramidal cells of the rat medial prefrontal cortex by

dopamine: Pharmacological evidence. Eur J Neurosci 17:1306–1312.

182. Nomikos GG, Iurlo M, Andersson JL, Kimura K, Svensson TH. 1994. Systemic

administration of amperozide, a new atypical antipsychotic drug, preferentially

increases dopamine release in the rat medial prefrontal cortex. Psychopharmacology

115:147–156.

183. Nordström AL, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G (1995) D1, D2, and 5-

HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of

schizophrenic patients. Am J Psychiatry 152:1444–1449

184. Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, et al. Decreased

prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 1997; 385:

634-6.

185. Opbroek A, Delgado PL, Laukes C, et al. Emotional blunting associated with SSRI-

induced sexual dysfunction. Do SSRIs inhibit emotional responses? Int J

Neuropsychopharmacol. 2002;5:147–151.

186. Padala PR, Padala KP, Monga V, Ramirez DA, and Sullivan DH. Reversal of SSRI-

Associated Apathy Syndrome by Discontinuation of Therapy. Ann Pharmacother

2012;46:e8.

187. Pandina G, Lane R, Gopal S, Gassmann-Mayer C, Hough D, Remmerie B et al. (2012). A

double-blind study of paliperidone palmitate and risperidone long-acting injectable in

adults with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 35: 218–226.

188. Pani L, Gessa GL. The substituted benzamides and their clinical potential on dysthymia

and on the negative symptoms of schizophrenia. Mol Psychiatry 2002;7:247–253.

189. Pehrson AL, Sanchez C. Serotonergic modulation of glutamate neurotransmission as a

strategy for treating depression and cognitive dysfunction. CNS Spectr. 2013 Aug 1:1-

13.

190. Pitsikas N, Zisopoulou S, Pappas I, Sakellaridis N (2008) The selective 5-HT(6) receptor

antagonist Ro 04-6790 attenuates psychotomimetic effects of the NMDA receptor

antagonist MK-801. Behav Brain Res 188(2):304–309

191. Potkin SG, Cohen M, Panagides J (2007) Efficacy and tolerability of asenapine in acute

schizophrenia: a placebo- and risperidonecontrolled trial. J Clin Psychiatry (in press)

192. Potkin SG, Fleming K, Binneman B, Keller DS, Alphs L, Panagides J (2006) Asenapine

effects on cognitive function during acute episodes of schizophrenia: a randomized

placebo- and risperidone-controlled trial. Neuropsychopharmacology 31:251

193. Poyurovsky M, Shardorodsky M, Fuchs C, Schneidman M, Weizman A. 1999. Treatment

of neuroleptic-induced akathisia with the 5-HT2 antagonist mianserin. Double-blind,

placebo-controlled study. Br J Psychiatry 174:238–242.

194. Poyurovsky M, Koren D, Gonopolsky I, Schneidman M, Fuchs C, Weizman A, Weizman

R. 2003. Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic

schizophrenia patients: An add-on, double-blind placebo-controlled study. Eur

Neuropsychopharmacol 13:123–128.

195. Pozzi L, Invernizzi R, Cervo L, Vallebuona F, Samanin R. 1994. Evidence that

extracellular concentrations of dopamine are regulated by noradrenergic neurons in

the frontal cortex of rats. J Neurochem 63:195–200.

196. Price J, Goodwin GM. Emotional blunting or reduced reactivity following remission of

major depression. Medicographia. 2009;31:152–156.

197. Price J, Cole V, Goodwin GM. Emotional side-effects of selective serotonin reuptake

inhibitors: qualitative study. Br J Psychiatry. 2009;195:211–217.

198. Reinblatt SP, Riddle MA. Selective serotonin reuptake inhibitorinduced apathy: a

pediatric case series. J Child Adolesc Psychopharmacol. 2006;16:227–233.

199. Reynolds GP. Receptor mechanisms of antipsychotic drug action in bipolar disorder –

focus on asenapine. Ther Adv Psychopharmacol. 2011 December; 1(6): 197–204.

200. Rodefer JS, Murphy ER, Baxter MG (2005) PDE10A inhibition reverses sub-chronic PCP-

induced deficits in attentional setshifting in rats. Eur J Neurosci 21:1070–1076

201. Rotaru DC, Lewis DA, Gonzalez-Burgos G. The role of glutamatergic inputs onto

parvalbumin-positive interneurons: relevance for schizophrenia. Rev. Neurosci., Vol.

23(1): 97–109, 2012

202. Roth BL, Sheffler DJ, Kroeze WK (2004) Magic shotguns versus magic bullets:

Selectively non-selective drugs for mood disorders and schizophrenia.Nat Rev Drug

Discov3:353–359.

203. Sanacora G, Berman RM, Cappiello A, Oren DA, Kugaya A, Liu N, Gueorguieva R, Fasula

D, Charney DS. Addition of the 2-Antagonist Yohimbine to Fluoxetine: Effects on Rate

of Antidepressant Response. Neuropsychopharmacology (2004) 29, 1166–1171.

204. Sansone RA, Sansone LA, SSRI-induced indifference, Psychiatry (Edgemont)

2010;7(10):14–18

205. Sato S, Asada T. Sertraline-Induced Apathy Syndrome. J Neuropsychiatry Clin Neurosci

23:1, Winter 2011

206. Saykin AJ, Gur RC, Gur RE, Mozley PD, Mozley LH, Resnick SM, Kester DB, Stafiniak P

(1991) Neuropsychological function in schizophrenia: selective impairment in memory

and learning. Arch Gen Psychiatry 48(7):618–624

207. Schechter LE, Lin Q, Smith DL, et al. (May 2008). "Neuropharmacological profile of

novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466".

Neuropsychopharmacology 33 (6): 1323–35.

208. Schroeter S, Apparsundaram S, Wiley RG, Miner LH, Sesack SR, Blakely RD. 2000.

Immunolocalization of the cocaine- and antidepressant-sensitive l-norepinephrine

transporter. J Comp Neurol 420:211–232.

Page 21: STPN_2014_(Atypical Antipsychotics. Part 1 + 2)_Extended

209. Sesack SR, Hawrylak VA, Matus C, Guido MA, Levey AI. 1998. Dopamine axon

varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse

immunoreactivity for the dopamine transporter. J Neurosci 18:2697–2708.

210. Shahid M, Summer BEH, Wong EHF, Henry B (2007a) Asenapine displays distinctive

induction patterns of c-fos mRNA expression in rat forebrain regions. Biol Psychiatry

61(8):256S–256S 826 Suppl. 2

211. Shahid M, Walker GB, Zorn SH, Wong EHF (2007b) Asenapine: a novel

psychopharmacologic agent with a unique human receptor signature. J

Psychopharmacol (in press)

212. Shahid M, Walker GB, Zorn SH, Wong EH. 2009. Asenapine: A novel

psychopharmacologic agent with a unique human receptor signature. J

Psychopharmacol 23:65–73

213. Shapiro DA, Renock S, Arrington E, Sibley DR, Chiodo LA, Roth BL, et al. Aripiprazole, a

novel atypical antipsychotic drug with a unique and robust pharmacology.

Neuropsychopharmacology 2003; 28: 1400-11

214. Shiloh R, Zemishlany Z, Aizenberg D, Valevski A, Bodinger L, Munitz H, Weizman A.

2002. Mianserin or placebo as adjuncts to typical antipsychotics in resistant

schizophrenia. Int Clin Psychopharmacol 17:59–64.

215. Simpson MD, Lubman DI, Slater P, Deakin JF (1996) Autoradiography with [3H]8-OH-

DPAT reveals increases in 5-HT(1A) receptors in ventral prefrontal cortex in

schizophrenia. Biol Psychiatry 39(11):919–928

216. Snigdha S, Horiguchi M, Huang M, Li Z, Shahid M, Neill JC, Meltzer HY (2010)

Attenuation of phencyclidine-induced object recognition deficits by the combination of

atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A)

receptor inverse agonist. J Pharmacol Exp Ther 332(2):622–631

217. Snigdha S, Idris N, Grayson B, Shahid M, Neill JC. 2011. Asenapine improves

phencyclidine-induced object recognition deficits in the rat: Evidence for engagement

of a dopamine D(1) receptor mechanism. Psychopharmacology (Berl) 214:843–853.

218. Spencer K, Nestor PG, Niznikiewicz MA, et al. Abnormal neural synchrony in

schizophrenia. J Neurosci 2003;23:7407–7411.

219. Spencer K, Niznikiewicz MA, Nestor PG, et al. Left auditory cortex gamma

synchronization and auditory hallucination symptoms in schizophrenia. BMC Neurosci

2009;10:85.

220. Stefani MR, Moghaddam B (2002) Effects of repeated treatment with amphetamine or

phencyclidine on working memory in the rat. Behav Brain Res 134:267–274

221. Steinpreis RE, Salamone JD (1993) The role of nucleus accumbens dopamine in the

neurochemical and behavioral effects of phencyclidine: a microdialysis and behavioral

study. Brain Res 612(1–2):263–270

222. Stenberg JH, Terevnikov V, Joffe M, Tiihonen J, Tchoukhine E, Burkin M, Joffe G. 2010.

Effects of add-on mirtazapine on neurocognition in schizophrenia: A double-blind,

randomized, placebo-controlled study. Int J Neuropsychopharmacol 13:433–441.

223. Strange PG. Antipsychotic drug action: antagonism, inverse agonism or partial

agonism. Trends in Pharmacological Sciences, 2008, Vol.29 No.6

224. Sumiyoshi T, Matsui M, Yamashita I, Nohara S, Uehara T, Kurachi M, Meltzer HY (2000)

Effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory

functions in schizophrenia. J Clin Psychopharmacol 20(3):386–388

225. Sumiyoshi T, Matsui M, Yamashita I, Nohara S, Kurachi M, Uehara T, Sumiyoshi S,

Sumiyoshi C, Meltzer HY (2001b) The effect of tandospirone, a serotonin(1A) agonist,

on memory function in schizophrenia. Biol Psychiatry 49(10):861–868

226. Sumiyoshi T, Stockmeier CA, Overholser JC, Dilley GE, Meltzer HY (1996) Serotonin1A

receptors are increased in postmortem prefrontal cortex in schizophrenia. Brain Res

708(1–2):209–214Swanson CJ, Schoepp DD (2002) The group II metabotropic

glutamate receptor agonist (-)-2-oxa-4-aminobicyclo[3.1.0]-hexane-4, 6-dicarboxylate

(LY379268) and clozapine reverse phencyclidine-induced behaviors in monoamine-

depleted rats. J Pharmacol Exp Ther 303:919–927

227. Svenningsson P, Tzavara ET, Qi H, Carruthers R, Witkin JM, Nomikos GG, Greengard P

(2007) Biochemical and behavioral evidence for antidepressant-like effects of 5-HT6

receptor stimulation. J Neurosci 27(15):4201–4209

228. Szegedi A, Zhao J, van Willigenburg A, Nations KR, Mackle M, Panagides J. 2011. Effects

of asenapine on depressive symptoms in patients with bipolar I disorder experiencing

acute manic or mixed episodes: A post hoc analysis of two 3-week clinical trials. BMC

Psychiatry 11:101

229. Takahashi H, Yamada M, Suhara T. Functional significance of central D1 receptors in

cognition: beyond working memory. J of Cerebral Blood Flow and Metabolism

2012;32(7):1248-58

230. Tallon-Baudry C, Bertrand O, Peronnet F, Pernier J. Induced gamma-band activity

during the delay of a visual short-term memory task in humans. J Neurosci

1998;18:4244–4254.

231. Tallon-Baudry C, Mandon S, Freiwald WA, Kreiter AK. Oscillatory synchrony in the

monkey temporal lobe correlates with performance in a visual short-term memory

task. Cereb Cortex. 2004;14:713–720.

232. Tamminga CA. Schizophrenia and glutamatergic transmission. Crit Rev Neurobiol 1998;

12: 21-36.

233. Tanaka H, Tatsuno T, Shimizu H, Hirose A, Kumasaka Y, Nakamura M (1995) Effects of

tandospirone on second messenger systems and neurotransmitter release in the rat

brain. Gen Pharmacol 26 (8):1765–1772

234. Tandon R (2002) Safety and tolerability: how do newer generation “atypical”

antipsychotics compare? Psychiatr Q 73:297–311

235. Tarazi FI, Yeghiayan SK, Baldessarini RJ, Kula NS, Neumeyer JL. Long-term effects of

S(+)N-n-propylnorapomorphine compared with typical and atypical antipsychotics:

differential increases of cerebrocortical D2-like and striatolimbic D4-like dopamine

receptors. Neuropsychopharmacology. 1997 Sep;17(3):186-96.

236. Tarazi FI, Zhang K, Baldessarini RJ. Long-term effects of olanzapine, risperidone, and

quetiapine on dopamine receptor types in regions of rat brain: implications for

antipsychotic drug treatment. J Pharmacol Exp Ther. 2001 May;297(2):711-7.

237. Tarazi FI, Zhang K, Baldessarini RJ. Long-term effects of olanzapine, risperidone, and

quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions.

Psychopharmacology (Berl). 2002 May;161(3):263-70. Epub 2002 Apr 4.

238. Tarazi FI, Moran-Gates T, Wong EHF, Henry B, Shahid M. Differential regional and

dose-related effects of asenapine on dopamine receptor subtypes.

Psychopharmacology (2008) 198:103–111

239. Tarazi FI, Moran-Gates T, Wong EH, Henry B, Shahid M. Asenapine induces differential

regional effects on serotonin receptor subtypes. J Psychopharmacol. 2010

Mar;24(3):341-8.

240. Tarazi FI, Riva MA. The preclinical profile of lurasidone: clinical relevance for the

treatment of schizophrenia. Expert Opin. Drug Discov. (2013) 8(10):1297-1307

241. Tauscher J, Kapur S, Verhoeff NP, Hussey DF, Daskalakis ZJ, Tauscher-Wisniewski S,

Wilson AA, Houle S, Kasper S, Zipursky RB (2002) Brain serotonin 5-HT(1A) receptor

binding in schizophrenia measured by positron emission tomography and [11C]WAY-

100635. Arch Gen Psychiatry 59(6):514–520

242. Tecott et al. Nature 1995 Eating disorder and epilepsy in mice lacking 5-HT2C

serotonin receptors.

243. Tecott et al. Nature 1995 Gavin P Reynolds GP. Receptor mechanisms of antipsychotic

drug action in bipolar disorder – focus on asenapine. Ther Adv Psychopharmacol. 2011

December; 1(6): 197–204.

244. Terevnikov V, Stenberg JH, Tiihonen J, Joffe M, Burkin M, Tchoukhine E, Joffe G. 2011.

Add-on mirtazapine improves depressive symptoms in schizophrenia: A double-blind

randomized placebocontrolled study with an open-label extension phase. Hum

Psychopharmacol Clin Exp 26:188–193.

245. Thompson MR, Callaghan PD, Hunt GE, Cornish JL, McGregor IS (May 2007). "A role for

oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4

methylenedioxymethamphetamine ("ecstasy")". Neuroscience 146 (2): 509–14.

246. Tsutsumi T, Hirano M, Matsumoto T, Nakamura K, Hashimoto K, Hondo H, Yonezawa Y,

Tsukashima A, Nakane H, Uchimura H et al (1995) Involvement of dopamine D1

receptors in phencyclidine-induced behavioral stimulation in rats. Clin

Neuropharmacol 18(1):64–71

247. Turkoz I, Bossie C, Lindenmayer J, Scooler N, Canuso C (2011). Paliperidone ER and oral

risperidone in patients with schizophrenia: a compoarative database analysis. BMC

Psychiatry 11: 21.

248. Uhlhaas PJ, Singer W. Abnormal neural oscillations and synchrony in schizophrenia.

Nat Rev Neurosci 2010;11:100–113.

249. Ungerstedt U, Arbuthnott GW. Quantitative recording of rotational behavior in rats

after 6-hydroxy- dopamine lesions of the nigrostriatal dopamine system. Brain Res

1970; 24: 485-93

250. Urban, J. D.; Clarke, W. P.; von Zastrow, M.; Nichols, D. E.; Kobilka, B.; Weinstein, H.;

Javitch, J. A.; Roth, B. L.; Christopoulos, A.; Sexton, P. M.; Miller, K. J.; Spedding, M.;

Mailman, R. B. Functional selectivity and classical concepts of quantitative

pharmacology. J. Pharmacol. Exp. Ther. 2007, 320, 1−13.

251. Volman V, Behrens MM, Sejnowski TJ. Downregulation of Parvalbumin at Cortical

GABA Synapses Reduces Network Gamma Oscillatory Activity. J. Neurosci., December

7, 2011; 31(49):18137–18148

252. Wagner M, Quednow BB, Westheide J, Schlaepfer TE, Maier W, Ku¨ hn KU: Cognitive

improvement in schizophrenic patients does not require a serotonergic mechanism:

randomized controlled trial of olanzapine vs amisulpride. Neuropsychopharmacology

2005, 30:381-390.

253. Wadenberg M-L, Hertel P, Fernholm R, Blakeman KH, Ahlenius S, Svensson TH.

Enhancement of antipsychotic-like effects by combined treatment with the �1-

adrenoceptor antagonist prazosin and the dopamine D2 receptor antagonist

raclopride in rats. J Neural Transm 2000; 107: 1229-38.

254. Wadenberg ML, Hicks PB, Richter JT, Young KA. 1998. Enhancement of

antipsychoticlike properties of raclopride in rats using the selective serotonin2A

receptor antagonist MDL 100,907. Biol Psychiatry 44:508–515.

255. Wadenberg ML, Wiker C, Svensson TH. 2007. Enhanced efficacy of both typical and

atypical antipsychotic drugs by adjunctive alpha2 adrenoceptor blockade:

Experimental evidence. Int J Neuropsychopharmacol 10:191–202.

256. Wang Y, Liu J, Gui ZH, Ali U, Fan LL, Hou C, Wang T, Chen L. 2011. alpha(2)-

Adrenoceptor regulates the spontaneous and the GABA/glutamate modulated firing

activity of the rat medial prefrontal cortex pyramidal neurons. Neuroscience 182:193–

202.

257. Ward RP, Hamblin MW, Lachowicz JE, Hoffman BJ, Sibley DR, Dorsa DM (1995)

Localization of serotonin subtype 6 receptor messenger RNA in the rat brain by in situ

hybridization histochemistry. Neuroscience 64(4):1105–1111

258. Weinberger DR, Egan MF, Bertolino A, Callicott JH, Mattay VS, Lipska BK, Berman KF,

Goldberg TE (2001) Prefrontal neurons and the genetics of schizophrenia. Biol

Psychiatry 50:825–844

Page 22: STPN_2014_(Atypical Antipsychotics. Part 1 + 2)_Extended

259. Whitton PS, Biggs CS, Pearce BR, Fowler LJ (1992) MK-801 increases extracellular 5-

hydroxytryptamine in rat hippocampus and striatum in vivo. J Neurochem 58:1573–

1575

260. Wiker C, Linner L, Wadenberg ML, Svensson TH. 2005. Adjunctive treatment with

mianserin enhances effects of raclopride on cortical dopamine output and, in parallel,

its antipsychotic-like effect. Neuropsychiatr Dis Treat 1:253–260.

261. Winstanley CA, Theobald DE, Dalley JW, Robbins TW. (2005). "Interactions between

serotonin and dopamine in the control of impulsive choice in rats: therapeutic

implications for impulse control disorders". Neuropsychopharmacology. 30 (4): 669–

682.

262. Winters BD, Saksida LM, Bussey TJ (2008) Object recognition memory: neurobiological

mechanisms of encoding, consolidation and retrieval. Neurosci Biobehav Rev

32(5):1055–1070

263. Winters BD, Saksida LM, Bussey TJ (2010) Implications of animal object memory

research for human amnesia. Neuropsychologia 48:2251–2261

264. Wirkner K, Krause T, Koles L, Thummler S, Al-Khrasani M, Illes P. 2004. D(1) but not

D(2) dopamine receptors or adrenoceptors mediate dopamine-induced potentiation of

N-methyl-D-aspartate currents in the rat prefrontal cortex. Neurosci Lett 372:89–93.

265. Wongpakaran N, van Reekum R, Wongpakaran T, Clarke D. Selective serotonin

reuptake inhibitor use associates with apathy among depressed elderly: a case-

controlled study. Ann Gen Psychiatry. 2007;6:7.

266. WPA. OFFICIAL JOURNAL OF THE WORLD PSYCHIATRIC ASSOCIATION (WPA) Volume

10, Number 1 February 2011. World Psychiatry NEW IMPACT. p. 53

(http://www.wpanet.org/uploads/Publications/WPA_Journals/World_Psychiatry/Past

_Issues/English/wpa-02-2011.pdf)

267. Young JW, Powell S, Risbrough V, Marston HM, Geyer MA (2009) Using the MATRICS

to guide development of a preclinical cognitive test battery for research in

schizophrenia. Pharmacol Ther 122(2):150–202

268. Yun H-M, Rhim H. The Serotonin-6 Receptor as a Novel Therapeutic Target. Exp

Neurobiol. 2011 Dec;20(4):159-168.

269. Zheng H, Loh HH, Law P. Agonist-Selective Signaling of G Protein-Coupled Receptor:

Mechanisms and Implications. IUBMB Life. 2010 February ; 62(2): 112–119.

270. Zuideveld KP, Rusiç-Pavletiç J, Maas HJ, Peletier LA, Van der Graaf PH, Danhof M

(December 2002). "Pharmacokinetic-pharmacodynamic modeling of buspirone and its

metabolite 1-(2-pyrimidinyl)-piperazine in rats". J. Pharmacol. Exp. Ther. 303 (3):

1130–7.


Top Related